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CHAPTER 1 11 
 
 
Phenomenology of psychosis 
 
Psychotic disorders, such as schizophrenia or other non-affective psychoses, are 
characterized by profound problems in the recognition of and interaction with 
reality [1]. Among the core symptoms are delusions and hallucinations, commonly 
referred to as the positive symptom cluster, and flattened affect, lack of motivation 
and anhedonia, also called the negative symptom dimension of psychosis [2]. Also, 
depressive mood, manic features and disorganized behavior are common in 
psychosis. According to the 4th version of the Diagnostic and Statistical Manual of 
Mental Disorders [2], a diagnosis of schizophrenia or other psychotic disorder is 
fulfilled when symptoms occur independent of substance use or other medical 
conditions, are present a significant portion of time during one month, and interfere 
with social and occupational activities. Although not included in the classification of 
the DSM IV, psychotic disorders are further often accompanied by impairments in 
neurocognitive and social cognitive domains, including memory, executive functioning 
and theory of mind [3-5]. Some of the neurocognitive disturbances have been shown 
to strongly correlate with the negative and disorganized symptom clusters, yet not 
with the positive and depressive symptom dimensions [6], suggesting the existence of 
different cerebral mechanisms underlying the different symptom clusters. This is also 
in line with the proposed distinction between positive syndrome type I schizophrenia 
and negative syndrome type II schizophrenia [7-9]. While the former subtype is 
thought to be more common in females and characterized by mostly positive and 
affective symptoms, a better outcome, and a rather episodic and recurrent course, 
the latter subtype appears to be more common in males and has been associated 
with negative and cognitive symptoms, a worse outcome, and a rather deteriorating 
course [7-9]. Still, the distinction into two separable subtypes of schizophrenia 
remains a matter of debate. Notably,  although neurocognition has been shown to 
correlate with certain symptom dimension, it does not seem to be a good predictor 
of functional outcome in psychotic disorders, which has been shown to more strongly 
correlate with measures of social cognition, in particular theory of mind [10].  
 
The expression of psychosis does not appear to be restricted to clinically relevant 
psychotic disorders. Qualitatively similar psychotic experiences have been shown to 
be distributed in the general population [11-14]. Therefore, a dimensional view  of 
psychosis, in which developmental expression of subclinical psychotic experiences is 
distinguished from clinically relevant psychotic symptoms by quantitative differences 
in symptom expression, might constitute a more adequate approach in contrast to the 
classic categorical view of a discrete and qualitatively different illness [15, 16]. In 
support of the dimensional approach of psychosis are studies demonstrating that 
psychotic experiences show continuity with psychotic disorders such as schizophrenia 
in terms of familial clustering and shared etiological factors [17-20]. In addition, 
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given the fact that transient psychotic experiences may, under certain circumstances, 
become abnormally persistent, giving rise to clinical psychotic disorder [13, 21-24], 
psychotic experiences represent an important phenotype for the investigation of 
mechanisms by which environmental risk factors such as cannabis impact on psychosis 
risk [24]. Therefore, these so-called sub-clinical psychotic symptoms are targeted in 
the epidemiological studies presented in this thesis (chapters 2, 3, and 4). 
 
Etiology of psychosis 
 
The risk factors for psychotic disorders such as schizophrenia are diverse. Besides a 
strong genetic component – first-degree relatives of patients with schizophrenia 
have a ten times higher risk of developing the disease compared to the general 
population [25] – research has identified a number of environmental factors that 
impact on psychosis risk [26]. Among the most common environmental influences are 
growing up in an urban environment [27-29], migration and discrimination [30-32], 
social deprivation and isolation [33-35], abuse and victimization [36, 37], obstetric 
complications [38-40] and cannabis use [41]. The latter being the central topic of 
investigation in this thesis.  
 
The development and expression of vulnerability to psychosis might best be 
understood in terms of interaction between genes and environment [42]. Unlike 
gene-environment correlation, where a certain genetic make-up predisposes an 
individual to the exposure to certain environmental influences, gene-environment 
interaction implies that the degree to which environmental risk factors impact on 
psychosis risk is dependent on the level of individual, pre-existing genetic 
vulnerability for psychosis [43, 44]. Statistically speaking, interaction between genes 
and environment may either be additive or multiplicative (discussed in more detail in 
chapter 3) and it has been suggested that interaction on the additive scale is 
biologically more plausible, yielding information on the extent to which two causes 
biologically depend on each other or co-participate in disease causation [45]. In line 
with these considerations, synergistic interaction between genetic predisposition for 
psychosis and environmental risk factors in causing psychosis has been identified for 
urbanicity [28], prenatal exposure to infections [46], psychosocial stress [47], trauma 
[37] and cannabis use [48].  
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Cannabis use as cause of psychosis 
 
After tobacco and alcohol, cannabis is the most widely used recreational drug in the 
world [49]. According to the European Monitoring Centre on Drugs and Drug 
Addiction (EMCDDA), about 22.5 % of European adults aged 15 to 65 have used 
cannabis at least once in their life and more than 6 % have used cannabis in the last 
year [50]. Cannabis use is particularly prominent among young adults, with lifetime 
prevalence rates of about 31.6 % in 15-34 year olds [50], which is alarming given 
the fact that the adolescent, still maturing brain might be particularly vulnerable to 
the adverse effects of cannabis [51, 52]. Notably, the prevalence of cannabis use 
differs largely throughout Europe but seems to be independent of availability in the 
respective countries: In the Netherlands, where cannabis is legally sold and 
consumed in so-called ‘coffeeshops’, the prevalence is rather moderate (22.6 %), 
compared to high-prevalence countries, which include Denmark (38.6 %), Italy 
(32.0 %) and the United Kingdom (31.1 %) [50].  
Biological and psychological effects of cannabis  
Cannabis is derived from the female plant of Cannabis Sativa and most of the 
effects associated with its use are caused by delta-9-tetrahydrocannabinol (THC), 
the main psychoactive constituent of cannabis. In the human brain, THC mainly binds 
to cannabinoid-1-receptors (CB1), where it acts as a partial agonist [53]. CB1 
receptors, which are the primary binding site of endogenous cannabinoids (eCBs) 
are densely distributed in various regions of the brain, including hippocampus, basal 
ganglia, amygdala, prefrontal cortex and cerebellum [54]. Among the best 
characterized eCBs are anandamide (N-arachidonoylethanolamide) and 2-AG (2-
arachidonoylglycerol) [55, 56]. Being synthesized in and released on demand from 
the postsynaptic neuron, eCBs act in a retrograde fashion and bind to CB1 receptors 
located on neighboring presynaptic terminals [57]. Activation of CB1 receptors 
inhibits neurotransmitter release and thereby modulates several neurotransmitter 
systems, including the dopamine system [58]. The endocannabinoid system thus plays 
an important role in the fine-tuning of synaptic neurotransmission and activation of 
this system by exogenous cannabinoids such as THC can lead to profound and long-
lasting changes in synaptic functioning [52]. Yet, the exact effects of THC on the 
brain remain unknown, in particular with regard to long-term effects on mental 
health. The acute, psychological effects of cannabis include relaxation, sociability 
and euphoria but also anxiety, panic attacks or paranoia [49, 59]. Furthermore, 
cannabis use has been shown to affect cognitive functioning, in particular mnemonic 
and executive functioning as well as psychomotor speed, both in the short-term and 
beyond the period of acute intoxication [60-62]. Whether the neurocognitive effects 
of chronic long-term use are reversible remains unclear, since some level of 
impairment might still be detectable in abstinent users [63]. Intriguingly, in patients 
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with schizophrenia, cannabis use has been associated with superior neurocognitive 
functioning compared to non-using patients [64, 65]. With regard to the effects of 
cannabis use on brain structure, there is accumulating evidence for cannabis-related 
changes in brain morphology of chronic users, such as ventricular enlargement, 
reduced hippocampal and amygdala volume, and structural abnormalities in the 
corpus callosum [66-70]. Some studies further suggest that these changes occur dose-
dependent and are related to early age of onset of use [67, 68, 70]. With regard 
to long-term effects of cannabis use on mental health, cannabis use has been 
particularly associated with an increased risk to develop psychotic symptoms and 
schizophrenia [41].  
Epidemiological studies of cannabis as cause of psychosis  
Early evidence for a role of cannabis use in the emergence of psychosis was 
provided by a number of experimental studies on the acute effects of cannabis 
which demonstrated its ability to induce paranoid delusions and visual and auditory 
hallucinations in healthy individuals [71-73]. Later experimental studies on the acute 
effects of THC on psychopathology and cognitive endophenotypes of psychosis have 
replicated these psychotomimetic effects of cannabis [74-76]. One of the first large 
epidemiological studies that investigated the link between cannabis use and 
psychosis was conducted in 1987 [77]. The researchers examined the association 
between cannabis use and the development of schizophrenia during a 15-year 
follow-up in 45 570 Swedish conscripts and revealed a dose-response effect: 
Individuals, who had used cannabis on 11 to 50 occasions had a three-fold 
increased risk of developing schizophrenia compared to non-users and in individuals 
who had used cannabis on more than fifty occasions the risk was increased even six-
fold [77]. A later re-analysis of the same cohort for reasons of methodological 
refinement similarly reported a strong dose-response relationship between cannabis 
use and later development of schizophrenia, which was not explained by use of 
other drugs [78]. The link between cannabis use and psychosis was subsequently 
investigated by numerous epidemiological studies. By now, meta-analytic work has 
confirmed cannabis use as a risk factor for any psychotic outcome, including 
psychotic symptoms, schizophrenia or schizophreniform disorder, independent of 
factors such as age, gender, socio-economic status, and use of other drugs [41, 79-
82]. Yet, a much discussed topic in the cannabis-psychosis debate remains the issue 
of self-medication or reverse causality [83-86]: Is the association between cannabis 
use and psychosis indeed causal, or do early psychotic experiences in fact prompt 
cannabis use as a means of self-medication? 
Neurobiological aspects of the association between cannabis and psychosis 
It has been suggested that the psychosis-inducing effects of cannabis are mediated 
by increased dopaminergic neurotransmission in striatal regions of the brain [87]. 
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Dysregulation of the dopamine system, in particular hypoactivity in the mesocortical 
dopamine pathway along with hyperactivity in subcortical dopamine pathways, has 
been implicated in the emergence and experience of psychotic symptoms for many 
year [88]. However, experimental studies employing neurochemical imaging 
techniques to investigate cannabis-induced changes in striatal dopamine 
neurotransmission in healthy human volunteers produced inconsistent results: While 
one study found increased striatal dopamine release following the acute 
administration of THC [89], two other studies failed to detect such an effect [90, 91]. 
Yet, no study has investigated striatal dopamine release in response to THC in 
individuals with psychotic disorder. More research is therefore needed in order to 
clarify the apparent inconsistencies and to investigate neurobiological effects of THC 
in at-risk populations such as patients with psychotic disorder or their first-degree 
relatives. 
Differential sensitivity to cannabis as cause of psychosis  
The use of cannabis is neither sufficient nor necessary to precipitate psychotic 
symptoms. Cannabis use thus most likely constitutes a component cause of psychotic 
disorder, interacting with other genetic and environmental risk factors in increasing 
the risk for psychotic outcomes [92]. Accordingly, an important goal in recent 
research has been to identify factors that moderate the cannabis-psychosis 
relationship, rendering some individuals particularly vulnerable to the psychosis-
inducing effects of cannabis. Patients with a diagnosis of psychotic disorder have 
been found to show increased sensitivity to the acute effects of cannabis on 
behavioral outcomes such as cognition and psychotic reactivity [93]. Recently it was 
furthermore demonstrated that patients as well as their siblings showed increased 
cerebral cortical sensitivity to cannabis in terms of stronger reductions in cortical 
thickness compared to healthy controls [94]. Increased sensitivity with regard to the 
long-term effects of cannabis exposure on psychotic outcomes has also been 
demonstrated in individuals with underlying psychosis vulnerability or high schizotypy 
[48, 95, 96]. Studies on genetic moderation of the cannabis-psychosis relationship 
have mostly focused on the gene, which codes for the enzyme COMT (Catechyl-O-
Methyl-Transferase, an enzyme that is involved in the degradation of dopamine in 
the PFC). A functional single nucleotide polymorphism (SNP) at codon 158, the 
COMT val158met polymorphism, has been shown to modulate dopamine levels in the 
human PFC [97, 98]. Caspi and colleagues [99] were the first to demonstrate COMT 
val158met moderation of the effects of adolescent cannabis use on later psychotic 
outcome. The risk for adult schizophreniform disorder was highest among individuals 
with the val/val genotype and lowest for the met/met genotype. The risk was 
intermediate for individuals with the val/met genotype. Experimental [100] as well 
as observational [101] studies have since replicated the moderating role of COMT 
val158met genotype. Yet, this idea has been challenged by a non-replication by 
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now [102]. Recently, two other SNPs situated in the schizophrenia candidate gene 
AKT1 were identified in relation to increased sensitivity to the psychosis-inducing 
effects of cannabis [103]. Overall, research thus suggests that (genetic) 
predisposition for psychosis as well as genetic variation of specific functional SNPs 
contributes to differential sensitivity to cannabis. Environmental factors, on the other 
hand, that might impact on the pathway from cannabis to psychosis have received 
only little attention. Some studies have indicated that early exposure to trauma 
induces differential sensitivity to cannabis effects in terms of psychosis risk [104, 
105].  
Clinical implications  
Cannabis use is extremely common in clinical populations [106, 107] and has been 
associated with poor compliance, higher relapse rates and worse outcome among 
patients with schizophrenia [107-110]. Accordingly, cannabis use is often a major 
concern in the treatment of these patients and has been targeted by intervention 
strategies, albeit with little success [111, 112]. Yet, our understanding of patterns of 
initiation and continuation of use in at-risk populations and patients with established 
psychotic disorder is limited [113]. Self-reported reasons for cannabis use in patients 
with schizophrenia include enhancement of positive affect, alleviation of negative 
affect and dysphoria as well as avoidance of isolation and getting ‘high’ [114, 115]. 
These reasons similarly seem to apply to healthy controls  [115], and are supported 
by research findings showing that cannabis use is associated with decreased 
negative symptoms in patients with schizophrenia [116]. In addition, evidence from 
Experience Sampling research suggests that cannabis use indeed increases positive 
affect and decreases negative affect in individuals with schizotypal traits [117]. 
Recently, Henquet and colleagues [118] investigated reactivity to cannabis use in 
daily life in patients with schizophrenia and healthy controls. In line with previous 
research, the study revealed a mood-enhancing effect of cannabis in both groups. 
Yet, the effect was greater in the patient group, suggesting that patients with 
schizophrenia were more sensitive to the positive effects of cannabis on mood. In 
addition, cannabis use was followed by an increase in hallucinatory experiences in 
patients only, which is in line with experimental research showing increased 
vulnerability to the acute psychotogenic effects of THC in patients with schizophrenia 
[93]. Furthermore it was demonstrated that the mood-enhancing effects occurred 
acutely, while the effect on hallucinations emerged only sub-acutely [118]. The 
temporal dissociation of cannabis effects in daily life might help to explain why 
patients continue to use: Cannabis use might be mostly associated with its positive 
effects while its negative psychosis-inducing effects are obscured. On the contrary, 
Dekker and colleagues recently demonstrated that, both implicitly and explicitly, 
patients tend to have negative associations with cannabis use [119].  
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Recently it has been suggested for the first time that patients with psychotic disorder 
experience higher levels of craving compared to healthy controls, independent of 
frequency of cannabis use [120]. Yet, this study did not control for the effects of 
antipsychotic medication and there is evidence that craving is associated with type 
of antipsychotic treatment [121]. Still, increased craving might be particularly 
instrumental for continuation of use in individuals with psychotic disorder. Increasing 
our understanding of patterns of cannabis use in such vulnerable populations is thus 
of great clinical relevance, in particular for the development of new and effective 
treatment strategies.  
 
Aims of this thesis  
 
Taken together, (genetic) epidemiological as well as experimental research has 
identified cannabis use as a component cause of psychotic disorder. Yet, issues such 
as reverse causality, differential sensitivity and environment-environment interaction, 
as well as the biological basis of the cannabis-psychosis relationship remain in need 
for further investigation. The research presented in this thesis aimed at shedding light 
on these matters by combining epidemiological (chapters 2, 3 and 4), observational 
(chapter 8) and experimental imaging research techniques (chapter 7) to elucidate 
both epidemiological and biological mechanisms by which exposure to cannabis 
increases the risk of psychotic disorder:  
 
In order to clarify the temporal association, including the issue of reverse causality, 
between cannabis use and the development of psychotic symptoms and to shed light 
on possible mechanisms underlying this association, chapter 2 tests the hypothesis 
that adolescent cannabis use increases risk for psychotic outcomes by impacting on 
incidence and persistence of sub-clinical psychotic experiences in the general 
population.  
 
The link between cannabis use and psychotic outcomes can best be understood in 
terms of gene-environment and environment-environment interactions. However, little 
is known about the moderating role of other environmental risk factors. Therefore, 
chapters 3 and 4 investigate possible environmental determinants of differential 
sensitivity to the long-term psychosis-inducing effects of cannabis, in particular 
urbanicity and trauma.  
 
The neurotransmitter dopamine plays an important role in the pathophysiology of 
psychosis and interacts with the endocannabinoid system. Both systems might be 
involved in the psychosis-inducing effects of cannabis. Therefore, in chapters 5 and 6, 
evidence for the involvement of the dopamine system in the pathophysiology of 
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psychosis is reviewed and the interaction between the dopamine and the 
endocannabinoid system is discussed, presenting possible biological mechanisms by 
which cannabis might increase psychosis risk. In line with these considerations, we 
subsequently test the hypothesis that the use of cannabis increases psychosis risk 
partly by inducing striatal dopamine release (chapter 7).  
 
In order to shed further light on patterns and mechanisms of cannabis use in 
psychosis, chapter 8 applied the Experience Sampling Method to elucidate the role 
of craving and its association with continuation of use in the daily lives of patients 
with psychotic disorder and healthy controls.  
 
Finally, chapter 9 discusses cannabidiol, another constituent of cannabis, as a 
potential antipsychotic agent and emphasizes the need to take into account 
differences in potency when investigating the effects of cannabis in future studies.  
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Abstract 
 
Objective To test the hypothesis that adolescent cannabis use increases risk for 
psychotic outcomes by impacting on incidence and persistence of sub-threshold 
expression of psychosis in the general population.  
Design Analysis of data from a prospective population-based cohort study in 
Germany (Early Developmental Stages of Psychopathology study).  
Participants 1923 individuals from the general population (aged 14-24 years at 
baseline).  
Main outcome measure Incidence and persistence of sub-threshold psychotic 
symptoms following adolescent cannabis use. Cannabis use and psychotic symptoms 
were assessed three times (baseline, T2, T3) over a 10-year follow-up period using 
the Munich version of the Composite International Diagnostic Interview (M-CIDI). 
Results In individuals who were negative for lifetime psychotic symptoms and 
lifetime cannabis use at baseline, incident cannabis use over the baseline-T2 period 
increased the risk of later incident psychotic symptoms over the T2-T3 period 
(adjusted odds ratio 1.85, 95% confidence interval 1.10 to 3.13, P = 0.021). 
Furthermore, continued use of cannabis increased the risk of persistence of psychotic 
symptoms over the T2-T3 period (adjusted odds ratio 2.20, 95% confidence interval 
1.16 to 4.17, P = 0.016). The incidence rate of psychotic symptoms over the 
baseline-T2 period was 31% in exposed versus 20% in non-exposed individuals; 
over the period T2-T3 these rates were 14% and 8%, respectively. 
Conclusion Cannabis use is a risk factor for the development of incident psychotic 
symptoms. Furthermore, the data suggest that continued cannabis use increases the 
risk for psychotic disorder by impacting on the persistence of psychotic symptoms. 
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Introduction 
 
Cannabis is the most frequently used illicit drug in the world, particularly in 
adolescents [1, 2]. The use of cannabis is consistently associated with mental illness 
[3], in particular psychotic disorder [4-9]. It remains a matter of debate, however, 
whether the association between cannabis and psychosis is causal, or whether early 
psychotic experiences may in fact prompt cannabis use as a means of self-
medication [10, 11]. This issue can only be resolved if incident cannabis use is 
investigated in relation to later incident psychotic symptoms or disorder. Rarely have 
studies been able to examine the longitudinal relationship between cannabis use 
and psychosis in this fashion. 
  
The issue of self-medication was addressed by Henquet and colleagues [6], using 
data from the German prospective EDSP cohort study [12, 13]. The authors 
investigated the association between cannabis use at baseline and subsequent 
development of psychotic symptoms at four-year follow-up, and reported that after 
adjustment for pre-existing psychotic symptoms, cannabis use at baseline still 
remained significantly associated with psychotic symptoms at four-year follow-up. 
There was no evidence for self-medication effects, as pre-existing psychotic 
symptoms did not significantly predict later cannabis use [6]. Ferdinand and co-
workers [11] investigated the role of pre-existing self-reported psychotic symptoms 
and demonstrated a bi-directional association between cannabis and psychotic 
symptoms over a 14-year follow-up study in the general population. The authors 
showed that cannabis use predicted later psychotic symptoms in individuals with no 
evidence of psychotic symptoms prior to onset of cannabis use and that the reverse 
was also true, in that psychotic symptoms predicted cannabis use in those who were 
cannabis naïve prior to onset of psychotic symptoms [11]. Evidence for a self-
medication effect was also demonstrated in a prospective population-based cohort 
study [14], in which it was found that individuals with self-reported hallucinations at 
the age of 14 years had a higher risk of using cannabis on a daily basis at 21-
years. However, in a sibling pair analysis, this study also suggested an independent 
effect of cannabis use on self-reported delusional ideation later in life [14]. Thus, 
although the cannabis-psychosis link has been investigated in many studies, results on 
the temporal association between cannabis use and psychotic symptoms remain 
conflicting. Longitudinal cohort studies with multiple, repeated, interview-based 
measures of cannabis use and psychotic symptoms are needed to clarify this issue. 
The EDSP study [12, 13], which completed its recent 10-year follow-up, representing 
the fourth assessment (assessments at baseline, T1, T2 and T3, see also figure 1) is 
uniquely suitable for the renewed investigation of the temporal association between 
cannabis and psychosis.  
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Another issue regards the mechanism by which cannabis may increase risk for 
psychotic symptoms, particularly the question whether cannabis may increase the risk 
for psychotic disorder by causing persistence of normally transitory developmental 
expression of psychotic experiences. For most individuals, sub-threshold psychotic 
phenomena are of a transitory nature and never progress to psychotic illness [15]. 
However, it has been shown that sub-threshold psychotic experiences may become 
abnormally persistent, depending on the degree of additional exposure to 
environmental risk factors [16-18], and that progressively greater levels of 
persistence are associated with greater risk for transition to clinical psychotic 
disorder [19]. Spauwen and colleagues [16] showed that the persistence rate of 
psychotic experiences was much higher for individuals growing up in an urban 
environment compared to those growing up in a rural environment [16]. Similarly, 
Cougnard and co-workers [17] provided evidence that childhood trauma, urbanicity 
and cannabis act additively in increasing the risk of persistence of psychotic 
experiences [17]. The fact that cannabis use increases psychosis risk in a dose-
response fashion [6, 14, 20] and the finding that psychotic patients with continued 
cannabis use show more severe and persistent symptoms [21] suggests that cannabis 
use may increase the risk for psychotic illness by impacting on the persistence rate of 
psychotic experiences that under normal circumstances (i.e. without exposure to 
cannabis) would have remained transitory phenomena for the majority of 
individuals.  
 
The aim of the present study, therefore, was to investigate, in a population-based 
10-year follow-up cohort study of adolescents and young adults, the association 
between incident cannabis use and (i) true incidence of psychotic experiences (i.e. 
after exclusion of individuals with lifetime pre-existing psychotic experiences), and 
(ii) risk of persistence of psychotic experiences.  
 
Method                         
Sample and study design 
The observation frame was part of the Early Developmental Stages of 
Psychopathology (EDSP) study, which collected data on the prevalence, incidence, 
risk factors, comorbidity, and course of mental disorders in a random, representative 
population sample of adolescents and young adults in the general population [12, 
13]. The baseline sample, following ethics committee approval, was randomly 
drawn, in 1994, from the respective population registry offices of Munich and its 29 
counties, to mirror the distribution of individuals expected to be 14–24 years of age 
at the time of the baseline interview in 1995. The base population were all those 
born between June 1, 1970, and May 31, 1981, registered as residents in these 
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localities and having German citizenship. These registers can be regarded as highly 
accurate because (1) each German is registered by his town, (2) they are regularly 
updated, (3) in the interest of scientific studies, any number of randomly drawn 
addresses with a given sex and age-group can be obtained, and (4) strict 
enforcement of registration by law and the police applies. More details on the 
sampling, representativeness, instruments, procedures, and statistical methods of the 
EDSP Study sample have been presented previously [12, 13]. 
 
 
baseline T3T2
3.5 years
8.4 years
Incident cannabis use Incident psychotic experiences 
baseline T3T2
3.5 years
8.4 years
Cannabis continuation Persistence of psychotic 
experiences
A
B
 
 
Figure 1. Study design. 
A. Testing the association between incident cannabis use with onset in the period baseline-T2, and incident 
psychotic symptoms with onset in the period T2-T3, in individuals who were cannabis naïve at baseline and who 
had not reported any psychotic experience at T2 (i.e. no lifetime psychotic experiences by T2). 
B. Testing the association between different cannabis exposure states (the combinations of cannabis use at 
baseline (lifetime) and/or T2 (interval) and persistence of psychotic experiences (i.e. presence of psychotic 
experiences at both T2 (lifetime) and T3 (interval)).  
 
 
The overall design of EDSP is longitudinal and prospective, consisting of a baseline 
and 3 follow-up surveys, covering a time period of on average 1.6 years (baseline–
T1, SD = 0.2), 3.5 years (baseline–T2, SD = 0.3), and 8.4 years (baseline–T3, 
range = 7.3–10.5 y, SD = 0.7). Because the primary goal of the study was to 
examine the incidence and developmental risk factors for psychopathology, the 
younger group (14–15 y), presumed to have the highest incidence density, was 
sampled at twice the rate of persons aged 16–21 years, and the oldest group (22–
24 y) was sampled at half this rate. For the same reason, subjects aged 14–17 
years at baseline were examined at the 4 time points and subjects aged 18–24 
years were assessed only 3 times (baseline, T2, T3). The present study is based on 
the whole cohort assessed at baseline, T2 and T3. For a schematic illustration of the 
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overall design and the current analyses see figure 1. Response rates were 84% at 
T2 and 74% at T3 (Fig. 2).  
 
 
Baseline sample 
N = 3021
T2 (3.5 year follow-up) 
N = 2548 (response rate 84%)
Partial missing 
information in 287 
individuals
T3 (8.4 year follow-up) 
N = 2210 (response rate 73%)
Risk set N = 1923
Loss to follow-up: 338 individuals
Main reason: refusal to participate, failure to 
contact the individual, lack of time
Loss to follow-up: 473 individuals
Main reason: refusal to participate, failure to 
contact the individual, lack of time
 
 
Figure 2. Schematic illustration of response rates and reasons for loss to follow-up. 
 
Instruments 
Participants were assessed using the computerized version of the Munich-Composite 
International Diagnostic Interview (DIA-X/M-CIDI) [22], an updated version of the 
World Health Organization’s CIDI version 1.2. [23]. The DIA-X/M-CIDI is a 
comprehensive, fully standardized diagnostic interview and assesses symptoms, 
syndromes, and diagnoses of various mental disorders in accordance with the 
definitions and criteria of the International Classification of Diseases, Tenth Revision, 
and Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), along 
with information about onset, duration, severity of symptoms, and psychosocial 
impairment. The CIDI has been primarily designed for use in epidemiological studies 
of mental disorders and can also be used for clinical purposes. It is divided into 16 
sections: 1 sociodemographic section, 12 sections assessing 288 symptoms of groups 
of mental disorders (including ‘somatoform and dissociative,’ ‘phobic and other 
anxiety,’ ‘depressive and dysthymic,’ ‘manic and bipolar affective,’ ‘schizophrenia 
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and other psychotic,’ ‘eating,’ ‘dementia and other cognitive,’  ‘posttraumatic stress,’ 
as well as ‘tobacco,’ ‘alcohol,’ and ‘substance-related’ disorders), and 3 final sections 
containing concluding questions, interviewer observations, and interviewer ratings. 
The instrument, designed for use by trained interviewers who are not clinicians, has 
shown high inter-rater [24, 25] and test-retest reliability [22, 26]. However, the 
assessment of psychosis with CIDI by lay interviewers is not considered reliable. 
Therefore, in the EDSP Study, trained clinical interviewers at the level of clinical 
psychologist, who were allowed to probe with follow-up clinical questions, conducted 
the interviews in the respondents’ homes. At baseline, the DIA-X/M-CIDI lifetime 
version was used. At each of the follow-up assessments, participants applied the 
interval version, which covers the period of assessment from the last interview until 
the next. Data on the G section concerning psychosis and its clinical relevance were 
only collected at T2 (lifetime version) and T3 (interval version). Since the assessment 
of substance use was part of the diagnostic interview with the DIA-X/M-CIDI, 
psychologists who did the interviews were not blinded for cannabis use.  
Assessment of psychotic symptoms 
Data on positive psychotic experiences were collected at time T2 (lifetime version) 
and T3 (interval version) using the G-section of the DIA-X/M-CIDI. Since the primary 
objective of the EDSP study was to investigate the early stages of substance abuse 
in adolescents and young adults, data on the occurrence of psychotic symptoms as 
assessed with the G-section were added at T2 (measuring lifetime experience of 
psychotic symptoms) and T3 (measuring interval experience of psychotic symptoms) 
[13]. Conform previous work [6, 19] presence of positive psychotic experiences was 
broadly defined as any rating of ‘present’ on any of the 20 DIAX/M-CIDI core 
psychosis items (G1, G2a, G3–G5, G7–G13, G13b, G14, G17, G18, G20, G20C, 
G21, and G22a), including 14 delusion items, 5 hallucination items, and 1 item on 
passivity phenomena. Items relate to classic psychotic symptoms involving, e.g., 
persecution, thought interference, auditory hallucinations, and passivity phenomena. 
Participants were first invited by the psychologist to read a list of all the psychotic 
experiences and then asked whether they ever experienced such symptoms (list and 
phrasing available upon request). All these psychosis items were rated in 2 ways: 
‘absent’ and ‘present’. Thus, all the psychosis DIA-X/M-CIDI items used in the present 
study were coded in a dichotomous manner without intermediate levels. Psychotic 
symptoms at T2 accordingly referred to lifetime occurrence of minimally one positive 
rating on any psychosis item in the G-section; T3 psychotic symptoms denote interval 
occurrence of minimally one positive rating on any psychosis item in this section. 
Assessment of cannabis use  
Cannabis use was assessed with the L-section of the DIA-X/M-CIDI at all three 
assessments. The question ‘Have you ever used cannabis more than five times’ was 
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used to define cannabis exposure. Consistent with previous work in this sample [6], 
the CIDI cut-off of use of five times or more was used to define cannabis exposure 
(yes versus no). Thus, at baseline, cannabis use was defined as lifetime use of 
cannabis of five times or more (‘baseline cannabis use’, dichotomously defined yes 
versus no). At T2, and similarly at T3, cannabis use was defined as interval use of 
cannabis of five times or more, applied to the intervals of baseline-T2 and T2-T3, 
respectively (‘T2 cannabis use’, ‘T3 cannabis use’, both dichotomously defined yes 
versus no). As assessment of frequency of cannabis use differed between time points 
(i.e. at baseline: ‘How often do you use cannabis on a five point scale ranging from 
less than monthly to almost daily?’; at T2: ‘How many times have you used cannabis 
since the last assessment?’), the frequency variable was not included in the analyses.  
Statistical analyses 
Data were analyzed using STATA, release 10.0 (StataCorp, College Station, TX). 
Associations were expressed as odds ratios from logistic regression models. 
 
All analyses were a priori adjusted for the following fixed and time-varying 
confounding factors: age at baseline (in years), gender (0=female, 1=male), socio-
economic status (lower, middle, upper, other, as assessed at baseline), use of other 
drugs at baseline and T2, childhood trauma (i.e. trauma before the age of 14 years 
as assessed at baseline) [27] and urbanicity [28, 29]. The variable ‘use of other 
drugs’ included psychostimulants, sedatives, opiates, cocaine, phencyclidine and 
psychedelic drugs and refers to CIDI-rated use of 5 times or more (lifetime or 
interval use at baseline and T2 respectively) of any of these drugs, as assessed with 
the L-section of the M-CIDI. ‘Childhood trauma’ refers to experience of any traumatic 
experience during childhood (i.e. before the age of 14 years) as assessed with the 
N-section of the M-CIDI at baseline and was dichotomously defined as ‘present’ 
versus ‘absent’. As demonstrated recently by Fisher and colleagues [30], self-report 
questionnaires constitute a valid method to assess childhood trauma in individuals 
presenting with psychotic features. Urbanicity was assessed at baseline by retrieving 
data on place of residence from the population registry offices of the city and the 
29 counties of Munich, and was defined as either living in the city of Munich (4061 
persons per square mile) or in the rural surroundings (553 persons per square mile) 
at baseline. To examine whether associations between cannabis use and psychotic 
symptoms were independent of other psychiatric diagnoses at baseline, analyses 
were additionally adjusted for any psychiatric diagnosis other than psychosis at 
baseline. A dichotomous variable ‘any psychiatric diagnosis’ (present versus absent) 
was calculated, summarizing main psychiatric diagnoses other than psychosis at 
baseline (i.e. major depressive disorder, hypomania, dysthymic disorder, bipolar 
disorder, panic disorder, obsessive compulsive disorder, posttraumatic stress 
disorder, conversion disorder, somatisation disorder, eating disorders). Sensitivity 
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analyses were conducted to investigate whether attrition occurred at random and to 
assess potential bias introduced by missing data. This was done by multiple 
imputation of missing values using the ICE routine in Stata 11.1. This method imputes 
several alternative versions of the complete dataset using the data that is not 
missing.   
Incident cannabis use and incidence of psychotic symptoms 
Logistic regression analyses were used to investigate the association between 
baseline-T2 incident cannabis use and T2-T3 incident psychosis outcome (Fig. 1a). In 
order to investigate true incidence of psychotic symptoms following cannabis use, 
rather than persistence of pre-existing psychotic experiences, individuals who had 
admitted to lifetime presence of any psychotic symptom at T2 (n = 574, 22.7 %) 
were excluded from the analysis. Similarly, all individuals with cannabis use at 
baseline were excluded, thus only including individuals with de novo cannabis 
exposure between baseline and T2. Reverse causality (i.e. self-medication) was 
investigated by testing the association between baseline-T2 psychosis and T2-T3 
cannabis use in individuals without cannabis use at both baseline and T2. 
Cannabis use and risk of persistence of psychotic symptoms 
A dichotomous ‘persistence’ variable was calculated (‘no persistence’ versus 
‘persistence’), ‘no persistence’ referring to experience of psychotic symptoms either 
never or only once (at T2 or T3), and ‘persistence’ referring to to experience of 
psychotic symptoms at both T2 and T3. In order to investigate whether different 
levels of exposure to cannabis affected persistence of psychotic symptoms 
differentially, a categorical ‘cannabis continuation’ variable (0 = never cannabis 
use; 1= cannabis use at baseline but not at T2; 2 = cannabis use at T2 but not at 
baseline, 3 = cannabis use at both baseline and T2) was calculated. Logistic 
regression analyses were used to investigate the association between cannabis 
continuation and psychosis persistence (Fig. 1b).  
 
Results 
Sample 
A total of 2210 individuals completed the T3 assessment. 287 participants had 
partial missing information on substance use and psychotic symptoms, resulting in a 
final risk set for analysis of 1923 individuals of which 926 (48%) were men (Figure 
2). Mean age was 18.3 years (SD = 3.3 years) at baseline, 21.8 (SD = 3.4 years) 
at T2 and 26.6 (SD = 3.5 years) at T3. Further participant characteristics of the risk 
set are summarized in table 1. 
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Table 1. Participant characteristics per T2 cannabis usage group in the risk set (N = 1923). Figures are 
numbers (percentages organized by column). 
 
 T2 cannabis use no T2 cannabis use 
Gender   
Male 119 (30.3%) 807 (52.7%) 
Female 274 (69.7%) 723 (47.3%) 
Socio-economic status*   
Lower 30 (7.3%) 85 (5.6%) 
Middle 220 (53.8%) 894 (59.2%) 
Upper 137 (33.5%) 524 (34.7%) 
Other 22 (5.4%) 6 (0.4%) 
Urbanicity   
Urban 295 (75.1%) 1050 (68.6%) 
Rural 98 (24.9%) 480 (31.4%) 
Childhood trauma   
Present 97 (24.7%) 266 (17.4%) 
Absent 296 (75.3%) 1264 (82.6%) 
Use of other drugs 
baseline 
  
Present 25 (6.4%) 11 (0.7%) 
Absent 368 (93.6%) 1519 (99.3%) 
Use of other drugs T2   
Present 40 (10.2%) 3 (0.2%) 
Absent 353 (89.8%) 1527 (99.8%) 
Any psychiatric disorder 
baseline** 
  
Present 76 (19.3%) 180 (11.8%) 
Absent 317 (80.7%) 1350 (88.2%) 
   
Note. Socio-economic status: lower (lower class, lower middle class), middle (middle middle class), upper (higher 
middle class, upper class) other (none of the above or missing). Residence: urban (the city of Munich, 4061 
persons per square mile), rural (the surroundings of Munich, 553 persons per square mile). Childhood trauma: 
any traumatic experience during childhood. Use of other drugs more than five times baseline (lifetime) and T2 
(interval). 
* SES in N=1918 due to missing values of 5 participants. 
** denotes any psychiatric disorder at baseline according to M-CIDI diagnoses other than psychosis. 
 
 
At baseline, 247 participants (12.8%, lifetime use) reported cannabis use. Of those, 
56 participants (22.7%) used cannabis almost every day, 69 (27.9%) reported 
weekly use and 57 (23.1%) used cannabis monthly; 65 participants (26.3%) 
reported cannabis use at a frequency of less than monthly. At T2, 392 participants 
(20.4%, interval use) reported cannabis use. Mean frequency of those who reported 
cannabis use at T2 was 130 times within the baseline-T2 period (minimum 5 and 
maximum 997 times). Psychotic symptoms were reported by 436 participants 
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(22.7%) at T2 (lifetime) and by 231 participants (12.0 %) at T3 (interval). Table 2 
summarises patterns of cannabis use in relation to psychotic symptoms.  
 
 
Table 2. Patterns of cannabis use in relation to psychotic symptoms in N=1923 (columns: numbers of 
participants and percentages*).  
 
 Psychotic symptoms at follow up1 
   Cannabis use2 T2 T3 
 Yes No Yes No 
baseline     
                          
 
Yes
No 
81 (4.2%) 
355 (18.4%) 
166 (8.6%) 
1.321 (68.7%) 
42 (2.2%) 
189 (9.8%) 
205 (10.7%) 
1.487 (77.3%) 
T2     
                                         
 
Yes
No 
126 (6.7%) 
310 (16.1%) 
267 (13.9%) 
1.220 (63.5%) 
69 (3.6%) 
162 (8.4%) 
324 (16.8%) 
1.368 (71.2%) 
 
*Some percentages do not total 100 due to rounding. 
1Any psychotic symptom lifetime (T2) and interval (T3) as assessed with the M-CIDI (G) section.  
2Use of more than 5 times lifetime (baseline) and interval (T2) as assessed with the M-CIDI (L) section.  
 
Incident cannabis use and incidence of psychotic symptoms 
Lifetime cannabis use as assessed at T2 significantly increased the risk of psychotic 
experiences at T3 (adjusted odds ratio = 1.49, 95% confidence interval 1.07 to 
2.07, P = 0.018; tables 3 and 4). After excluding all individuals who had used 
cannabis at baseline and had reported psychotic experiences at T2, incident 
cannabis use over the baseline-T2 period similarly increased the risk for incident 
psychotic experiences between T2 and T3  (adjusted odds ratio = 1.85, 95% 
confidence interval 1.10 to 3.13, P = 0.021). Results were unchanged after 
additional adjustment for any psychiatric diagnosis other than psychosis at baseline 
(adjusted odds ratio = 1.86, 95% confidence interval 1.10 to 3.13, P = 0.020). 
There was no evidence for self-medication effects, as T2 psychotic experiences did 
not predict incident cannabis use between T2 and T3 (adjusted odds ratio = 0.82, 
95% confidence interval 0.57 to 1.17, P = 0.3). 
Cannabis use and persistence of psychotic experiences 
Analyses revealed a significant association between continuation of cannabis use 
and risk of persistence of psychotic experiences (adjusted χ² = 16.22, P = 0.001; 
tables 4 and 5). After adjustment for age, gender, socio-economic status, use of 
other drugs at baseline and T2, childhood trauma and urbanicity, occasional 
cannabis use (cannabis use at either baseline or T2, exposure states 1 and 2) effect 
sizes were attenuated, with statistical significance only for the combination of 
cannabis use at both baseline and T2 (exposure state 3; adjusted odds ratio = 2.20, 
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95% confidence interval 1.16 to 4.17; P = 0.016). Additional adjustment for any 
psychiatric diagnosis other than psychosis at baseline only occasioned a slight 
reduction in the association between cannabis use at both baseline and T2 and the 
risk for persistence of psychotic symptoms (adjusted odds ratio = 1.99, 95% 
confidence interval 1.04 to 3.81, P = 0.037). 
 
 
Table 3. Association between incident cannabis use and incident psychotic experiences (columns: odds ratios 
and 95% confidence intervals; P-values). 
 
 Risk of psychotic experiences at T3 
T2 Cannabis use Unadjusted Adjusted* 
Whole sample 1.8 (1.32 to 2.44; 0.000) 1.49 (1.07 to 2.07; 0.018) 
After exclusion1 2.06 (1.26 to 3.38; 0.004) 1.85 (1.10 to 3.13; 0.021) 
 
*Adjusted for age, gender, socio-economic status, use of other drugs, childhood trauma and urbanicity.  
1 Individuals with baseline cannabis use and pre-existing psychotic symptoms were excluded from the analyses. 
 
 
Table 4. Course of psychotic experiences in relation to level of continued cannabis use (columns: numbers of 
participants and percentages). 
 
 Psychotic experiences at follow-up 
Cannabis continuation1 none at either T2 or T3 at both T2 and T3 
0 1.071 (75%) 303 (21%) 64 (4%) 
1 59 (64%) 25 (27%) 8 (9%) 
2 144 (60%) 75 (32%) 19 (8%) 
3 90 (58%) 48 (31%) 17 (11%) 
 
10 = no use (reference category), 1 = cannabis use at baseline but not at T2, 2 = cannabis use at T2 but not at 
baseline, 3 = cannabis use at baseline and T2 
 
 
Table 5. Association between cannabis exposure states and persistence of psychotic experiences (columns: odds 
ratios and 95% confidence intervals; P-values). 
  
 Risk of persistence of psychotic experiences 
 Cannabis continuation1 Unadjusted Adjusted* 
0 1 1 
1 2.04 (0.95 to 4.40; 0.068) 2.07 (0.92 to 4.66; 0.078) 
2 1.86 (1.09 to 3.17; 0.022) 1.43 (0.82 to 2.49; 0.202) 
3 2.64 (1.51 to 4.64; 0.001) 2.20 (1.16 to 4.17; 0.016) 
 
*Adjusted for age, gender, socio-economic status, use of other drugs baseline and T2, childhood trauma and 
urbanicity.  
10 = no use (reference category), 1 = cannabis use at baseline but not at T2, 2 = cannabis use at T2 but not at 
baseline, 3 = cannabis use at baseline and T2. 
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Missing data  
Imputation of 20 datasets with the ICE routine in Stata 11.1, which imputes multiple 
alternatives based on data that is not missing revealed that the association between 
continued cannabis use and the risk of persistence of psychotic symptoms remained 
significant (adjusted χ² = 16.65, P = 0.001). Again, the strongest association was 
found for exposure state 3 (i.e. cannabis use at both baseline and T2) with an 
adjusted odds ratio of 1.99 (95% confidence interval 1.08 to 3.66, P = 0.028).  
 
Discussion 
 
This 10-year follow up study showed that incident cannabis use significantly 
increased the risk of incident psychotic experiences in individuals. The association 
was independent of age, gender, socio-economic status, use of other drugs, 
urbanicity and childhood trauma; additional adjustment for other psychiatric 
diagnoses similarly did not change the results. There was no evidence for self-
medication effects, since psychotic experiences did not predict later cannabis use. 
The results thus aid in clarifying the temporal association between cannabis use and 
psychotic experiences by systematically addressing the issue of reverse causality, 
given that the long follow-up period allowed all individuals with sensitively assessed 
pre-existing psychotic experiences or pre-existing cannabis use to be excluded. In 
addition, cannabis use was confirmed as an environmental risk factor impacting on 
the risk of persistence of psychotic experiences (Fig. 3).  
 
 
 
 
Figure 3. The cannabis-psychosis-persistence model.  
Person A has “normal” developmental expression of sub-threshold psychotic experiences that are mild and 
transient. Person B has similar expression but longer persistence due to additional environmental exposure 
(here cannabis). Person C has prolonged persistence and subsequent transition to clinical psychotic disorder due 
to repeated environmental exposure, i.e. repeated cannabis use. 
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Cannabis and psychosis: what is the mechanism behind the association? 
The present study investigated the association between cannabis use and psychosis 
risk by analyzing the expression of psychotic experiences. Psychotic experiences 
share many characteristics with clinically relevant psychosis, such as demographic, 
environmental and genetic risks, and are thought to represent a behavioural marker 
for psychosis liability [18, 31, 32]. It has been shown that psychotic experiences are 
a common and generally transitory phenomenon in the general population, that 
nevertheless may become abnormally persistent and progress to clinical psychotic 
disorder if combined with exposure to environmental risks [19, 33, 34]. The current 
study confirmed cannabis as an environmental risk factor, impacting on psychosis risk 
by (i) increasing the risk of incident psychotic experiences, and, if use continues over 
time, (ii) increasing the risk of persistence of psychotic experiences.  
 
The finding that longer exposure to cannabis was associated with greater risk for 
persistence of psychotic experiences is in line with an earlier study showing that 
continued cannabis use over time increases the risk for psychosis in a dose-response 
fashion [5]. This is also in agreement with the hypothesis that a process of 
sensitization may underlie emergence and persistence of psychotic experiences [35] 
as an indicator of liability to psychotic disorder [18, 31]. Sensitization refers to the 
phenomenon that repeated exposure to an (environmental) stressor leads to 
progressively greater responses over time [35-38]. In rats, repeated exposure to 
THC (delta-9-tetrahydrocannabinol, the main psychoactive component of cannabis) 
induces behavioural sensitization: rats pre-treated with increasing doses of THC show 
greater behavioural (locomotor) responses to a THC challenge after a 14-day 
washout period than do THC-naïve rats [39, 40]. However, in humans, direct 
evidence for cannabis sensitization is lacking. Still, since the present study showed 
that the risk of persistence of psychotic experiences increases with longer periods of 
cannabis exposure, it is attractive to hypothesize that a process of sensitization 
underlies the association between cannabis and psychosis [32]. 
Methodological issues 
The results should be interpreted in the light of several limitations. First, information 
on substance use and psychosis outcome was acquired using the DIA-X/M-CIDI, which 
essentially provides self-reported information. However, the interview was 
conducted face-to-face by clinical psychologists who were allowed to follow up with 
clinical questioning in order to ensure systematic and valid assessment of outcomes 
and can therefore be assumed to yield better and more valid results than a self-
report questionnaire. Secondly, the analyses were not directly adjusted for the 
possible confounding effects of a positive family history of psychosis, since this 
information was not available in the EDSP data. However, previous research has 
shown that associations between cannabis use and psychotic symptoms are not 
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reducible to family history of psychosis [41, 42] and that genetic liability for 
psychotic disorder does not predict cannabis use [43]. In addition, individuals with a 
positive family history of psychosis report more positive symptoms than individuals 
without such predisposition [44, 45]. As all individuals with at least one T2 lifetime 
psychotic symptom were excluded from the analysis, the possible confounding effect 
of positive family history for psychosis was indirectly adjusted for to a degree. 
Further, we used a rather broad outcome measure, defined as a minimum of one 
positive rating on a G-section item, representing psychotic experiences rather than 
clinically relevant psychotic disorder. It has been shown however, that psychotic 
experiences show continuity with psychotic disorders such as schizophrenia [18, 46]. 
In addition, given the fact that transient psychotic experiences may, under certain 
circumstances, become abnormally persistent, giving rise to clinical psychotic disorder 
[15, 17, 19], psychotic experiences represent an important phenotype for the 
investigation of mechanisms and pathways by which environmental risk factors such 
as cannabis impact on psychosis risk. A further limitation concerns the use of the G-
section of the DIA-X/M-CIDI. This section was administered at T2 with a view to 
assess lifetime occurrence of symptoms which represents a long period for 
retrospective assessment of psychotic phenomena, possibly resulting in false 
negatives. As participants with T2 lifetime experience of psychotic symptoms were 
excluded from the analyses, underreporting would have resulted in false negatives 
being incorrectly kept in the analyses. It is unlikely however, that underreporting 
would have occurred as a function of cannabis use, which could have resulted in 
biased estimates. In addition, T2 lifetime subclinical psychotic symptoms were 
reported by 23%, which is in keeping with the literature on the estimated 15-28% 
rate of subclinical psychotic symptoms in the general population [47]. Therefore, the 
influence of underreporting is likely limited. Finally, since the time between follow-up 
visits was 4 years on average, selective recall may have influenced the results. 
Spurious findings may have arisen if those with psychotic symptoms had better recall 
of earlier cannabis use. However, given the well-known link between psychosis 
liability and cognitive alterations including impaired memory, any influence of 
selective recall likely would have been conservative rather than anti-conservative.   
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Abstract 
 
Background Cannabis use is considered a component cause of psychotic illness, 
interacting with genetic and other environmental risk factors. Little is known, however, 
about these putative interactions. The present study investigated whether an urban 
environment plays a role in moderating the effects of adolescent cannabis use on 
psychosis risk. 
Methods Prospective data (N= 1923, aged 14-24 years at baseline) from the 
longitudinal population-based German Early Developmental Stages of 
Psychopathology (EDSP) cohort study were analysed. Urbanicity was assessed at 
baseline and defined as living in the city of Munich (4061 individuals per square 
mile) or in the rural surroundings (553 individuals per square mile). Cannabis use and 
psychotic symptoms were assessed three times over a 10-year follow-up period 
using the Munich version of the Composite International Diagnostic Interview (M-CIDI).  
Results Analyses revealed a significant interaction between cannabis and urbanicity 
(10.9% adjusted difference in risk, 95%CI: 3.2-18.6, p = 0.005). The effect of 
cannabis use on follow-up incident psychotic symptoms was much stronger in 
individuals who grew up in an urban environment (adjusted risk difference 6.8%, 
95%CI: 1-12.5, p = 0.021) compared to individuals from rural surroundings 
(adjusted risk difference -4.1%, 95%CI: -9.8-1.6, p = 0.159). The statistical 
interaction was compatible with substantial underlying biological synergism. 
Conclusions Exposure to environmental influences associated with urban upbringing 
may increase vulnerability to the psychotomimetic effects of cannabis use later in 
life. 
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Introduction 
 
Adolescent cannabis use may increase the risk of psychotic disorder [1-3], the first 
stage of which is expressed as abnormal persistence of subclinical psychotic 
symptoms [4, 5]. However, only a minority of cannabis users will eventually develop 
a psychotic disorder and many individuals with psychotic illness have never been 
exposed. Therefore, cannabis use likely constitutes a component cause, co-
depending on other causal influences in shaping risk for psychosis [6]. Little is known, 
however, about the nature of these putative interactions [1, 7, 8].  
 
Using data from the prospective German Early Developmental Stages of 
Psychopathology study [9, 10], Henquet and colleagues [11] showed that individuals 
scoring high on schizotypy had a much higher risk of developing psychotic symptoms 
after cannabis use compared to individuals with low or average schizotypy scores 
[11]. A subsequent study suggested that the moderating effect of schizotypy on the 
psychotomimetic effect of cannabis use may be mediated by genetic risk for 
psychotic disorder [12] with some evidence for specific molecular genetic variation 
[8, 13, 14]. Environmental factors may similarly moderate the long term effects of 
cannabis on psychosis outcomes, as both Houston and colleagues [15] and Harley 
and colleagues [16] reported that individuals who were exposed to trauma early in 
life, compared to those without trauma, had a much higher risk to develop psychotic 
outcomes following adolescent cannabis use. Thus, the risk conveyed by the 
combination of cannabis and trauma was much higher than the sum of the risk posed 
by either factor alone [15, 16].  
 
Other environmental risk factors may also interact with cannabis use. For example, 
there is evidence that cannabis use, childhood trauma and growing up in an urban 
environment independently increase the risk of onset and persistence of psychotic 
symptoms [4] and it has been hypothesized that all three may be associated with the 
same underlying mechanism of behavioural ‘sensitisation’ over time [17-19]. Meta-
analyses suggest that growing up in an urban environment is consistently associated, 
in a dose-response fashion, with increased psychosis risk [20, 21], particularly if 
there is additional evidence of genetic risk [22-24]. The aim of the present study 
was to investigate whether environmental factors associated with urbanicity 
moderate the strength of the cannabis-psychosis relationship. Data from the German 
Early Developmental Stages of Psychopathology (EDSP) study [9, 10] were 
analyzed to investigate interaction between cannabis use and urbanicity on later 
expression of psychotic symptoms in adolescents and young adults. 
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Method 
Sample and study design 
The Early Developmental Stages of Psychopathology (EDSP) study collected data on 
the prevalence, incidence, risk factors, comorbidity, and course of mental disorders in 
a random, representative population sample of adolescents and young adults in the 
general population [9, 10]. The baseline sample, following ethics committee 
approval, was randomly drawn, in 1994, from the respective population registry 
offices of Munich and its 29 counties, to mirror the distribution of individuals 
expected to be 14–24 years of age at the time of the baseline (T0) interview in 
1995. The base population were all those born between June 1, 1970, and May 
31, 1981, registered as residents in these localities and having German citizenship. 
These registers can be regarded as highly accurate because (1) each German is 
registered by his town, (2) they are regularly updated, (3) in the interest of scientific 
studies, any number of randomly drawn addresses with a given sex and age-group 
can be obtained, and (4) strict enforcement of registration by law and the police 
applies. More details on the sampling, representativeness, instruments, procedures, 
and statistical methods of the EDSP Study sample have been presented previously 
[9, 10]. 
 
The overall design of the cohort study is longitudinal and prospective, consisting of a 
baseline (T0) and 3 follow-up surveys, covering a time period of on average 1.6 
years (T0–T1, SD = 0.2), 3.5 years (T0–T2, SD = 0.3), and 8.4 years (T0–T3, range 
= 7.3–10.5 y, SD = 0.7). Because the primary goal of the study was to examine the 
incidence and developmental risk factors for psychopathology, the younger group 
(14–15 y), presumed to have the highest incidence density, was sampled at twice 
the rate of persons aged 16–21 years, and the oldest group (22–24 y) was 
sampled at half this rate. For the same reason, subjects aged 14–17 years at 
baseline were examined at the 4 time points and subjects aged 18–24 years were 
assessed only 3 times (T0, T2, T3). The present study is based on the whole cohort 
assessed at T0, T2 and T3. Response rates were 84% (N=2548) for T2 and 74% 
(N=2210) for T3. 
Instruments 
Participants were assessed using the computerized version of the Munich-Composite 
International Diagnostic Interview (DIA-X/M-CIDI) [25], an updated version of the 
World Health Organization’s CIDI version 1.2 [26]. The DIA-X/M-CIDI is a 
comprehensive, fully standardized diagnostic interview and assesses symptoms, 
syndromes, and diagnoses of various mental disorders in accordance with the 
definitions and criteria of the International Classification of Diseases, Tenth Revision, 
and Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), along 
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with information about onset, duration, severity of symptoms, and psychosocial 
impairment. The CIDI has been primarily designed for use in epidemiological studies 
of mental disorders and can also be used for clinical purposes. It is divided into 16 
sections: 1 sociodemographic section, 12 sections assessing 288 symptoms of groups 
of mental disorders (including ‘somatoform and dissociative,’ ‘phobic and other 
anxiety,’ ‘depressive and dysthymic,’ ‘manic and bipolar affective,’ ‘schizophrenia 
and other psychotic,’ ‘eating,’ ‘dementia and other cognitive,’  ‘posttraumatic stress,’ 
as well as ‘tobacco,’ ‘alcohol,’ and ‘substance-related’ disorders), and 3 final sections 
containing concluding questions, interviewer observations, and interviewer ratings. 
The instrument, designed for use by trained interviewers who are not clinicians, has 
shown high inter-rater [27, 28] and test-retest reliability [25, 29]. However, the 
assessment of psychosis with CIDI by lay interviewers is not considered reliable. 
Therefore, in the EDSP Study, trained and experienced clinical interviewers at the 
level of clinical psychologist, who were allowed to probe with follow-up clinical 
questions, conducted the interviews in the respondents’ homes. At baseline, the DIA-
X/M-CIDI lifetime version was used. At each of the follow-up assessments, 
participants applied the interval version, which covers the period of assessment from 
the last interview until the next. Data on the G section concerning psychosis and its 
clinical relevance were collected at T2 (lifetime version) and T3 (interval version). 
Assessment of psychotic experiences 
Data on positive psychotic experiences were collected at time T2 (lifetime version) 
and T3 (interval version) using the G-section of the DIA-X/M-CIDI. Presence of 
positive psychotic experiences was broadly defined as any rating of ‘present’ on 
any of the 20 DIAX/M-CIDI core psychosis items (G1, G2a, G3–G5, G7–G13, 
G13b, G14, G17, G18, G20, G20C, G21, and G22a), including 14 delusion items, 
5 hallucination items, and 1 item on passivity phenomena. Items relate to classic 
psychotic symptoms involving, e.g., persecution, thought interference, auditory 
hallucinations, and passivity phenomena. Participants were first invited by the 
psychologist to read a list of all the psychotic experiences and then asked whether 
they ever experienced such symptoms. All these psychosis items were rated in 2 
ways: ‘absent’ and ‘present’. Thus, all the psychosis DIA-X/M-CIDI items used in the 
present study were coded in a dichotomous manner without intermediate levels.  
Assessment of urbanicity 
Urbanicity was assessed at baseline and was defined dichotomously as either living 
in the city of Munich (4061 persons per square mile) or in the rural surroundings (553 
persons per square mile) at time of inclusion. Data on living location were derived 
from the population registry offices of the city and the 29 counties of Munich. 
52 DO CANNABIS AND URBANICITY CO-PARTICIPATE IN CAUSING PSYCHOSIS? 
 
 
Assessment of cannabis use  
Cannabis use was assessed with the L-section of the DIA-X/M-CIDI at all three 
assessments. Conform previous analyses [11], cannabis use at T0 was defined as 
lifetime use of cannabis of five times or more (‘T0 cannabis use’) and cannabis use at 
T2 was defined as use of cannabis of five times or more since T0 (‘T2 cannabis use’).  
Statistical analyses 
Data were analyzed using STATA, release 10.0 (StataCorp, College Station, TX). 
Associations are expressed as risk differences (RD) from logistic regression models. 
Cannabis X urbanicity interaction 
To investigate whether the effects of incident cannabis use over the T0-T2 period on 
expression of incident psychotic experiences over the T2-T3 period were moderated 
by the urban environment, interaction between T0-T2 cannabis use and urbanicity 
was calculated under an additive model [22, 23]. This was done as the additive 
interaction can be interpreted in a meaningful way, yielding information on the 
extent to which two causes biologically depend on each other or co-participate in 
disease causation [30]. Thus, we derived from the additive statistical interaction an 
estimate of the amount of biological synergism, as originally described by Darroch 
[30], and since successfully applied to psychiatric research [31-33]. The amount of 
biological synergism in this context can be understood as the proportion of 
individuals exposed to both cannabis use and urbanicity that developed the 
psychosis outcome because of the specific co-participation of these two factors.  If 
this proportion is low, the statistical interaction is of little practical importance as 
most individuals exposed to both cannabis use and urbanicity will have developed 
the outcome because of either cannabis or urbanicity in isolation, not because of 
their synergistic action [30]. How the amount of biological synergism can be 
estimated approximately from the additive statistical interaction has been described 
in detail previously [30, 33]. To ensure prediction of strictly incident psychotic 
symptoms over the T2-T3 follow-up period, all individuals who had reported lifetime 
psychotic experiences at T2 were excluded from the analyses. The interaction 
between T0-T2 cannabis use and urbanicity was calculated using the BINREG 
procedure in STATA yielding RD’s, followed by calculation of the appropriate linear 
combinations from the model with the interaction, using the STATA LINCOM 
command. In addition, in order to check for possible mediation between cannabis 
and urbanicity (in the sense of one factor influencing the occurrence of the other), 
logistic regression analysis was used to test whether urbanicity was associated with 
T0 cannabis use.  
 
All analyses were a priori adjusted for the following confounding risk factors: age 
(in years), sex (0=female, 1=male), socio-economic status (lower, middle, upper, 
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other), cannabis use at baseline (to control for possible mediating effects between 
urbanicity and cannabis use), use of other drugs and childhood trauma [34]. Use of 
‘other drugs’ included psychostimulants, sedatives, opiates, cocaine, phencyclidine 
and psychedelic drugs and refers to use of 5 times or more of any of these drugs, as 
assessed with the L-section of the M-CIDI. Conform previous analyses in this sample 
[35], ‘Childhood trauma’ was defined as lifetime experience of any traumatic 
experience during childhood as assessed with the N-section of the M-CIDI, 
dichotomously defined as ‘present’ versus ‘absent’. 
 
Results 
Sample 
A total of 2210 individuals completed the T3 assessment (response rate 74.0%). 
Two-hundred-ninety participants had partial missing information on substance use 
and psychotic symptoms, resulting in a final risk set for analysis of 1923 individuals 
of which 926 (48.2%) were men. Mean age was 18.3 years (SD = 3.3 years) at T0, 
21.8 (SD = 3.4 years) at T2 and 26.6 (SD = 3.5 years) at T3. Participant 
characteristics of the risk set are summarized in table 1.  
At T0, 247 participants (12.8%) reported lifetime cannabis use. At T2, 392 
participants (20.4%) reported using cannabis over the T0-T2 interval and 381 
individuals (27.1%) reported T2-T3 interval cannabis use at T3. Psychotic symptoms 
were reported by 436 participants (22.7% - lifetime) at T2 and by 231 
participants (12.0 % - interval) at T3. At the time of inclusion, 1.345 (69.9%) 
participants were registered as living in the city of Munich; 578 participants (30.1%) 
were registered as living in the rural surroundings.  
Main effects of cannabis and urbanicity 
In individuals with no history of psychotic symptoms, cannabis use over the T0-T2 
period was significantly associated with incident psychotic symptoms over the T2-T3 
period (unadjusted OR = 1.77, 95%CI: 1.16-2.70, p = 0.008). After adjustment for 
age, sex, socio-economic status, cannabis use at baseline, childhood trauma and use 
of other drugs, the strength of the association was reduced somewhat (adjusted OR 
= 1.59, 95%CI: 0.98-2.60, p = 0.061). There was no significant association 
between urbanicity and incident psychotic symptoms over the T2-T3 period (adjusted 
OR = 1.16, 95%CI: 0.77-1.76, p = 0.497). 
Interaction between cannabis and urbanicity 
Analysis revealed a significant interaction between T0-T2 cannabis use and 
urbanicity (test for additive interaction: 10.9% adjusted difference in risk, 95%CI: 
3.2-18.6, p = 0.005, table 2). The association between T0-T2 cannabis use and T2-
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T3 psychosis was much stronger for individuals from an urban environment (adjusted 
RD 6.8%, 95%CI: 1-12.5, p = 0.021, table 2) compared to individuals from rural 
surroundings (adjusted RD -4.1%, 95%CI: -9.8-1.6, p = 0.159, table 2). 
 
Further analyses revealed that biological synergism was between 51% and 66%, 
i.e. of all the individuals in the risk set exposed to both urbanicity and cannabis, the 
majority had developed the psychosis outcome because of the specific synergistic 
effect of the two, assuming causality. There was a small but significant positive 
association between urbanicity and T0 cannabis use (adjusted OR = 1.40, 95%CI: 
1.02-1.98, p = 0.038).  
 
 
Table 1. Participant characteristics of the risk set (N = 1923). 
 n % 
Gender   
Male 926 48.2 
Female 997 51.8 
Socio-economic status   
Lower 115 6 
Middle 1114 58 
Upper 661 34.4 
Other 33 1.7 
Urbanicity   
Urban 1345 69.9 
Rural 578 30.1 
Childhood trauma   
Yes 363 18.9 
No 1560 81.1 
Cannabis use (T0)   
Yes 247 12.8 
No 1676 87.2 
Use of other drugs (T0)   
Yes 36 1.9 
No 1887 89.1 
Note. Socio-economic status: lower (lower class, lower middle class), middle (middle middle class), upper (higher 
middle class, upper class) other (none of the above or missing). Urbanicity: urban (the city of Munich, 4061 
persons per square mile), rural (the surroundings of Munich, 553 persons per square mile). Cannabis use/Use of 
other drugs: Any use of more than five times. Childhood trauma: Any traumatic experience during childhood.  
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Discussion 
There was evidence that urbanicity may moderate the long-term effects of cannabis 
on psychosis: adolescents who grew up in the city of Munich were much more likely to 
develop psychotic symptoms after cannabis use than individuals who grew up in the 
rural surroundings of Munich. This interaction effect was independent of confounding 
factors such as age, gender, socio-economic status, use of other drugs and childhood 
trauma and was not irrelevant, as the majority of those exposed to both urbanicity 
and cannabis developed the psychosis outcome because of their co-action. There 
was also some evidence that this interaction could be interpreted in the sense of 
mediation (urbanicity leading to cannabis use leading to psychosis), as a small but 
significant association existed between urbanicity and cannabis use.    
Cannabis and urbanicity: moderation and possible mechanisms 
The present study identified urbanicity as one of the factors that may moderate the 
association between cannabis and psychosis. Previously, a similar interaction was 
reported between cannabis and developmental trauma, another environmental 
exposure associated with psychotic outcomes [15, 16]. Given evidence that cannabis, 
trauma, and urbanicity do not reflect the same environmental influence in the 
association with psychotic outcomes [4], the current analyses, in combination with the 
findings on similar moderation by developmental trauma [15, 16], suggest that they 
do share the same interactive pathway. A mechanism of developmental sensitization 
has been suggested to underlie this pathway [17].   
 
Epidemiological evidence indicates that although developmental expression of 
subclinical psychotic experiences in adolescence is mostly transient, repeated 
exposure to environmental risk factors causes subclinical psychotic experiences to 
persist and become more severe, resulting in onset of psychotic illness in a minority of 
individuals [4, 36, 37]. Urbanicity represents a complex proxy environmental 
influence, and the mechanism of its impact on psychosis remains largely unknown. The 
effect does not appear to be mediated by demographic factors, obstetric 
complications, childhood socio-economic position, neuropsychological impairment, air 
pollution, drug use or ethnic group, and there is evidence that exposure between the 
ages of 5-15 years is associated with the greatest effect [20, 21, 38], suggesting 
mediation by factors impacting during development. One study showed that an 
urban environment induced anxiety, negative feelings towards other people and 
reasoning biases associated with delusional ideation [39]. Allardyce and colleagues 
[40] showed that social fragmentation as well as deprivation had a significant effect 
on first psychosis admission rates independently of urbanicity, and that the effect of 
urbanicity on first psychosis admission rates disappeared after statistical adjustment 
for social fragmentation and deprivation [40]. Similarly, there is evidence that risk 
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for psychotic syndrome associated with indicators of social maladjustment, for 
example single parent family, single marital status and residential instability, 
similarly varies with the degree to which this represents the exception in relation to 
the wider social environment [41, 42]. This type of interaction between individual-
level and area-level social “fragmentation” may mediate the effect of the urban 
environment [41].  
 
The absence of an association between urban environment and incident psychotic 
symptoms in the current study is in line with previous research [43]. The likely 
explanation is that the time window of exposure to urban environment in relation to 
risk for psychosis outcomes is from 5-15 years [44]. Individuals with lifetime psychotic 
symptoms, assessed at baseline, that previous work in this sample showed were 
associated with urban environment [45], were excluded from the analyses. Later 
onset ‘incident’ psychotic symptoms could not be traced directly anymore to earlier 
exposure to the urban environment, although an indirect effect was still apparent, 
through moderation of sensitivity to the psychotomimetic effects of cannabis. It may 
be hypothesized that early exposure, i.e. between the ages of 5-15 years, to 
increased social fragmentation associated with an urban environment may constitute 
an environmental stressor that, through epigenetic mechanisms, leads to permanent 
neurodevelopmental alterations, which in turn result may contribute to enhanced 
sensitivity to the psychotomimetic effects of cannabis later in life. 
Cannabis and urbanicity: Moderation or mediation? 
In the present study, a small but significant association was found between urbanicity 
and cannabis use: Individuals living in the urban environment were more likely to use 
cannabis at baseline than individuals from the rural area. This finding indicates that 
the interaction between cannabis use and urbanicity may represent not only an 
underlying mechanism of moderation (the psychotomimetic effect of cannabis is 
larger in urban areas) but also of mediation (living in the city may enhance cannabis 
use). Both mechanisms would be important form a public health perspective. 
Cannabis X urbanicity: What it does and what it does not tell us? 
One of the limitations of epidemiological research concerns the inability to make 
inferences about underlying molecular mechanisms. Therefore, our findings are not 
informative with regard to molecular mechanisms such as developmental 
sensitization. However, when epidemiological research is followed by targeted 
experimental animal and human research, it may constitute the first step in a chain of 
research efforts to uncover the biological mechanisms of environment-environment or 
gene-environment interaction [7]. Thus, the fact that the majority of those exposed to 
both cannabis and urbanicity developed the psychosis outcome because of a specific 
mechanism of co-participation between these two factors suggests the finding 
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constitutes an important starting point requiring follow-up experimental research 
targeting a final common pathway that both factors may impact on. 
 
The interest of epidemiological findings like these lies in the area of public health 
and disease causation. As shown by Darroch [30], evidence of non-additivity 
represents a way to estimate the population amounts of biological synergism (the 
population exposed to both risk factors that developed the outcome because of the 
specific co-participation between the two factors) and biological parallelism (the 
population exposed to both risk factors that developed the outcome because of the 
action of only one factor). Examination of biological synergism and parallelism is of 
vital interest to epidemiologists and public health, since it allows identification of 
populations that would benefit most from a given intervention: If synergism is large, 
public health gains could be obtained by targeting either factor. On the other hand, 
if parallelism is large, public health may gain by targeting both factors. In the 
current study, synergism was between 50-65%, indicating that targeting either 
factor could potentially result in public health gains. 
Limitations/methodological issues 
There are several limitations. First, information on substance use and psychosis 
outcome was acquired using the M-CIDI, which is meant to essentially provide self-
reported information. Nevertheless, the interview was conducted face-to-face by 
clinical psychologists who were allowed to follow up with clinical questioning in order 
to ensure systematic and valid assessment of outcomes and can therefore be 
assumed to yield better and more valid results than a self-report questionnaire.  
 
Secondly, urbanicity was assessed by retrieving data on living location from the 
German registry offices. Although these registers can be considered as highly 
accurate since in Germany registration is obligatory and registries are regularly 
updated, the information is restricted to current living location and therefore does 
not provide information on duration of living at a certain location. Pedersen en 
Mortensen [44] showed that increasing duration of living in urban areas leads to 
increased psychosis risk in a dose-response fashion. Research has furthermore 
suggested that the effect of urbanicity on psychosis risk operates during upbringing 
rather than at birth [44] or around illness onset [46]. Considering the current study, 
even under the hypothetical assumption that participants registered as living in the 
city of Munich had just moved there from the rural surroundings or, the other way 
around, individuals from the rural surroundings had just moved to the city, this would 
have yielded an under-,  rather than an overestimation of the effects size. In 
addition, previous work suggest current urban residence in young people reflects 
urban upbringing in the majority [46]. The paradigm used in the current study was 
based on the notion that psychotic symptoms can be expressed below the threshold 
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of diagnosis and are meaningful in relation to the clinical phenotype. Meta-analytic 
work of sub-diagnostic expression of psychotic experiences in the general 
population has shown aetiological, psychopathological and longitudinal continuity 
between the extended subclinical phenotype and clinical expression of psychotic 
disorder, as well as a similar age-related developmental pattern of expression [47]; 
a recent landmark general population birth cohort study confirmed this pattern of 
findings [48]. Further, since transient and normally expressed psychotic experiences 
may, under certain circumstances, become abnormally persistent and develop into 
clinical psychosis [4, 36, 49], psychotic experiences represent an important 
phenotype for the investigation of mechanisms and pathways by which 
environmental risk factors such as cannabis impact on psychosis risk [5].   
 
Finally, in interpreting the findings of this current study, it was assumed that in this 
area in Germany, cannabis used in the city does not differ from cannabis used in 
rural areas. Although this cannot be formally explored the assumption may be valid, 
since availability of cannabis in Germany is limited in general (compared to 
countries such as the Netherlands, where ‘coffeeshops’ are allowed to sell cannabis 
on a semi-legal basis) and access to cannabis is likely comparable between rural 
and urban areas. 
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Dear Editors, 
 
Cannabis use is considered a component cause of psychotic disorder interacting with 
genetic and environmental risk factors in increasing psychosis risk [1]. Recently, two 
cross-sectional and one prospective study provided evidence that cannabis use 
interacts additively with trauma to increase psychosis risk [2-4]. In an attempt at 
further replication, we examined prospective data from the German Early 
Developmental Stages of Psychopathology (EDSP) study [5, 6].  
 
The EDSP study collected data on the prevalence, incidence, risk factors, 
comorbidity, and course of mental disorders in a random, representative population 
sample of adolescents and young adults in the general population [5, 6]. Individuals 
were assessed three times (at T0, T2, and T3) over a 10-year follow-up period. 
More details on the sampling, representativeness, instruments, procedures, and 
statistical methods of the EDSP Study sample have been presented elsewhere [5, 6]. 
Data on psychotic symptoms, cannabis use and trauma were acquired with the 
computerized version of the Munich-Composite International Diagnostic Interview 
(DIA-X/M-CIDI) [7], an updated version of the World Health Organization’s CIDI 
version 1.2 [8]. At T0, the DIA-X/M-CIDI lifetime version was used. At each of the 
follow-up assessments, participants applied the interval version, covering the period 
of assessment from the last interview until the next. Data on positive psychotic 
symptoms were collected at T2 (lifetime version, representing lifetime experience of 
symptoms) and T3 (interval version, representing symptoms that occurred over the 
T2-T3 period). Presence of positive psychotic experiences was broadly defined as 
any rating of ‘present’ on any of the DIAX/M-CIDI core psychosis items. All items 
were dichotomously rated as ‘absent’ or ‘present’. Cannabis use was assessed at all 
three assessments. Conform previous analyses [9], cannabis use at T0 was defined as 
lifetime use of cannabis of five times or more and cannabis use at T2 was defined as 
use of cannabis of five times or more since T0. Trauma was assessed at T0 and was 
dichotomously defined as having experienced any of the following events at least 
once lifetime: war experiences, physical threats or attacks, rape, sexual abuse, 
natural disasters, serious accidents, kidnapping and hostage-taking, and witnessing 
any of the aforementioned events. 
 
Data were analyzed using STATA, release 11.1 (StataCorp, College Station, TX). 
Associations were expressed as odds ratios (OR) derived from logistic regression 
models. Interaction between T2 cannabis use and trauma was calculated under an 
additive model [10], using the BINREG procedure in STATA yielding risk differences 
(RD), followed by calculation of the appropriate linear combinations from the model 
with the interaction, using the STATA LINCOM command. To ensure prediction of 
strictly incident psychotic symptoms over the T2-T3 follow-up period, all individuals 
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who had reported lifetime psychotic experiences at T2 were excluded from the 
analyses. Analyses were adjusted for the following confounding risk factors: age (in 
years), sex (0=female, 1=male), socio-economic status (lower, middle, upper, other), 
cannabis use at baseline, use of other drugs at baseline  
(including psychostimulants, sedatives, opiates, cocaine, phencyclidine and 
psychedelic drugs), and urbanicity, defined dichotomously as living in the city of 
Munich (‘urban’, 4061 persons per square mile) or in the rural surroundings (‘rural’, 
553 persons per square mile) at the time of inclusion.  
 
We analyzed data of 1923 individuals of which 926 (48.2%) were men. Mean age 
was 18.3 years (SD = 3.3 years) at T0, 21.8 (SD = 3.4 years) at T2 and 26.6 (SD 
= 3.5 years) at T3. There was no evidence that trauma moderated the association 
between T2 cannabis use and incident psychotic symptoms over the T2-T3 period 
(see table 1 for statistics). The interaction remained small and non-significant when 
examining a more stringent outcome criterion, defined as having experienced at 
least two psychotic symptoms, and when examining the influence of having been 
exposed to at least two or three traumatic events, respectively. In order to strictly 
predict incident psychotic symptoms over the T2-T3 period, the above described 
analyses excluded all individuals with lifetime pre-existing psychotic symptoms as 
assessed at T2. Accordingly, the remaining group of subjects exclusively consisted of 
individuals who had not developed any psychotic symptoms by the time of the T2 
assessment, possibly constituting a relatively resilient subgroup. However, the 
interaction remained non-significant also when analyzing the whole cohort (-1.3% 
adjusted difference in risk, 95% CI: -11.1- 8.4, p = 0.782).  
 
Opposed to what was hypothesized and in contrast to previous findings [2-4], the 
current analyses did not provide evidence for interaction between cannabis use and 
trauma in increasing psychosis risk. This may be due to sampling variation, or 
alternatively, the relatively long follow-up between T2 and T3 was insensitive to this 
type of analysis. More work in the area of environment-environment interactions in 
predicting psychosis is necessary. 
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Abstract 
 
Schizophrenia has long been associated with an imbalance in dopamine (DA) 
neurotransmission, and brain imaging has played an important role in advancing our 
knowledge and providing evidence for the dopaminergic abnormalities. This chapter 
reviews the evidence for DA dysfunction in different brain regions in schizophrenia, 
in particular striatal, extrastriatal and prefrontal regions, with emphasis on recently 
published findings. As opposed to the traditional view that most striatal 
dopaminergic excess, associated with the positive symptoms of schizophrenia, 
involves the dopaminergic mesolimbic pathway, recent evidence points to the 
nigrostriatal pathway as the area of highest dysregulation. Furthermore, evidence 
from translational research suggests that dopaminergic excess may be present in the 
prodromal phase, and may by itself, as suggested by the phenotype observed in 
transgenic mouse with developmental overexpression of dorso-striatal D2 receptors, 
be an early pathogenic condition, leading to irreversible cortical dysfunction.  
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Introduction 
 
The psychotomimetic effects of stimulant drugs, in combination with the observed 
antipsychotic effects of D2-blocking drugs, gave rise to the initial dopamine (DA) 
hypothesis of schizophrenia [1-3]. Refined and modified in the intervening years, this 
theory to date remains central to the pathophysiology of schizophrenia [4-6].   
 
Based on the observation that DA-enhancing drugs such as amphetamine show 
psychotomimetic properties while the effectiveness of classic antipsychotic 
medication, blocking DA D2 receptors, had been shown to directly correlate with its 
affinity for the D2 receptor [7], the dopamine hypothesis initially assumed a general 
dopaminergic hyperfunction [1, 2]. However, subsequent findings, including reduced 
cerebral blood flow in the prefrontal cortex (PFC) of patients with schizophrenia and 
the observation that negative symptoms such as flattened affect, anhedonia and 
compromised cognitive function did not respond to classic antipsychotic treatment 
targeting D2 receptors, were incompatible with a generally overactive DA system. 
Accordingly, the dopamine hypothesis was reformulated as an imbalance in DA 
neurotransmission in different regions of the brain, characterized in particular by 
hyperactivity in the subcortical DA pathway and hypoactivity in the cortical DA 
system [8-10]. It was also suggested that DA hyperactivity in subcortical brain 
regions, in particular striatal areas, accounted primarily for the positive symptoms of 
schizophrenia, while the negative symptoms were mostly associated with DA 
hypoactivity in cortical areas, particularly PFC [11].  
 
In this chapter, we present the history as well as the latest research findings relating 
to dopamine dysfunction in schizophrenia.  The two main new findings that will be 
emphasized here are the following: Unlike the traditional thinking that most 
dopaminergic excess causing positive symptoms involves the dopaminergic 
mesolimbic pathway, recent evidence points to the nigrostriatal pathway, projecting 
to the anterior caudate, part of the associative striatum, as the area of highest 
dysregulation.  Furthermore, as opposed to the thinking that dopamine is a final 
common pathway, recent evidence from translational research suggests that 
dopamine dysregulation may be an early pathogenic mechanism that leads to 
further dysregulation of brain function.  We will review the evidence and outline 
future research needed to understand the molecular mechanisms and develop better 
therapeutic interventions. 
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Evidence for DA dysfunction in schizophrenia  
 
Direct empirical evidence for DA alterations in schizophrenia was initially elusive. 
Postmortem studies were difficult to interpret due to the possible confounding by 
prior neuroleptic exposure and the first imaging studies using Positron Emission 
Tomography (PET) and Single Photon Emission Tomography (SPECT) produced 
inconsistent findings. Advances in PET and SPECT imaging techniques, such as the 
development of new, high affinity radiotracers, made it possible to study DA 
neurotransmission in several regions of the brain, including striatal, extrastriatal and 
prefrontal cortical regions with more anatomical detail than previously possible. 
Striatal DA alterations 
Using PET and SPECT imaging techniques, different paradigms have been employed 
in order to study aspects of presynaptic and postsynaptic striatal DA alterations in 
schizophrenia. These include markers of DA synthesis, release and reuptake, as well 
as DA receptor availability and differences in receptor affinity states [12-14].  
Presynaptic DAergic parameters  
Dopamine synthesis. DA is synthesized by hydroxylation of the precursor tyrosine to 
L-DOPA, which then is decarboxylated to DA by aromatic acid decarboxylase 
(AADC). Radioactive analogues of L-DOPA, such as [11C]L-DOPA and [18F]DOPA, 
have been used to estimate enzymatic activity of AADC, as an indicator of DA 
synthesis capacity [15-18]. However, this is overly simplified and other factors may 
affect the overall signal measured with [11C]L-DOPA and [18F]DOPA, including 
delivery of [11C]L-DOPA and [18F]DOPA to the brain, crossing the plasma 
membrane, storage in presynaptic vesicles as a result of VMAT activity, release of 
[11C]L-DOPA and [18F]DOPA, and degradation, all may play a role in addition to 
the activity of DOPA decarboxylase. Better knowledge of these mechanisms is 
needed to better understand the exact molecular processes underlying [11C]L-DOPA 
and [18F]DOPA uptake and their disturbance in schizophrenia. Nevertheless, a 
number of studies have used radiolabelled L-DOPA, such as [11C]L-DOPA or 
[18F]DOPA in schizophrenia. The first study, by Reith and colleagues [19], revealed 
significantly elevated [18F]DOPA uptake in drug-naïve patients compared to healthy 
controls [19]. While the majority of the following studies using the same technique 
replicated this finding [20-26], two studies failed to find markers of elevated DA 
synthesis capacity: One study reported a small but not significant increase in 
[18F]DOPA uptake [27], while another found decreased levels of [18F]DOPA uptake 
[28]. This discrepancy might be explained by differences in study population: 
Studies reporting positive findings were all conducted in acutely psychotic, mostly 
drug-naïve, patients (with the exception of McGowan and colleagues), while the two 
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studies reporting negative or inverse findings were done in chronic, previously 
medicated, patients. Recently, DA synthesis capacity was investigated in twins 
discordant for schizophrenia. No elevation in striatal DA synthesis was observed in 
the unaffected twin, nor in the low-symptomatic medicated twin with chronic 
schizophrenia when compared to controls, suggesting that increased DA synthesis is 
not a genetic marker for schizophrenia [29].  
 
Dopamine release. The next step in DA transmission is the release of DA from the 
presynaptic terminal. An estimation of DA release from striatal DA neuron terminals 
can be obtained by measuring changes in D2 binding potential after 
pharmacologically induced DA release with SPECT (Single Emission Computed 
Tomography) and PET imaging techniques [30-32]. One of the first studies to 
investigate amphetamine-induced DA release in schizophrenia was conducted by 
Laruelle and colleagues [33], using SPECT and the radiotracer [123I]IBZM, an 
antagonist at D2/3 receptors. Changes in D2/3 binding potential as an estimation 
of amphetamine-induced DA release were measured in 15 medication-free patients 
with schizophrenia and 15 healthy control participants. The decrease in binding 
potential induced by amphetamine was significantly greater in patients with 
schizophrenia compared to controls. Furthermore, the amphetamine-induced 
decrease in D2/3 binding potential was associated with the transient increase in 
positive symptoms induced by amphetamine in the schizophrenia group [33]. The 
results of a subsequent PET study using [11C]raclopride as radiotracer were in line 
with these observations [34]: The schizophrenia group showed greater 
amphetamine-induced decreases in [11C]raclopride binding compared to controls, 
indicative of greater amphetamine-induced DA release. Furthermore, the study did 
not find differences in amphetamine effects on [11C]raclopride binding between 
medication-free (N=5) and medication-naïve (N=6) patients with schizophrenia, 
indicating that the effect occurs independent of earlier treatment with neuroleptics. 
Abi-Dargham and colleagues [35] have since then replicated these findings. 
Furthermore, it was shown that changes in amphetamine-induced dopamine release 
in schizophrenia might be associated with illness phase, as amphetamine-induced 
transient worsening of psychotic symptoms correlated with changes in [11C]raclopride 
binding in patients with schizophrenia and no difference in [11C]raclopride binding 
was seen in patients in remission compared to controls [36]. The amphetamine 
paradigm shows stimulated release, as amphetamine increases dopamine levels by 
reversing DAT.  Another aspect of DA transmission is uncovered with depletion 
paradigms: The administration of alpha-methyl-para-tyrosine (αMPT), a reversible 
competitive inhibitor of tyrosine hydroxylase, causes acute depletion of endogenous 
DA and can be used as a method to assess the degree of baseline (non-stimulated) 
intrasynaptic DA activity [37], most likely reflecting basal release as a result of 
neuronal firing. Abi-Dargham and colleagues [38] used this technique in combination 
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with SPECT and [123I]IBZM in 18 untreated patients with schizophrenia and 18 
matched control participants before and after αMPT-induced DA depletion. 
Exposure to αMPT led to increased D2 receptor availability in both patients with 
schizophrenia and healthy controls, however, the effect was larger in schizophrenia 
patients, indicative of higher baseline DA activity in this group. The magnitude of the 
effect did not differ between medication-naïve patients with schizophrenia and 
those, previously treated with antipsychotics [38]. Similar results were recently 
obtained by Kegeles and colleagues [39], who employed the same depletion 
paradigm in combination with PET and [11C]raclopride [39]. Kegeles and colleagues 
furthermore showed that the largest effect of acute DA depletion on D2 receptor 
binding was observed in the associative striatum and not in limbic striatum as was 
long hypothesized. Recently it was shown that amphetamine-stimulated DA release 
and baseline DA activity are related in patients with schizophrenia but not in controls 
[40]. Pilot data from Canada furthermore suggest that DA release in patients with 
schizophrenia and individuals at high risk compared to healthy controls is also 
increased in response to psychosocial stress [41]. Altogether, studies have 
consistently demonstrated increased amphetamine-stimulated DA release in 
schizophrenia. Depletion studies further suggest that schizophrenia is characterized 
by increased baseline DA activity.  
 
Dopamine reuptake. DA transmission in the striatum is regulated by DA transporters 
(DAT), which are located on the presynaptic membrane of DA terminals and rapidly 
remove DA from the synaptic cleft [42]. Several studies have investigated DAT 
density in schizophrenia, using PET or SPECT, to obtain an index of density of DA 
terminals and striatal innervation [43-54]. The majority of studies did not observe 
differences in DAT availability between neuroleptic-naïve patients with 
schizophrenia and controls [43, 45, 46, 49, 51-53]. Two studies reported reduced 
DAT binding in patients with schizophrenia compared to controls [47, 50]. However, 
since the patients were not medication-naïve, the researchers concluded that the 
observed reduction in DAT binding was secondary to prior treatment with 
neuroleptics. In order to clarify this issue, Mateos and colleagues [48] repeated the 
experiment in a cohort of neuroleptic-naïve patients with schizophrenia and also 
found lower DAT density [48]. Still, this remains the only study, which reported 
decreased DAT binding in schizophrenia. So, taken together the evidence suggests 
that schizophrenia is not associated with changes in DAT density. Recently, two dual-
isotope SPECT studies used [99mTc]TRODAT and [123I]IBZM to simultaneously measure 
DAT and D2 receptor availability in drug-naïve patients with schizophrenia and 
controls [44, 54]. In line with most of the previous findings, no overall differences in 
DAT or D2 receptor availability were observed. However, in patients but not 
controls, DAT density correlated positively with D2 receptor availability [54], which 
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was most pronounced in patients presenting with predominantly positive symptoms 
[44].  
Postsynaptic DAergic parameters 
DA receptor availability. The most extensively studied receptor in schizophrenia is the 
D2 receptor, which is abundantly present in the human striatum. Numerous studies 
have measured the density of striatal D2 receptors in schizophrenia, both in vivo and 
postmortem, and three meta-analyses have reviewed the strength and consistency of 
the reported findings [14, 55, 56]. The first of these meta-analyses was conducted 
by Zakzanis and Hansen [56] and included 17 studies of which 7 were postmortem. 
The results from 511 patients with schizophrenia and 534 controls suggested that, 
although D2 receptor availability was elevated in approximately 70% of the 
patients, increased receptor density failed to discriminate patients from controls and 
is therefore unlikely to represent a general marker of schizophrenia [56]. In line with 
this are the findings of the second meta-analyses, which included 15 in vivo studies 
on D2 receptor density in schizophrenia, and concluded that there was small but 
significant elevation of receptor availability along with greater variability in 
schizophrenia patients compared to controls [14]. The more recent, comprehensive 
meta-analysis by Kestler and colleagues [55] included 20 postmortem studies and 
17 in vivo studies on D2 receptor availability in schizophrenia and took into account 
differences in methodology such as in vivo versus postmortem measures (which are 
likely to be confounded by prior treatment with neuroleptics, which results in 
upregulation of D2 when administered chronically) as well as the possible influence 
of sample characteristics such as age, gender or medication status. The authors 
concluded that the data were compatible with the idea of a subgroup of patients 
with schizophrenia being characterized by elevated D2 density [55]. The results of a 
recent study using the high affinity D2/D3 ligand [18F]fallypride were also in line 
with this, showing selective alterations in D2 density in schizophrenia patients [57]. 
Several lines of research indicate that, in addition to the D2 receptor, the D3 
receptor might play an important role in the pathophysiology of schizophrenia [58-
60]. However, until recently it was not feasible to selectively target D3 receptors 
with neurochemical imaging to obtain a direct measure of D3 in schizophrenia, since 
the available radiotracers exhibited similar affinities for the D2 and D3 receptors 
and therefore could not distinguish between them. Using the D2/3 agonist 
radiotracer [11C]PHNO, which has higher affinity for D3 than for D2, a recent study 
did not reveal differences in receptor occupancy between patients with 
schizophrenia compared to controls [61], although a more selective tracer would be 
needed to replicate this initial finding. Several studies have used ligand subtraction 
methods to measure the distribution of striatal D4 receptors in schizophrenia. 
However, these studies produced inconsistent results, some reporting increased 
availability of D4 [62-65], while others did not find differences in D4 between 
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schizophrenia patients and controls [66-68]. More selective tracers are needed to 
better characterize these receptors. Most (postmortem) studies did not find altered 
levels of D1 receptors in the striatum [69-74], one reported a slight decrease in D1 
density [75]. The results of two in vivo studies of striatal D1 density in schizophrenia 
are in line with the majority of postmortem findings and do not suggest alterations in 
striatal D1 receptor levels in schizophrenia [76, 77]. Taken together, it seems that a 
subgroup of schizophrenia patients is characterized by increased density of D2-like 
(i.e. D2/D3) receptors, independent of age, gender and prior neuroleptic exposure. 
The density of striatal D1 receptors on the other hand seems to be unaltered. No 
conclusive data is available for D4. 
 
Balance in D2 receptor affinity states. Being the primary target of antipsychotic 
medication, the D2 receptor plays a major role in schizophrenia and psychosis [78, 
79], although, as discussed above, its involvement in the pathophysiology of 
psychotic disorders remains unclear [14, 55, 56]. The D2 receptor has been shown to 
exist in two different affinity states: a high affinity, active state (D2high) and a low 
affinity, inert state (D2low) [80, 81]. Preclinical work has shown that radiolabelled DA 
agonists such as (+)-PHNO, which selectively binds to D2/3 receptors in the high-
affinity state, in combination with PET can be used to study the distribution of D2high 
both in-vitro [82] and in-vivo [83, 84]. The distribution of D2high using PET and [11C]-
(+)-PHNO was recently demonstrated also in human volunteers [81, 85]. For 
schizophrenia, it has been suggested that the observed super-sensitivity to DA-
enhancing drugs such as amphetamine is the result of an imbalance in D2 affinity 
states, in particular elevated availability of D2high receptors [86, 87]. However, 
evidence for this primarily stems from animal models of schizophrenia [for a review 
see 86]. Recently, the distribution of D2high was for the first time studied in patients 
with schizophrenia, and contrary to what could be expected from pre-clinical work, 
no elevation in D2high was observed in medication-free patients with schizophrenia 
compared to controls [61]. Although the authors acknowledge that differences in 
D2high between schizophrenia patients and controls could have been masked by 
endogenous DA, to date, there is no evidence for D2high dysregulation in 
schizophrenia.  
Extrastriatal DA alterations 
Several studies have now used high affinity radiotracers such as [18F]fallypride, 
[11C]FLB 457, and [123I]epidepride, to measure the distribution of D2 receptors in 
low-density brain regions such as the thalamus, anterior cingulate cortex, temporal 
cortex or substantia nigra, in unmedicated and medication-naïve patients with 
schizophrenia. Some studies found decreased D2 receptor availability in the 
thalamus [88-92], anterior cingulate cortex [91, 93], temporal cortex [91, 94] and 
midbrain [95], while some found no differences in the thalamus [95], anterior 
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cingulate and temporal cortex [88, 92, 96], and one study found an increase in D2 
receptor availability in schizophrenia in the substantia nigra [92]. A very large 
recent study did not confirm any of the above reported extrastriatal D2 receptor 
alterations in schizophrenia [57]. 
 
Another recent study has used the radiotracer [11C]PE21 in combination with PET to 
visualize thalamic DAT in patients with schizophrenia, who were either medication-
naïve or off medication for at least six months [97]. In contrast to striatal brain 
regions, where DAT seems to be unaffected in schizophrenia, this study reported 
increased DAT binding in the thalamus of patients with schizophrenia compared to 
controls. Another study measured extrastriatal DA synthesis capacity using PET and 
[11C]L-DOPA and found no differences between medication-naïve patients with 
schizophrenia and controls with regard to DA synthesis capacity in the thalamus or 
anterior cingulate and temporal cortex [20], although the ability of this tracer to 
measure extrastriatal dopamine synthesis is questionable [98]. 
Prefrontal cortical DA alterations 
While D2 receptors are abundantly present in striatal regions of the brain, the 
predominant DA receptors in prefrontal cortical regions are of the D1 type [99]. The 
distribution of D1 receptors in schizophrenia has been studied using the PET 
radiotracers [11C]NNC 112 or [11C]SCH 23390. However, the few studies that have 
been conducted produced conflicting results. While Okubo and colleagues [76], 
using [11C]SCH 23390, found a decrease in receptor binding in patients with 
schizophrenia compared to controls, the study by Karlsson and colleagues [100], 
using the same radiotracer, did not reveal any differences between groups [76, 
100]. However, patients in this latter study were all drug-naïve, while the former 
study also included drug-free patients. The more recent study by Hirvonen and 
colleagues [101] reported decreased [11C]SCH 23390 binding in frontotemporal 
brain regions of previously medicated patients with schizophrenia compared to their 
unaffected co-twins and healthy comparison twins and higher doses of antipsychotics 
were associated with greater decreases in D1 receptor binding [101]. Interestingly, 
unaffected monozygotic co-twins displayed increased receptor binding compared to 
healthy comparison twins, and unaffected dizygotic co-twins showed intermediate 
levels. Two other studies used the radiotracer [11C]NNC 112: One reported 
increased D1 receptor binding in the schizophrenia group, which correlated with 
deficits in working memory performance [77], and the second study found increases 
limited to the drug naïve patients but not the previously treated ones [102]. Studies 
on D1 receptor availability in schizophrenia are summarized in table 1. 
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Table 1. PET studies on D1 receptor availability in PFC in schizophrenia 
 
 
Study 
 
Ligand 
 
N 
 
Results 
Patients 
(drug-
naïve/drug-free) 
Controls 
 
Okubo et al., 
1997 
 
[11C]SCH23390 
 
17 (10/7) 
 
18 
 
Decreased receptor 
binding in patients versus 
controls 
 
 
Karlsson et al., 
2002 
 
[11C]SCH23390 
 
10 (10/0) 
 
10 
 
No difference between 
patients and controls 
 
 
Hirvonen et al., 
2006 
 
[11C]SCH23390 
 
9 (0/9) 
 
24 
 
Decreased receptor 
binding in patients versus 
controls (i.e. their 
unaffected co-twins and 
healthy comparison 
twins), but increased 
receptor binding in 
unaffected co-twins 
versus healthy 
comparison twins 
 
 
Abi-Dargham 
et al., 2002 
 
[11C]NNC112 
 
16 (9/7) 
 
16 
 
Increased receptor 
binding in patients versus 
controls 
 
 
Abi-Dargham 
et al.,  
in press 
 
[11C]NNC112 
 
25 (12/13) 
 
40 
 
Increased receptor 
binding only in drug-
naive patients versus 
controls; no change in 
drug-free patients 
 
 
 
While it is possible that the discrepancy in findings is due to the influence of 
neuroleptic medication, it might also be that differences in radioligand properties 
contributed to the diverging results, as shown by Guo and colleagues [103]: Using a 
DA depletion paradigm the researchers could demonstrate that the in vivo binding 
of the two radiotracers [11C]SCH 23390 and [11C]NNC 112 was affected 
differentially by changes in endogenous DA, indicating that the increased D1 
receptor availability observed in the studies by Abi-Dargham and colleagues using 
[11C]NNC 112 might reflect an upregulation of D1 receptors, secondary to 
chronically low DA levels. This would also be consistent with the observed correlation 
between increased D1 receptor binding and deficits in working memory [77]. 
However, since both radioligands also bind to the serotonergic 5-HT2A receptor 
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[104, 105], selective tracers are needed to pursue these investigations of the role of 
cortical D1 receptors in schizophrenia. 
Dopamine in at-risk and prodromal states 
The above described studies have revealed several aspects of DA dysfunction in 
patients with established schizophrenia. In order to extend these findings and shed 
light on the timing of DA dysfunction in schizophrenia, researchers have started 
recently to examine different aspects of DA transmission in individuals with 
prodromal signs of schizophrenia and individuals at genetic or psychometric risk for 
psychosis.  
 
Three studies have investigated striatal DA synthesis capacity with PET and [18F]F-
DOPA. While Huttunen and colleagues [106] observed increased [18F]F-DOPA 
uptake in the caudate-putamen in low-symptomatic first-degree relatives of patients 
with schizophrenia compared to controls, the study by Shotbolt and colleagues [29] 
did not reveal any changes in radiotracer uptake in unaffected and completely 
asymptomatic co-twins of schizophrenia patients compared to controls [29, 106]. 
Howes and colleagues [24] found increased [18F]-DOPA uptake in individuals with 
prodromal signs of schizophrenia compared to controls [24].  Interestingly, this effect 
was most pronounced in the associative striatum and correlated positively with 
severity of prodromal symptoms. Moreover, in a subsequent study the authors could 
indicate that the increase in DA synthesis capacity observed in individuals in the 
prodromal phase of the illness progressed over time only in those individuals who 
later developed schizophrenia, but not in those who did not develop the disease 
[107]. However, in contrast to the findings in prodromal individuals, where the effect 
was most pronounced in associative striatum, the progression in DA synthesis 
alteration in those who developed the disease was only seen in sensorimotor striatum 
[107]. Three other studies have examined stimulated DA release in individuals 
psychometrically at-risk for schizophrenia (i.e. individuals with schizoptypal traits). 
Soliman and colleagues [108] employed a psychosocial stress paradigm in 
combination with PET and [11C]raclopride to study stress-induced DA release in 
psychometric schizotypes compared to controls. No changes in DA release in 
response to stress were observed in normal controls, nor in the ‘positive’ schizotypes 
(i.e. individuals with perceptual aberrations). Only the ‘negative’ schizotypes (i.e. 
individuals with physical anhedonia) showed an increase in DA release in response to 
stress compared to baseline [108]. Abi-Dargham and colleagues [109] as well as 
Woodward and colleagues [110] studied amphetamine-induced DA release in 
individuals with schizotypal personality disorder (SPD) and individuals with 
schizotypal traits, respectively. In the SPD subjects of the first study, amphetamine 
caused a larger decrease in [123I]IBZM binding compared to controls [109]. 
Similarly, amphetamine-induced DA release measured with PET and [18F]fallypride 
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correlated positively with schizotypal traits in the second study [110]. In accordance 
with previous findings showing that DA dysregulation might be most pronounced in 
associated striatum as opposed to limbic or sensorimotor regions [24, 39], the 
correlation between stimulated DA release and schizotypal traits was strongest in 
associative striatum. Finally, one study has investigated striatal D2 receptor 
availability in six monozygotic and 5 dizygotic unaffected co-twins of patients with 
schizophrenia and compared them to control twins without a family history of 
psychosis. Elevated caudate D2 receptor availability was observed only in the 
monozygotic co-twins of schizophrenia patients, compared to dizygotic co-twins and 
controls. No changes however were revealed in the dizygotic co-twins compared to 
controls [111].  
 
In summary, studies suggest an increase in DA in schizotypal states and in relation to 
schizotypal and prodromal symptoms, linking DA dysfunction to the expression of the 
schizophrenia phenotype. Combined with the findings of Shotbolt and colleagues 
who did not observe any changes in DA synthesis capacity in unaffected co-twins of 
patients with schizophrenia [29], this suggests that DA dysfunction does not relate to 
a general genetic vulnerability in the absence of behavioral manifestations but 
rather represents a biological marker for the very early expression of schizophrenia 
symptomatology.  
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Figure 1. Schematic illustration of the course of the DA deficit in schizophrenia. DA dysregulation has been 
shown to occur already in the prodromal phase of the illness and seems to progress along with illness 
progression, peaking at illness onset. Adapted with permission from Lieberman [112]. 
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Summary 
The most consistently found dopaminergic alteration in schizophrenia is elevated 
presynaptic DA function in striatal brain regions (see figures 2 and 3 for an 
illustration), in particular associative striatum, as demonstrated by imaging studies 
showing i) increased L- DOPA uptake as an index of increased DA synthesis 
capacity, ii) elevated amphetamine-induced DA release and iii) elevated D2 
occupancy by DA as revealed by the acute DA depletion. DAT seems to be 
unaffected in schizophrenia, and increased D2 availability was only found in a 
subgroup of patients. Findings concerning the distribution of D3 and D4 remain 
understudied and equivocal. Although preclinical work suggests an imbalance in D2 
receptor affinity states being associated with psychosis, the only study in patients 
with schizophrenia did not find elevated D2high. The evidence concerning DA 
alterations in extrastriatal and prefrontal cortical brain areas in schizophrenia seems 
less consistent. While some studies found elevated levels of D2 in areas such as the 
thalamus, anterior cingulate and temporal cortex or the midbrain and substantia 
nigra, others did not. The results of the few studies on D1 receptor availability in 
prefrontal cortex in schizophrenia are also conflicting. Thus, while a lot of effort has 
been put into the investigation of striatal DA alterations in schizophrenia, research 
has been less successful with regard to extrastriatal and prefrontal cortical regions. 
More research is needed to resolve the inconsistencies in findings research has 
provided so far.  
 
Functional and clinical implications 
 
As defined in the current, fourth version of the Diagnostic and Statistical Manual of 
Mental Disorders [113], schizophrenia is a highly heterogeneous disease, presenting 
with positive, negative and cognitive symptoms. Positive symptoms include 
hallucinations and delusions, while negative symptoms refer to flattened affect, 
anhedonia and loss of motivation. Cognitive disturbances are mostly seen in domains 
such as working memory, executive function and aspects of social cognition. DA 
dysregulation plays a role within each of these dimensions. While positive symptoms 
seem to most directly relate to excessive striatal DA transmission, negative and 
cognitive symptoms have been associated with decreased DA function in PFC. The 
latter assumption was primarily based on the known and crucial involvement of the 
PFC in cognitive and emotional processes [114-116]. Still, after decades of research 
into DA and schizophrenia, it remains elusive how DA dysregulation actually 
translates into the complex and multifactorial symptoms that characterize the clinical 
picture of schizophrenia. 
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Figure 2. DA transmission at striatal medium spiny neurons. The most consistently found dysregulation in 
schizophrenia points to increased DA synthesis, increased stimulated DA release and increased D2 receptor 
binding after acute DA depletion. 
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Figure 3. New data bringing new evidence: The DA dysfunction in schizophrenia seems to be most pronounced 
in AST as opposed to VST as previously assumed. Adapted with permission from Simpson and colleagues [117]. 
SMST (sensorimotor striatum), AST (associative striatum), VST (ventral striatum), VTA (ventral tegmental area), 
SNc (substantia nigra pars compacta), SNr (substantia nigra pars reticulate).  
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Relating DA dysfunction to positive symptoms  
Several of the imaging studies discussed in this chapter, have reported associations 
between alterations in striatal DA function and symptomatology in patients with 
schizophrenia. Regarding DA synthesis, Hietala and colleagues found a negative 
correlation between striatal F-DOPA uptake and depressive symptoms and a 
positive correlation with paranoid symptoms, although this was significant at trend-
level only [22]. Howes and colleagues reported a positive correlation between 
severity of positive prodromal symptoms as well as neuropsychological impairment 
and increased DA synthesis capacity in associative striatum. However, this was not 
true for depressive symptoms [24]. With regard to DA release, Laruelle and 
colleagues [33] found that amphetamine-induced decrease in D2 binding potential 
was associated with positive symptoms. In a subsequent study the authors could 
furthermore establish a relation between amphetamine-stimulated DA release and 
illness-phase, as amphetamine-stimulated DA release was only increased in patients 
presenting with acute schizophrenia but not in patients in remission [36]. Recently, 
Woodward and colleagues revealed a positive correlation between stimulated DA 
release and schizoptypal personality traits in healthy individuals [110]. 
 
Assuming that striatal hyperdopaminergia plays a role in the emergence and 
experience of positive psychotic symptoms, the question arises as to how 
dopaminergic alterations in striatal brain regions ultimately give rise to the 
experience of hallucinations and delusions. Altered salience attribution has been 
suggested as a possible mechanism [118]. Burst firing of dopamine neurons in the 
ventral tegmental area markedly increases dopamine release in the striatum [119] 
and is believed to mediate the perception of salience or reward associated with 
stimuli [120-122]. The phasic bursts of dopamine release, which are highly 
dependent on glutamatergic excitatory afferents, have been shown to be regulated 
by constant low-frequency tonic firing of dopamine neurons [42]. Tonic dopamine 
tone in turn is under control of GABAergic inhibition. Increased levels of tonic 
dopamine firing may result in decreased amplitude of phasic dopamine burst firing, 
thus dampening responsivity of this system. Decreased tonic dopamine levels, on the 
other hand, may result in a heightened responsivity of the phasic dopamine 
component [42, 123]. Kapur has suggested that, in schizophrenia, dopamine 
dysregulation results in a psychological state of aberrant salience, in which mundane 
events and ideas may be attributed with undue significance  [118]. Thus, a 
hyperdopaminergic state in striatal brain regions, which most likely reflects 
dysregulation of the phasic component of DA release [124, 125], is believed to 
create a condition in which logically unconnected ideas and associations are weaved 
together and elaborated upon, eventually leading to the emergence of a delusional 
system. The process of salience attribution has been related to associative and 
reinforcement learning, in which what is called “reward prediction error” plays a key 
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role [126]. It is hypothesized that previous reward outcomes are used to form a 
reward prediction, which is then compared to the actual current reward. The 
difference between reward prediction and actual outcome is referred to as the 
reward prediction error [126], and has been shown to be mediated, in animals as 
well as in humans, by dopamine activity in ventral midbrain and striatum [127-130]. 
Compared to healthy controls, patients with psychosis seem to exhibit aberrant 
reward prediction and reward-related learning, both at the behavioral and the 
neural level [131, 132]. However, the relationship between dopamine dysfunction in 
these brain regions, alterations in reward processing and symptomatology in 
schizophrenia has not directly been studied and remains speculative.  
Relating DA dysfunction to negative and cognitive symptoms  
As intact dopaminergic neurotransmission is critical for PFC functioning and cognition, 
[114, 133], the negative and cognitive symptoms of schizophrenia have been 
particularly associated with cortical hypodopaminergia [77, 134, 135], although 
direct evidence for this association in schizophrenia is missing. The nature of 
dopamine dysfunction in the cortex remains unclear, although one study showing 
decreased tyrosine hydroxylase immunolabeling suggests decreased innervation 
[136]. Recently, the group of Simpson, Kellendonk and Kandel and colleagues 
suggested a role for the striatum in the etiology of negative and cognitive symptoms 
of schizophrenia [117]. Based on their preclinical work in D2 overexpressing mice, 
the researchers demonstrated that striatal DA alterations in form of overexpression 
of D2 leads to changes in DA turnover and prefrontal D1 receptor stimulation [137]. 
Behaviorally, this was accompanied by deficits in working memory [137] and 
operant performance, expressed in both reduced motivation and deficits in timing of 
the rewards [138]. It was moreover shown that the deficits in cognitive performance 
were secondary to the motivational deficit directly resulting from the D2 
overexpression [139], and remained even after the D2 overexpression had been 
reversed [138]. In line with these preclinical findings, studies in individuals with 
prodromal symptoms of schizophrenia have revealed an association between 
increased striatal DA synthesis capacity and altered activation in prefrontal cortical 
brain regions during cognitive engagement [140, 141]. 
 
Conclusions 
 
This chapter reviewed evidence for DA dysfunction in schizophrenia. Most of this 
evidence stems form imaging studies applying PET and SPECT techniques. Due to 
advances in these imaging techniques it has become possible to study neurochemical 
alterations in the DA system in several regions of the brain. Accordingly, recent 
studies were able to examine DA neurotransmission in the different substructures of 
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the striatum and revealed that, in contrast to the prevailing idea of DA hyperactivity 
in the mesolimbic DA pathway, it is rather hyperactivity in associative striatum that is 
implicated in schizophrenia pathology, as illustrated in figure 3. It further seems that 
the dysfunction is presynaptic rather than postsynaptic, characterized by increased 
DA synthesis capacity and increased phasic release to pharmacological and possibly 
also psychosocial challenges (see figure 2). Some of these alterations have been 
demonstrated also in individuals with prodromal signs of schizophrenia and seem to 
progress along with illness progression, suggesting that the dysfunction occurs early 
in the disease and may represent an early pathogenic process leading to further 
dysregulation (for an illustration on the course of the DA deficit see figure 1).  
 
Despite recent advances in the study of DA dysregulation in schizophrenia, the 
etiology of DA imbalance remains unknown. It has been assumed that striatal DA 
hyperactivity results from decreased activity in PFC, due to its functional role in 
inhibiting subcortical DA transmission [26, 142]. Conversely, preclinical work has 
recently shown that striatal DA abnormalities result in altered PFC DA activity [137]. 
The striatum is a complex integrative structure, receiving among others input from the 
hippocampus, an area of pathology in schizophrenia [143, 144], and in animal 
models changes in hippocampal activity lead to dysregulation of DA neuronal 
acitvity [145]. Future research should take into account these preclinical observations 
to understand the circuitry involved in the striatal and cortical dopamine dysfunction 
in schizophrenia. 
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Abstract 
 
General population epidemiological studies have consistently found that cannabis 
use increases the risk of developing psychotic disorders in a dose-dependent 
manner. While the epidemiological signal between cannabis and psychosis has 
gained considerable attention, the biological mechanism whereby cannabis increases 
risk for psychosis remains poorly understood. Animal research suggests that delta-9-
tetrahydrocannabinol (THC, the main psychoactive component of cannabis) increases 
dopamine levels in several regions of the brain, including striatal and prefrontal 
areas. Since dopamine is hypothesized to represent a crucial common final pathway 
between brain biology and actual experience of psychosis, a focus on dopamine 
may initially be productive in the examination of the psychotomimetic effects of 
cannabis. Therefore, this review examines the evidence concerning the interactions 
between THC, endocannabinoids and dopamine in the cortical as well as subcortical 
regions implicated in psychosis, and considers possible mechanisms whereby 
cannabis-induced dopamine dysregulation may give rise to delusions and 
hallucinations. It is concluded that further study of the mechanisms underlying the link 
between cannabis and psychosis may be conducted productively from the 
perspective of progressive developmental sensitization, resulting from gene-
environment interactions.  
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Introduction 
 
Stimulant drugs such as amphetamine have long been associated with psychotic 
symptoms. High doses can induce positive symptoms in people with no previous 
psychiatric history while even low doses can exacerbate positive symptoms in 
patients with a psychotic disorder [1, 2]. By the mid-1970s, experimental 
replications of the psychotomimetic effects of stimulant drugs, in combination with the 
observed antipsychotic effects of D2-blocking drugs, had given rise to the initial 
dopamine hypothesis of schizophrenia. Refined and modified in subsequent years, 
this theory remains central to theories about psychosis [3-6].   
 
Recent developments suggest that the dopamine hypothesis may need to be re-
examined in order to incorporate recent, seemingly unrelated research findings 
concerning risk factors for the development of psychosis [7]. One example concerns 
the insight that use of cannabis may impact negatively on mental health [8]. 
Cannabis use is associated with poor outcome in existing psychotic illness [9] and has 
consistently been shown to increase the risk to develop psychotic symptoms or 
disorder in healthy individuals [10-12]. However, the vast majority of cannabis users 
never develop any psychotic symptoms or mental health problems. Thus, cannabis is 
not a sufficient cause for psychotic illness but rather may constitute a component 
cause, interacting with other environmental and genetic factors [13]. Although the 
epidemiological link between cannabis and psychosis has been investigated 
extensively, the biological basis of this association remains poorly understood (see 
box 1 for a summary of main findings). Recent research suggests that heavy long-
term cannabis use, particularly when started during adolescence, may lead to 
abnormalities in brain structure [14-18], but it seems unlikely that the use of cannabis 
increases the risk of psychosis by inducing major structural brain changes [19, 20]. Its 
neurochemical interactions with neurotransmitters such as dopamine, however, are in 
urgent need of further investigation (DeLisi, 2008). Pharmacological and gene-
knockout studies have demonstrated that the central effects of THC are mediated via 
partial agonism at cannabinoid 1 receptors (CB1 receptors), the primary binding site 
of endogenous cannabinoids (eCBs) [21]. Expression of CB1 receptors is high in the 
hippocampus, cerebellum, basal ganglia, prefrontal cortex (PFC), amygdala and 
substantia nigra pars reticulata [22]. Endocannabinoids, of which the best 
characterized are anandamide (N-arachidonoylethanolamine; AEA) and 2-
arachidonoylglycerol (2-AG), are synthesized in and released from postsynaptic 
neurons but act predominantly at CB1 receptors located on neighboring presynaptic 
terminals, that is, they act in a retrograde fashion [23-25]. Activation of CB1 
receptors inhibits pre-synaptic neurotransmitter release (direct targets are GABA 
and glutamate terminals) and consequently modulates several neurotransmitter 
systems, including the dopamine system  [26]. Furthermore, it is thought that principal 
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output neurons, such as mesencephalic dopamine neurons, regulate their excitatory 
and inhibitory inputs via retrograde eCB signaling [26]. 
 
 
Box 1. What do we know about the association between cannabis and psychosis? 
 
1. Epidemiological studies have shown that cannabis use increases the risk of developing 
psychotic symptoms in a dose-response fashion, independent of possible confounding 
factors and self-medication effects. Effects may be more prominent during early 
adolescence [11, 28-30].  
2. Cannabis use is neither a necessary nor a sufficient cause of psychotic illness. Therefore, 
the link between cannabis use and psychosis may best be understood in terms of gene-
environment interactions [13]: 
a. Patients with a diagnosis of schizophrenia are more sensitive to the cognitive 
and behavioral effects of cannabis than controls [31]. 
b. High schizotypy, psychotic disorder and COMT val158met genotype have 
been found to moderate sensitivity to the psychosis-inducing effects of 
cannabis [31-35] . 
c. Environmental risk factors may induce differential sensitivity to cannabis in 
terms of psychosis risk, e.g. childhood trauma [36, 37] and urban rearing 
environment [38]. 
3. Cumulative exposure to environmental risks may increase the risk for psychosis in an 
additive fashion. The concept of behavioral sensitization may therefore provide a 
plausible mechanism for the link between cannabis and psychosis [27, 39, 40].  
4. Although some studies did not find cannabis-use related changes in brain morphology 
[41], others do suggest that long-term heavy cannabis use may lead to structural brain 
changes [14, 17, 18], possibly related to early onset of use [15, 16].  
5. Alterations in the endocannabinoid system have been revealed in schizophrenia, in 
particular increased levels of anandamide and increased CB1 receptor availability, 
independent of cannabis use [42-44]. 
 
 
In order to discuss how modulation of dopaminergic neurotransmission by 
cannabinoids, including THC, may contribute to the development of psychotic 
symptoms − and ultimately schizophrenia − following persistent cannabis use, the 
literature (using the databases Pubmed and Psychinfo) was searched systematically 
for relevant experimental, clinical and epidemiological findings across different 
disciplines, including molecular, neurobiological and behavioral findings. This review 
will therefore first outline the involvement of dopamine in the pathophysiology of 
schizophrenia, with an emphasis on mechanisms of how dopaminergic dysregulations 
may translate into delusions and hallucinations. Subsequently, the question of how 
cannabinoids, such as THC, may impact on dopaminergic pathways to provoke 
psychosis will be examined. We also address the potential role of cannabinoids in 
sensitization [27] processes in psychosis.  
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What are the dopaminergic pathways to psychosis? 
 
The involvement of dopamine in the pathophysiology of schizophrenia is still central 
to the understanding of psychosis [45-47]. The classic dopamine hypothesis of 
schizophrenia assumed a hyperfunctioning dopamine system to be the central 
feature of schizophrenia symptomatology, primarily in terms of the positive symptom 
cluster [48, 49]. Additional formulations later proposed that reduced dopaminergic 
activity in prefrontal cortical brain regions might be linked to negative and cognitive 
symptoms [50-52]. Although current models of schizophrenia pathophysiology also 
consider other neurotransmitters such as glutamate and GABA [4, 46], dopamine is 
still assumed to play a key role in the emergence and experience of positive as well 
as negative and cognitive symptoms in schizophrenia [6, 53].  
The subcortical pathway 
Indirect evidence supporting the notion of a hyperfunction in the mesolimbic 
dopamine system comes from observations that amphetamine, through a mechanism 
of hyperdopaminergia, induces positive psychotic symptoms whereas antipsychotic 
medications, blocking dopamine D2 receptors, dampen symptoms [48, 49, 54, 55]. 
Direct empirical support for hyperdopaminergia, showing alterations in the 
mesolimbic dopamine system of schizophrenia patients, was initially elusive. While 
some studies found increased striatal D2 receptor availability in schizophrenia 
patients compared to healthy controls [54, 56, 57], others failed to reveal such a 
difference [58-60]. However, more recent evidence suggests that it is elevated pre-
synaptic dopamine function that is associated with schizophrenia [reviewed in 
53].Furthermore, elevated pre-synaptic dopamine function was also reported in 
individuals with prodromal signs of schizophrenia [61] and  in first-degree relatives 
of patients with schizophrenia [62].   
 
Assuming that mesolimbic hyperdopaminergia plays an important role in the 
emergence and experience of psychotic symptoms, the question arises how 
dopaminergic alterations in mesolimbic brain regions actually give rise to the 
experience of hallucinations and delusions. Altered salience attribution has been 
suggested as a possible mechanism [63]. The mesolimbic dopamine system projects 
from the ventral tegmental area (VTA) to, among other areas, the ventral striatum. 
Burst firing of dopamine neurons in the VTA markedly increases dopamine release in 
the striatum [64] and is believed to mediate the perception of salience or reward 
associated with stimuli [65-67]. The phasic bursts of dopamine release, which are 
highly dependent on glutamatergic excitatory afferents, have been shown to be 
regulated by constant low-frequency tonic firing of dopamine neurons [68]. Tonic 
dopamine tone in turn is under control of GABAergic inhibition. Increased levels of 
tonic dopamine firing may result in decreased amplitude of phasic dopamine burst 
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firing, thus dampening responsivity of this system. Decreased tonic dopamine levels, 
on the other hand, may result in a heightened responsivity of the phasic dopamine 
component [68, 69]. Kapur has suggested that, in schizophrenia, dopamine 
dysregulation results in a psychological state of aberrant salience, in which mundane 
events and ideas may be attributed with undue significance  [63]. Thus, a 
hyperdopaminergic state in striatal brain regions is believed to create a condition in 
which logically unconnected ideas and associations are weaved together and 
elaborated upon, eventually leading to the emergence of a delusional system. Only 
a few experimental studies have actually studied the process of salience attribution 
in schizophrenia. This process has been related to associative and reinforcement 
learning, in which what is called “reward prediction error” plays a key role [70]. It is 
hypothesized that previous reward outcomes are used to form a reward prediction, 
which is then compared to the actual current reward. The difference between 
reward prediction and actual outcome is referred to as the reward prediction error 
[70]. Reward prediction error signaling is mediated, in animals as well as in humans, 
by dopamine activity in ventral midbrain and striatum [71-74]. Compared to healthy 
controls, patients with psychosis seem to exhibit aberrant reward prediction and 
reward-related learning, both at the behavioral and the neural level [75, 76]. G. K. 
Murray and colleagues [77] employed a functional magnetic resonance imaging 
(fMRI) paradigm using a monetary reward task, and found that patients were less 
able to distinguish between neutral and rewarding stimuli. This was also evident at 
the brain activation level as patients with schizophrenia showed an increased 
midbrain response to neutral prediction, but attenuated activity in response to 
reward prediction [77]. Taken together, these results support the notion that 
hyperactivity in the mesolimbic dopamine system promotes psychotic symptoms by 
disrupting the process of salience attribution.  
The cortical pathway 
In addition to mesolimbic dopamine hyperfunction, schizophrenia has been 
associated with decreased activity in the mesocortical dopamine pathway, which 
projects from the VTA to, among other areas, the PFC [1]. As dopaminergic 
neurotransmission at prefrontal dopamine D1 receptors is critical for PFC functioning 
and cognition [78, 79], cortical hypodopaminergia has been associated with the 
cognitive and negative symptoms of schizophrenia, such as impairments in working 
memory and executive functioning as well as anhedonia and flattened affect [50, 
80, 81]. Evidence for this, however, has been mainly indirect and primarily stems 
from neuroimaging studies investigating prefrontal D1 receptor availability [82, 83].   
Subcortical and cortical dopamine: two distinct pathways? 
As outlined above, schizophrenia may be associated with dopamine imbalances in 
both cortical and subcortical brain regions. Furthermore, the mesocortical dopamine 
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pathway, projecting from VTA to PFC, has been shown to exert inhibitory influences 
on mesolimbic dopamine activity [84, 85]. It has thus been proposed that mesolimbic 
hyperdopaminergia in schizophrenia may result from failed inhibition by cortical 
dopamine [84, 85]. Meyer-Lindenberg and colleagues [86] used Positron Emission 
Tomography to study regional cerebral blood flow (with [15O]H2O as radiotracer) 
and presynaptic dopaminergic function (with 6-[18F]DOPA as radiotracer) in the 
same session. Patients with a diagnosis of schizophrenia exhibited significantly lower 
levels of prefrontal cortical activity during an executive functioning task, compared 
to controls. Furthermore, the decrease in PFC activity in the patient group was 
predictive of a relative increase in striatal dopaminergic function, indicating that 
frontal hypodopaminergia leads to mesolimbic hyperdopaminergia.   
 
While the above suggests that striatal dopamine transmission is under the influence 
of PFC dopamine, Kellendonk and colleagues have demonstrated the opposite as 
well: mesolimbic dopamine activity may exert influences on prefrontal dopamine 
function [87-89]. Transgenic mice over-expressing striatal D2 receptors were found 
to be characterized by impairments in working memory and executive functioning, 
both of which are functions that critically require prefrontal dopamine activity. At the 
molecular level, over-expression of striatal D2 receptors was associated with 
increased dopamine turnover in the PFC and increased activation of prefrontal D1 
receptors [87]. It was further demonstrated that over-expression of striatal D2 
receptors resulted in disturbed motivational and associative learning [88, 89], core 
features of schizophrenia. There is thus some evidence that the cortical and 
subcortical dopamine pathways are subject to bi-directional influences.  
 
Does THC influence dopaminergic pathways to psychosis? 
 
Is it possible that some of the psychosis-inducing effects of exogenous cannabinoids 
such as THC may be mediated by dopamine? THC has been shown to affect 
endocannabinoid neurotransmission and much evidence indicates that eCBs are key 
components in the regulation of dopamine neurotransmission [90-92]. Animal 
research furthermore suggests that exogenous cannabinoids like THC facilitate 
dopaminergic neurotransmission in several regions of the brain, including striatum 
and PFC [93-95].  
Do cannabinoids influence subcortical dopamine? 
Dopamine neuronal firing in the VTA is controlled by excitatory glutamatergic and 
inhibitory GABAergic inputs, which in turn are reciprocally modulated by eCBs 
released from dopaminergic dendrites (figure 1) [91, 96, 97]. Findings from 
numerous animal studies have shown that the overall result of exogenous CB1 
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receptor agonists, such as THC, is to evoke burst-firing in the VTA and thereby 
increase extracellular dopamine concentrations in striatal brain regions (figure 1) 
[94, 98-100]. Recently, the acute effects of THC on striatal dopamine transmission 
have been investigated in human volunteers, using experimental Positron Emission 
Tomography (PET) paradigms. However, findings were inconsistent. While one study 
reported a THC-induced increase in striatal dopamine release [101], another study 
failed to detect such an effect [102]. An earlier Single Photon Emission Computed 
Tomography (SPECT) study, however, did find increased dopamine release in the 
striatum of a single patient with schizophrenia following cannabis exposure; in 
addition, the dopamine response in the patient was followed by an acute worsening 
of positive psychotic symptoms  [103]. Researchers have therefore asked whether D2 
blockade might prevent such an effect. D’Souza and colleagues showed that 
haloperidol (a D2 antagonist) did not significantly inhibit acute THC induced 
psychopathology in healthy subjects, which was in agreement with their earlier 
finding that ongoing D2 blockade in schizophrenia patients (i.e. antipsychotic 
treatment) offered no protection against THC-elicited acute positive psychotic 
symptoms [104, 105]. Liem-Moolenaar [106] on the other hand demonstrated that 
pre-treatment with haloperidol did reverse THC-induced increases in Positive and 
Negative Syndrome Scale scores in healthy volunteers [106].  
 
At the molecular level, both dopamine and eCBs are fundamental for the synaptic 
re-organisation which underpins new striatal learning [107-110]. So called spike-
timing dependent plasticity (STDP) has an absolute requirement for near-
simultaneous electrical activity in pre-synaptic terminals (cortical inputs) and the 
dendritic spines of medium spiny neurons (MSNs), the major striatal neuron. Crucially, 
change occurs rapidly, after only one or two spike pairings, conditions which are 
feasible under normal physiological conditions [111, 112]. In the striatum, long-term 
depression (LTD) of cortical inputs onto MSNs has repeatedly been shown to be 
mediated by retrograde endocannabinoid signaling [113-115]. In addition 
corticostriatal LTD often requires the activation of D2 receptors by dopamine (figure 
2) [111, 116, 117]. For instance, in mice in which dopamine was depleted by 
reserpine or 6-hydroxy-dopamine, LTD of corticostriatal synapses was absent but 
could be restored by administration of the D2 receptor agonist quinpirole; and 
quinpirole combined with an inhibitor of eCB clearance showed synergistic effects in 
improving the severe psychomotor impairments associated with dopamine depletion 
[118].  
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Figure 1. The convergence of dopamine and the endocannabinoids in the VTA.  
A. Firing patterns in midbrain dopaminergic (DA) neurons are influenced by a host of excitatory 
(glutamatergic, GLU, as indicated in grey) and inhibitory (GABAergic, GABA, as indicated in grey) inputs. DA 
neurons regulate neighboring presynaptic terminals via retrograde endocannabinoid (2-AG, as indicated in 
blue) signaling. 
B. When exogenous cannabinoids (THC, as indicated by cannabis leaves) bind to CB1 R’s located on 
glutamatergic (GLU) and GABAergic (GABA) terminals, retrograde endocannabinoid signaling (2-AG, as 
indicated in blue) is disrupted and stimulation of CB1 R’s by THC inhibits glutamate and GABA release.  
 
 
 
 
 
 
Figure 2.  Striatal plasticity at medium spiny neurons belonging to the indirect pathway. Cortical fibers form 
glutamatergic synapses (GLU) at the medium spiny neuron (MSN). At these synapses, endocannabinoid-
mediated (as indicated in blue) long-term depression (LTD) is induced as long as dopamine (as indicated in 
orange) is present at D2 receptors. In the absence of dopamine or in the presence of A2A receptor agonists (as 
indicated in grey) long-term potentiation (LTP) is induced.  
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New insights into the roles of dopamine and eCBs in striatal learning and plasticity 
have been provided by Shen and colleagues [112]. They investigated plasticity at 
identified populations of striatal MSNs. MSNs can be divided into two roughly 
equally sized groups. MSNs belonging to the direct pathway express D1 receptors 
while MSNs of the indirect pathway express D2 receptors. Shen et al. [112] showed 
that cortical inputs onto both MSN sub-types exhibit bi-directional plasticity 
(strengthening or weakening), dependent on the pattern of ongoing 
neuromodulation: At D2 MSNs, LTD was expressed pre-synaptically via retrograde 
endocannabinoid signaling, but only as long as dopamine was present at D2 
receptors. Co-joint adenosine A2a receptor and glutamate NMDA receptor 
stimulation could overpower LTD and trigger LTP instead (figure 2). For 
completeness, the opposite was observed at D1 expressing MSNs. Here, 
endocannabinoid-mediated LTD was induced in the absence of dopamine from D1 
receptors, whereas D1 agonists led to the induction of LTP [112].  These findings 
indicate that eCBs, glutamate, adenosine and dopamine act in concert to promote 
plasticity at simultaneously active corticostriatal synapses. One could speculate that 
under tonic D2 receptor stimulation, active MSN’s belonging to the indirect pathway 
weaken their cortical inputs via endocannabinoid-mediated LTD (figure 2) and a net 
positive signal would be returned to the cortex, facilitating an emerging 
psychomotor program. In contrast, if extracellular dopamine levels fall, albeit 
transiently following the non-arrival of a predicted reward [119], the indirect 
pathway would tend towards LTP (strengthening), and an overall negative signal 
would be returned to the cortex. Failure to signal the non-arrival of reward, that is, 
failure to inhibit tonic D2 signaling would be predicted to have major effects on 
corticostriatal loops and psychomotor health. 
 
Returning to the pharmacology, caffeine, an antagonist at A2A receptors (LTP 
blockade), has been shown to exacerbate positive psychotic symptoms as well [120, 
121], while A2A receptor agonists (LTP promotion) such as CGS 21680 appear to 
have anti-psychotic properties [122, 123]. Further, inhibitors of adenosine re-uptake 
or metabolic degradation have anti-psychotic properties in schizophrenia patients 
[124-127]. In addition, it is widely acknowledged that CB1 receptor agonists, such 
as THC (LTD promotion), are psychotomimetic and constitute a component risk factor 
for the development of schizophrenia, whereas cannabidiol (CBD) an allosteric 
inverse agonist at CB1 receptors (and inhibitor of adenosine re-uptake) has shown 
promise as an antipsychotic [128-131]. Overall, pharmaceutical manipulations which 
alter the balance of corticostriatal synapses of the indirect pathway display 
consistent pro- or anti-psychotic properties. Drugs which weaken cortical inputs onto 
MSNs of the indirect pathway (LTD) appear to be pro-psychotic. In contrast, drugs 
which favor a shift towards strengthening (LTP) of the same synapses appear to be 
anti-psychotic [132].  
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Do cannabinoids interact with the cortical dopamine pathway? 
In addition to influencing dopaminergic neurotransmission in the mesolimbic pathway, 
THC also seems to affect dopaminergic neurotransmission in the PFC, at least as far 
as evidence from animal studies is concerned [93, 133]. At the human behavioral 
level, the acute effects of THC include cognitive impairment in domains such as 
memory and attention [134, 135]. Furthermore, short term cognitive impairment 
following cannabis use has been suggested to overlap largely with cognitive 
dysfunctions as observed in schizophrenia [136]. It is well established that cognitive 
performance strongly depends on optimal prefrontal dopamine levels, with too low 
as well as too high levels of dopamine being equally detrimental to cognition [78]. 
In rats, acute administration of THC has been shown to increase prefrontal dopamine 
levels [137, 138], and to impair spatial working memory [139]. Furthermore, Pistis 
and colleagues [138] found that THC-induced increases in prefrontal dopamine 
could be prevented by administration of rimonabant, a CB1 receptor antagonist. 
This suggests that the effects of THC on dopamine transmission are mediated by the 
activation of CB1 receptors [138]. In contrast to these acute effects, repeated 
exposure to THC has been found to result in a reduction of dopamine metabolism in 
the rat PFC [133, 140]. The mechanism underlying the differences associated with 
acute and repeated exposure need to be investigated further – sensitization, as 
discussed below, may provide a concept to advance this field. The effects of 
repeated exposure again were accompanied by cognitive impairment, which follows 
the inverted U-curve association between dopamine levels and cognitive 
performance [141]. In an experimental study in human volunteers, carriers of the Val 
allele of the COMT (catechol-o-methyltransferase) val158met polymorphism who 
had repeatedly used cannabis were more sensitive to both the psychosis-inducing 
and the cognitive effects of THC than Met allele carriers [32]. The Val allele of this 
common polymorphism is associated with higher enzymatic activity of COMT and 
accordingly lower levels of prefrontal dopamine [142]. 
 
Although THC has been found to affect dopaminergic processes in PFC, the nature of 
endocannabinoid function in the human PFC remains largely unknown [143]. CB1 
receptors are densely expressed in the PFC [144] and studies on CB1 receptor 
knock-out mice have provided insights in prefrontal endocannabinoid function. By 
using the Morris water maze paradigm, Varvel & Lichtman [145] showed that CB1 
receptor knock-out mice did not differ from wild type control mice with regard to 
recognition memory. However, CB1 receptor knock-out mice made significantly more 
perseveration errors after the location of the platform had been changed. In 
addition, administration of THC was found to significantly worsen mnemonic 
performance in the wild type control mice, while task performance of the CB1 
receptor knock-out was unaffected [145]. Since memory function partly relies on 
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prefrontal brain functioning, it may be hypothesized that the observed performance 
impairments are attributable to THC effects in prefrontal brain regions.  
 
Taken together, it seems that the repeated administration of THC alters PFC function 
and impairs cognition by acting on dopamine signaling via activation of CB1 
receptors. In particular, repeated exposure to THC has been found to decrease 
dopamine levels in the PFC. As decreased prefrontal dopaminergic function is 
postulated to constitute a core feature of schizophrenia pathophysiology [82], 
cannabis use may increase the risk for psychosis partly by contributing to a 
hypodopaminergic state in the PFC. Taking into account THC effects in striatal 
regions, it thus appears that THC aggravates dopaminergic imbalances by 
increasing the dopaminergic tone in striatal regions of the brain, while, when 
administered repeatedly, decreasing dopamine levels in prefrontal regions of the 
brain. Evidence to support this idea predominantly stems from animal research and it 
remains speculative whether this applies to humans as well.  
Does dopamine-mediated behavioral sensitization constitute a potential mechanism 
behind the cannabis-psychosis relationship? 
The above suggests that repeated exposure to THC may cause changes in the 
dopamine system and subsequently progressively greater behavioral responses over 
time [146, 147]. A process of dopamine sensitization thus may constitute a possible 
mechanism by which environmental factors such as stress or stimulant drugs contribute 
to psychosis risk (figure 3) [27, 148, 149]. Rats pretreated with THC twice a day 
over a period of three days, were found to be more sensitive to the locomotor 
effects of a THC challenge, after a 14-day washout period, compared to rats that 
had not been pretreated [146]. Neurobiologically, the process of sensitization is 
thought to involve dopaminergic signaling in the mesolimbic pathway, as sensitization 
to stimulants, such as amphetamine, has frequently been shown to lead to increased 
activity of dopamine neurons in the VTA [150] and increased dopamine release in 
the striatum [151-154] [147].  
 
Cross-sensitization between stimulant drugs and stress has been shown as well. De 
Jong and colleagues [155] demonstrated that mice, after being exposed to 
psychosocial stress using a social defeat paradigm, exhibited an enhanced 
locomotor response to an amphetamine challenge compared to mice that had not 
been stressed previously. Using repeated maternal separation as a psychosocial 
stress paradigm, Kikusui and co-workers [156] found that mice which were kept 
separated from their mothers from day 1 to day 13 in the post-natal period, were 
more sensitive to the locomotor effects of a cocaine challenge at day 50, than mice 
which had not been stressed [156]. Most likely, cross-sensitization between stress and 
stimulants is mediated by striatal dopamine, as cocaine-induced striatal dopamine 
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increase was higher in rats which had been repeatedly pre-exposed to a stressor in 
form of foot shocks [157, 158].  
 
 
 
 
 
Figure 3. Sensitization Behavioral Phenotype. Person A has “normal” developmental expression of subclinical 
psychotic experiences that are mild and transient. Person B has similar expression but longer persistence due to 
additional environmental exposure such as stress (as indicated by zigzag arrows). Person C has prolonged 
persistence and subsequent transition to clinical psychotic disorder possibly due to severe repeated 
environmental exposure such as repeated cannabis use (as indicated by cannabis leaves) in addition to prior 
stress. Adapted with permission from Collip et al., 2008. 
 
 
Although THC shows cross-sensitization with other drugs such as amphetamine, heroin 
and morphine [146, 159], only a few studies have investigated cross-sensitization 
between THC and stress. Findings from animal studies have shown that the effects of 
THC seem to be contingent on the environmental conditions under which THC is 
administered [160]. In rats housed under normal conditions (housed in groups with 
water and food freely available) the exposure to THC only caused slight behavioral 
changes in form of mild sedation and hypothermia and did not alter dopaminergic 
neurotransmission. In contrast, under stressful housing conditions (isolation and food 
deprivation), THC administration had marked behavioral consequences, including 
immobility and hyperactivity. Furthermore, exposure to THC in the stressful 
environment resulted in significantly increased striatal dopamine uptake [160]. 
Mokler and colleagues [161] showed that in rats, pre-treatment with THC on days 4, 
6 and 8 postnatally changed the behavioral response to electric foot shocks in the 
adult period. THC pretreatment furthermore altered the stress-induced dopamine 
response in the hypothalamus and frontal cortex [161]. Houston [36] investigated 
interaction between early cannabis use and childhood sexual trauma on the 
development of psychotic disorder in a large population-based sample (N= 5877). 
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The data were suggestive of cross-sensitization between stress and early cannabis 
exposure, as the effect of cannabis on psychosis outcome was significant only in the 
individuals who had been exposed to trauma during early childhood. The interactive 
effective of cannabis use and childhood trauma on psychosis risk was replicated by 
Harley et al. [37]. 
 
At the molecular level, sensitization processes seem to involve endocannabinoid 
signaling. Filip and colleagues [162] demonstrated that administration of 
rimonabant, a CB1 receptor antagonist potently blocked the expression of 
hypersensitivity to cocaine [162]. Further, Corbille and colleagues showed that 
sensitization following a single dose of cocaine or amphetamine was reduced in CB1 
receptor knockout mice [163] and CB1 receptor knockouts failed to sensitize to 
amphetamine administered daily for 7 days [164]. In addition, it was shown that 
mice treated with the CB1 receptor antagonist AM251 in both a single and 7 day 
dosing paradigm showed a reduction in the development of sensitization to 
stimulants [165]. Finally, Chiang and Chen showed that microinjection of the CB1-R 
inverse agonist/antagonist SR147778 directly into the ventral striatum potently 
blocked the expression of hypersensitivity to methamphetamine (Chiang and Chen, 
2007). 
 
Thus, despite some contradictory findings, research suggests an important role for 
the endocannabinoid system in the neurochemical processes underlying sensitization. 
Repeated exposure to THC may sensitize an individual to the psychotic effects of 
THC, in interaction with other environmental risk factors such as stress, and this may 
be particularly relevant for individuals genetically at risk of dopamine dysregulation 
(Henquet, 2008). 
 
Conclusion  
 
Although advances in the understanding of endocannabinoid function have been 
made, the endocannabinoid system is still far from being understood and its 
interactions with other neurotransmitter systems including the dopamine system are 
complex. While in the VTA, dopamine seems to be downstream of endocannabinoid 
function, it appears that, in the ventral striatum, part of dopaminergic 
neurotransmission is actually upstream of endocannabinoid function, at least 
concerning its involvement in plasticity at striatal MSN’s. Accordingly, although THC 
might stimulate burst firing of DA neurons in the VTA and as a consequence increase 
DA levels in the striatum, here THC might additionally exert its effects by directly 
influencing synaptic plasticity [132].   
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Most evidence to date, however, stems from animal research and to date, a clear 
answer to the question of whether there is a case for dopamine mediating the 
psychosis-inducing effects of cannabis cannot be given. There is a lack of studies 
investigating the acute and long term effects of THC on dopaminergic 
neurotransmission, learning and reward experience in humans. Advances in imaging 
techniques, such as the development of novel radiotracers, as well as a growing 
understanding of the biology and psychology of positive psychotic symptoms, hold 
promise for the future study of how the biological underpinnings of the cannabis-
psychosis relationship may alter experience in such a way that psychotic symptoms 
ensue.  
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Abstract 
 
Cannabis use is associated with psychosis, particularly in those with expression of, or 
vulnerability for, psychotic illness. The biological underpinnings of these differential 
associations, however, remain largely unknown. We tested the hypothesis that THC 
(delta-9-tetrahydrocannabinol, the main psychoactive ingredient of cannabis) 
provokes psychotic experiences by differential induction of striatal dopamine 
release. Positron Emission Tomography and [18F]fallypride were used to investigate 
striatal dopamine release after pulmonary administration of THC in a group of 
healthy cannabis users (average risk psychotic disorder), patients with psychotic 
disorder (high risk psychotic disorder) and first-degree relatives (intermediate risk 
psychotic disorder). While THC was not associated with increased dopamine release 
in the control group, significant ligand displacement in striatal subregions indicative 
of dopamine release was detected in both patients and relatives, most pronounced 
in caudate nucleus. The results indicate that dopamine may mediate the 
psychotogenic effects of THC, in particular in individuals already at risk for 
dopamine dysregulation.  
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Introduction 
 
The use of cannabis, the most frequently used illicit drug in the world, has long been 
associated with an increased risk of developing psychotic symptoms in healthy 
individuals, and with poor outcome in patients with psychotic disorder [1-4]. While 
the epidemiological link between cannabis and psychosis is well established, very 
little is known about the biological underpinnings of this association [5, 6].  
 
Long-term heavy cannabis use, in particular when started during early adolescence, 
is associated with structural brain changes such as impaired structural integrity of the 
corpus callosum [7], alterations in white and gray matter [8, 9], and decreased 
hippocampal and amygdala volumes [10]. However, it has been argued that the use 
of cannabis is unlikely to increase the risk of psychosis by mechanisms that manifest 
themselves as major structural brain changes [11, 12]. Alternatively, neurochemical 
interactions between cannabis and neurotransmitters such as dopamine (DA) may 
constitute a biological link between cannabis and psychosis [6]. In the human brain, 
delta-9-tetrahydrocannabinol (THC, the main psychoactive constituent of cannabis) 
binds to cannabinoid 1 (CB1) receptors, the main binding site of endogenous 
cannabinoids (eCBs) [13, 14]. Activation of CB1 receptors inhibits pre-synaptic 
neurotransmitter release −direct targets being GABA and glutamate terminals− and 
consequently modulates several neurotransmitter systems, including the DA system 
[13, 15, 16]. DA is thought to play a role in schizophrenia pathophysiology [17, 18], 
and animal studies suggest that THC affects DA neurotransmission in several regions 
of the brain including prefrontal cortex (PFC) and mesolimbic regions [19-22]. 
However, direct evidence for interaction between THC and DA in the human brain to 
date remains scarce. First insights came from a single case report study with Single 
Positron Emission Computed Tomography (SPECT) and the radiotracer [123I]IBZM. In 
this study, a 20% decrease in striatal D2 receptor binding ratio was observed, 
indicating increased synaptic DA activity, in a medication-free patient with 
schizophrenia just after using cannabis [23]. Three subsequent studies used 
neurochemical imaging to examine the effects of THC on DA neurotransmission in 
healthy human volunteers. Bossong and colleagues [24] included seven healthy male 
recreational cannabis users and investigated the effects of THC on DA 
neurotransmission with Positron Emission Tomography (PET) and [11C]raclopride. The 
authors observed small (around 3.5%) but significant decreases in D2 receptor 
binding in two subregions of the striatum, the ventral striatum and the precommissural 
dorsal putamen after pulmonary THC administration [24]. The PET study by Stokes 
and colleagues [25] failed to find significant changes in D2 receptor binding after 
an oral dose of THC in thirteen healthy male volunteers. Similarly, Barkus and 
colleagues [26] did not observe DA release after intravenous THC studied with 
SPECT and [123I]IBZM [26].  
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The present study aimed to shed light on these inconsistencies, hypothesizing that 
inconsistencies in previous studies may be related to differential inclusion of 
individuals with increased sensitivity to THC. Thus, we not only investigated THC-
induced DA release using PET and the highly selective and high affinity DA D2/3 PET 
radioligand [18F]fallypride (Lataster and colleagues, [27]) in a group of healthy 
cannabis users, but also in groups with demonstrated increased sensitivity to THC: 
patient with psychotic disorder and their first-degree relatives. Patients with 
psychotic disorder have been shown to be more sensitive to the behavioral and 
cognitive effects of cannabis [28, 29] and individual differences in sensitivity to 
cannabis are in part mediated by genetic risk for psychotic disorder, siblings 
displaying more sensitivity than well controls [30, 31]. 
 
Materials and methods 
Participants 
A total of 30 volunteers (10 patients with psychotic disorder, 10 first-degree 
relatives of patients with psychotic disorder, and 10 healthy controls agreed to 
participate in the study. Participants were recruited through flyers in local coffee 
shops (cafes where cannabis is sold and consumed legally) and newspaper 
advertisements, as well as through in- and outpatient mental health service facilities 
in South Limburg, The Netherlands. Inclusion criteria were i) age 18-60 years, ii) 
sufficient command of the Dutch language, iii) no intellectual impairment (i.e. IQ > 
80) as ensured by the Dutch version of the Wechsler Adult Intelligence Scale [32], iv) 
having smoked cannabis at least once in the past 12 months, v) patients only: a 
diagnosis of psychotic disorder according to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) [33], and vi) relatives only: having a first degree relative 
with a diagnosis of psychotic disorder. Exclusion criteria were i) head trauma with 
loss of consciousness or neurological disorder, ii) endocrine or cardiovascular 
disorder, iii) a diagnosis of  psychiatric illness according to the DSM-IV in the 
relatives and the controls and, controls only, a positive family history of psychotic 
disorder, iv) current use of psychotropic medication, v) current use of illicit drugs 
other than cannabis, vi) current use of alcohol in excess of 5 standard units per day, 
vii) presence of metal elements in the body, viii) pregnancy or lactation, and ix) a 
history of claustrophobia.  
 
The study was carried out in accordance with the World Medical Association’s 
declaration of Helsinki and approved by the standing medical ethics committee of 
Maastricht University Medical Center. Written informed consent was obtained from 
all participants.   
CHAPTER 7 127 
 
 
Design and procedure 
The study made use of a single-blind placebo-controlled design. This was done in 
order to apply statistical modeling as previously described by Christian and 
colleagues [34] and recently by Lataster and colleagues [27], which requires only a 
single radiochemical synthesis and administration, thereby avoiding session effects 
and minimizing the amount of radiation exposure. All participants attended a 
screening session, during which inclusion and exclusion criteria were confirmed and 
baseline clinical measures taken. During the actual testing session, which was 
separated by approximately one week from the screening session, participants 
received both 8 mg of THC and placebo in a single-blind manner: participants first 
received the placebo followed by the active drug separated by approximately 2 
hours, but were told that the order of administration was random. Participants were 
asked to abstain from cannabis at least five days prior to the testing session and 
from caffeine and nicotine 4 hours prior to the testing session. At the beginning of the 
testing session, participants received a standardized meal and a caffeine-free 
beverage. Baseline clinical measures were repeated in case the screening session 
and testing session were more than one week from each other. Urinalysis was 
carried out to verify drug and medication abstinence and a pregnancy test was 
done to rule out pregnancy in the female participants. Additionally, abstinence from 
alcohol was assured by means of a breathalyzer. Finally, the inhalation procedure 
was practiced. The PET procedure started approximately 1 hour after the start of 
the testing session (see figure 1 for an illustration of the PET protocol). Effects of THC 
on subjective experience and psychopathology were assessed using computer-
assisted tasks and self-report questionnaires, which were applied after the 
administration of placebo and THC, respectively. At the end of each session, blood 
pressure and heart rate was measured. All participants stayed under psychological 
observation until the acute effects of the THC had faded and it was safe for the 
participants to return home.   
 
 
 
 
 
Figure 1. Schematic illustration of the scan protocol. The first three scan segments provided a total of 53 
frames, representing tracer kinetics during the baseline condition; the 25 frames of the last scan segment 
represented tracer kinetics during the exposure condition. Each scan segment was preceded by a 2 min CT scan 
and followed by a short break.   
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Baseline clinical measures 
Diagnoses were confirmed using the Operational Criteria Checklist and associated 
OPCRIT computer program [35]. Presence and severity of psychotic symptoms during 
the past two weeks was assessed in all participants with the Positive and Negative 
Syndrome Scale (PANSS) [36]. Current and past cannabis and other drug use was 
assessed using the appropriate sections of the WHO Composite International 
Diagnostic Interview [37] and the Structured Clinical Interview for DSM Disorders 
[38].  
Drug preparation and administration  
Preparation and administration of drugs was performed according to Zuurman and 
colleagues [39]. THC was purified from Cannabis sativa by Farmalyse BV, Zaandam, 
The Netherlands, in agreement with GMP guidelines, and was dissolved in 200µl 
100 vol% alcohol. The solvent was used as placebo. Drugs were administered by 
means of a vaporizer (Volcano®, Storz-Bickel GmbH, Tuttlingen, Germany). 
Cannabis vaporization is a technology designed to safely and effectively deliver 
THC while avoiding the respiratory hazards of smoking by heating THC to a 
temperature where active THC vapors are produced, but below the point of 
combustion where noxious pyrolytic by products are formed [40, 41]. Approximately 
five minutes before administration, 8mg of THC was vaporized and stored in an 
opaque polythene bag equipped with a valved mouthpiece preventing the loss of 
THC in between inhalations. As practiced at the beginning of the testing session, 
subjects were instructed to inhale the volume of the bag in 3-5 subsequent 
inhalations, holding their breath for 10 seconds after each inhalation and without 
speaking during the inhalation process. The same procedure was followed for the 
administration of placebo.  
Blood sampling 
Venous blood samples were taken at baseline and 5, 10, 15, and 75 minutes after 
THC administration to determine plasma concentrations of THC and its two main 
metabolites 11-OH-THC and 11-nor-9-carboxy-THC, as indicated by Zuurman and 
colleagues [39, 42]. To prevent unblinding of participants, sham samples were taken 
at baseline and 5, 10, 15 and 75 minutes after placebo administration. Plasma 
samples were analyzed by ABL, Analytisch Biochemisch Laboratorium BV, Assen, The 
Netherlands.  
Visual Analogue Scales 
For experimental validation, Visual Analogue Scales (VAS) on alertness, feeling 
‘high’ and external and internal perception [39, 43] were used to assess subjective 
changes in perception induced by THC.  
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PET scans 
Radiotracer preparation 
The fluorinated substituted benzamide [18F]fallypride is a high affinity antagonist 
radiotracer used to visualize and estimate both striatal and extrastriatal DA D2/3 
receptors [44, 45]. The use of [18F]fallypride in combination with the linear extension 
of the simplified reference region model as described by Alpert and colleagues [46] 
allows for a single experimental session requiring only a single radiochemical 
synthesis and administration, baring the advantage of avoiding session effects and 
minimizing amount of radiation exposure for the participants as previously 
demonstrated in an environmental exposure paradigm [27].  The precursor for 
tracer synthesis was obtained from ABX (Radeberg, Germany) and labeling was 
performed on-site using a Raytest Synchrom R&D synthesis module (Raytest, 
Straubenhardt, Germany). The final product was obtained after reverse-phase high 
performance liquid chromatographic (HLPC) purification using a Waters XTerraTM 
RP18 5 µm 7.8 mm x 150 mm column and sodium acetate 0.05M pH5.5/ethanol 
70:30 V/V as mobile phase at a flow rate of 1.5 ml/min. The [18F]fallypride eluted 
after 18 minutes. The collected peak (2ml) was diluted with 8ml of NaCl 0.9% and 
sterile filtered over a Millipore Cathivex-GS 0.22 µm filter. The final product of the 
radioligand was administered as a sterile solution of 7mM sodium acetate buffer pH 
5.5, 0.72% and 6% ethanol. The specific radioactivity at the time of injection was 
greater than 37 GBq/µmol (1000 Ci/mmol). Radiochemical purity was > 95%.  
Data acquisition and processing  
Subjects were placed on the scanner bed with their head fixated using a vacuum 
bed and the body strapped to the bed to avoid movement during PET acquisition. 
Positions of the monitor and response box were adjusted to allow for optimal 
comfort. Subjects received 185 MBq of [18F]fallypride in a slow intravenous bolus 
injection through a catheter in the left antecubital vein. Upon tracer injection, 
dynamic emission scans were initiated in three-dimensional mode using a PET/CT 
scanner (Philips, Eindhoven, The Netherlands). Data were acquired in frames of 60 
seconds during the first 6 minutes and in frames of 120 seconds thereafter. PET 
emission was performed based on the PET imaging protocol for [18F]fallypride used 
previously by Christian and colleagues [34], adapted for detecting [18F]fallypride 
displacement in striatal brain regions according to a simulation study (Ceccarini et 
al., submitted). Emission data were acquired in four segments, separated by a total 
of three breaks (figure 1). Given the use of an “activation” parameter in the kinetic 
model used for analyses (Alpert et al., 2003; discussed below), representing 
presence or absence of additional DA release, and the hypothesis of THC 
administration being associated with increased DA activity, the THC condition was 
always presented after the placebo condition. The first three PET segments with a 
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total duration of 170 min thus represented tracer kinetics during the placebo 
condition. Administration of placebo occurred between the first and the second 
segment. THC was administered at 220 min post-injection, followed by the last PET 
segment with duration of 50 min, representing tracer kinetics during the exposure 
condition. The timing of THC administration was adjusted such that the proportional 
distribution of radioligand was optimized for striatal brain regions, high in 
dopamine D2/3 receptor density [34]. Each PET segment was preceded by a low-
dose CT scan (80kV tube potential, 11 mAs) to correct for attenuation. PET data 
were reconstructed using a 3D OSEM (ordered-subset expectation maximization) 
iterative reconstruction including model-based scatter as well as attenuation 
correction based on a measured attenuation map acquired by the CT, with a final 
spatial resolution of 4mm. All subjects additionally received a high-resolution T1-
weighted structural MRI for anatomical co-registration purposes (1.5 Tesla Scanner, 
Phillips, Netherlands). Reconstructed PET data were transferred in DICOM (Digital 
Imaging and Communications in Medicine) and converted to Analyze using PMOD 
software version 2.95 (PMOD Inc., Zurich Switzerland). To correct for head motion 
during the scan segments, all PET frames were realigned, co-registered to the 
subject’s MRI and then spatially normalized to a specific T1-weighted template 
constructed in MNI (Montreal Neurological Institute) stereotaxic space using SPM2 
(Statistical Parametric Mapping, The Wellcome Department of Cognitive Neurology, 
London, UK). To increase signal to noise ratio, the normalized images were then 
smoothed with a 3D gaussian filter (4mm full width at half maximum) before 
applying the pharmacokinetic model.  
Statistical analysis 
Given hierarchical clustering of the data, each person contributing minimally two 
observations (placebo and THC), behavioral (VAS) data were analyzed using 
multilevel random regression analysis in Stata using the XTREG routine, examining 
the effects of condition (placebo versus THC) on subjective experience.   
 
To estimate THC-induced DA release, PET data were analyzed applying the linear 
extension of the simplified reference region model (LSRRM) [46], a kinetic model 
described and used in functional neurotransmitter [18F]fallypride PET studies on DA 
D2/3 receptors [34, 47]. This method takes into account the THC-induced temporal 
perturbations in ligand specific binding, including a baseline condition and a DA 
activation paradigm during a single scan session. The design has several practical 
advantages, such as the requirement for only a single radiochemical synthesis and 
administration and avoidance of session effects. The LSRRM accounts for time-
dependent changes in ligand concentration, assuming that the steady state is not 
maintained. The LSRRM therefore allows the dissociation rate of the ligand, k2a, to 
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change throughout the paradigm in response to fluctuating levels of DA (k2a = k2/[1 
+ BPND], where k2 is the tissue to plasma efflux constant and BPND is the non-
displaceable binding potential). Changes in BPND in activation studies are usually 
assumed to reflect changes in the concentration of available receptor sites (Bavail), 
and a decrease in BPND is assumed to reflect increased neurotransmitter release. The 
temporal change of k2, via a change in BPND, is obtained by introducing the 
additional term γ ·h(t), where γ represents the amplitude of the ligand displacement 
and the function h(t) describes a rapid change following activation onset and 
dissipation over time. The exponential decay function h(t) = exp[-τ(t-T)] accounts for 
temporal variation in the model parameters, where τ controls the rate at which 
activation effects die away (τ = 0.03 min-1) and T indicates activation initiation (T = 
220 min). It follows that, through linearization of the simplified reference region 
model (SRRM), an increased k2a reflected in a decreased BPND for DA receptors due 
to increased DA release would result in a positive value of γ. The cerebellum, 
representing an area with negligible density of DA D2/3 receptors, was used as 
reference region [48]. For each subject, two binary masks were created based on 
the corresponding normalized MRI, using an in-house created set of volumes-of-
interests (VOIs) based on the Talairach atlas [49]. One binary mask contained all 
brain regions of interest (i.e. the striatal subregions, in particular caudate nucleus, 
putamen, pallidum and nucleus accumbens), and a second mask was drawn only on 
the cerebellum. For each subject, VOI analysis was performed by estimating the 
kinetic parameters using the LSRRM and the PET time-activity curves (TACs) for all 
VOIs. A voxel-wise t-statistic map of the γ parameters was computed to localize 
those areas with estimated increased DA release following THC administration. 
These statistic t maps were generated as t = γ/sd(γ), where the standard deviation 
parametric image of γ (sd[γ]) was created based on the estimated covariance 
matrix, consistent with previous work by Christian and colleagues [34] and Lataster 
and colleagues [27]. The false discovery rate (FDR) [50] correction was utilized to 
control statistical significance thresholds in the context of multiple comparisons at the 
voxel level [51]. In order to identify the spatial extent of the neuromodulation for 
each region of interest showing significant activation-induced DA release, the 
percentage of voxels exceeding an FDR-corrected significance threshold of p(α(FDR) 
= 5%) < 0.05 was calculated. Group differences in the spatial extent of THC-
induced DA release were then tested using regression models within STATA. 
Inspection of residuals from the regression models indicated substantial 
heteroscedasticity of the error variances across the three groups. To account for this, 
we used a regression model that allowed the error variances to differ between 
groups. All analyses were a priori adjusted for age (in years), sex, nicotine use 
(continuous: number of cigarettes per day), alcohol use (continuous: grams of alcohol 
per week) and use of other medication (dichotomous: yes versus no). 
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Results 
Participants  
The initial sample consisted of 10 patients with a DSM-IV diagnosis of psychotic 
disorder, 10 first-degree relatives of patients with psychotic disorder, and 10 
healthy controls. However, two patients were excluded due to protocol violation in 
terms of use of antipsychotic medication. In addition, two individuals (one relative 
and one control subject) were excluded due to excessive movement during the scan, 
yielding uncorrectable movement artifacts in the PET data. The resulting final sample 
thus consisted of 8 medication-free patients with a diagnosis of psychotic disorder, 9 
first-degree relatives and 9 healthy controls. Of the patients, five individuals fulfilled 
criteria for non-affective psychotic disorder and three individuals fulfilled criteria for 
affective psychotic disorder. Controls and relatives did not fulfill criteria for any 
psychiatric disorder. There were not suggestive differences between three groups 
with regard to mean age, male/female ratio and mean intellectual functioning as 
indexed by IQ (Table 1).  Patients had higher scores on the positive syndrome 
dimension of the PANSS. All participants had used cannabis during the past 12 
months: 16 participants reported daily use during the past 12 month, 3 participants 
admitted to weekly use and 7 participants used cannabis monthly or less than 
monthly (Table 1).  
Drug screening 
Urinalysis was positive for THC in 18 participants (6 patients, 6 relatives and 6 
controls). Since the majority of the sample reported daily use of cannabis, urinalysis 
can be expected to reveal traceable amounts of THC; all participants indicated 
compliance with the protocol and gave verbal confirmation of abstention from 
cannabis minimally 5 days before testing.  One participant tested positive for 
cocaine (a relative). For power reasons and since exclusion of this latter individual 
did not change the results, this observation was kept in the analyses. All participants 
tested negative for benzodiazepines, amphetamine, methamphetamine, opiates and 
alcohol.  
Blood sample analysis 
The concentration of THC in plasma reached a maximum of 37.3 ± 19.3 ng/ml at 5 
minutes post inhalation and decreased subsequently. The two main metabolites 11-
OH-THC and THC-COOH reached a maximum concentration of 1.6 ± 1.5 ng/ml 
and 25.2 ± 22.4 ng/ml at 5 and 15 minutes post-inhalation, respectively (see table 
2 and figure 2).  
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Table 1. Participant characteristics.  
 
 
 
Controls  
(n = 9) 
Relatives  
(n = 9) 
Patients  
(n = 8) 
Mean Age (SD) 31.4 (11.4) 36.1 (12.0) 31.1 (8.9) 
Percentage male (n) 55.6 (5) 66.7 (6) 75.0 (6) 
Mean IQ (SD) 102.8 (14.0) 105.5 (11.8) 102.7 (15.6) 
Cannabis use % (n)*    
Monthly or less 33.3 (3) 22.2 (2) 25.0 (2) 
Weekly  11.1 (1) 11.1 (1) 12.5 (1) 
Daily 55.6 (5) 66.7 (6) 62.5 (5) 
Mean PANSS score (SD)    
Positive 1.0 (0.0) 1.0 (0.1) 1.5 (0.7) 
Negative 1.0 (0.0) 1.0 (0.1) 1.1 (0.2) 
Global  1.2 (0.1) 1.1 (0.1) 1.2 (0.2) 
Total 1.0 (0.0) 1.0 (0.1) 1.1 (0.1) 
Nicotine usea % (n)    
0 44.4 (4) 22.2 (2) 25 (2) 
1 - 10 22.2 (2) 44.4 (4) 25 (2) 
11 – 20  33.3 (3) 33.3 (3) 37.5 (3) 
> 20  0.0 (0) 0.0 (0) 12.5 (1) 
Alcohol useb % (n)    
0 – 50 66.7 (6) 44.4 (4) 62.5 (5) 
50 – 150 33.3 (3) 44.4 (4) 0.0 (0) 
150 - 350 0.0 (0) 11.1 (1) 37.5 (3) 
Other medication use % (n)    
Yes  0.0 (0) 11.1 (1) 25.0 (2) 
No  100.0 (9) 88.9 (8) 75.0 (6) 
Use of contraceptives % (n)    
Yes 22.2 (2) 11.1 (1) 0.0 (0) 
No 77.8 (7) 88.9 (8) 100.0 (8) 
 
Note. Percentages do not always total 100 due to rounding.  
* Refers to cannabis use in the last 12 month. 
a Refers to number of cigarettes per day. 
b Refers to grams per week. Standard drink/unit size in the Netherlands contains 9.9 g of ethanol.  
 
 
 
 
Table 2. Mean maximum plasma concentration of THC, 11-OH-THC and THC-COOH 
 
 Patients 
(n = 9) 
Relatives 
(n = 9) 
Controls 
(n = 8) 
THC 43.5 (22.4) 36.1 (19.3) 33.0 (17.0) 
11-OH-THC 1.6 (1.3) 2.2 (2.0) 1.2 (0.9) 
THC-COOH 25.7 (30.3) 28.0 (21.9) 22.0 (16.3) 
 
Note. Numbers are ng/ml (SD). 
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Figure 2. Plasma concentrations of THC and its two main metabolites 11-OH-THC and 11-nor-9-carboxy-THC 
(THC-COOH) at baseline (0) and at 5, 15, and 75 minutes post inhalation across groups.  
 
Visual Analogue Scales 
From the 13 VAS composite scores on ‘external perception’ (5 scales) and ‘internal 
perception’ (7 scales) were calculated. The scale on ‘feeling high’ was analyzed 
separately. As expected, THC induced significant increases in ‘feeling high’ (β = 
11.74, 95% CI: 6.90-16.59, p < 0.001), ‘external perception’ (β = 2.16, 95% CI: 
0.84-3.47, p = 0.001) and ‘internal perception’ (β = 1.19, 95% CI: 0.01-2.38, p = 
0.049) (figure 3).  
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Figure 3. Effects of pulmonary THC on subjective feelings of ‘high’, ‘internal perception’, and ‘external 
perception’ across groups, measured with Visual Analogue Scales at baseline (0) and 5, 15, and 25 minutes 
post-inhalation.  
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In vivo DA release following THC administration 
Inspection of the scatterplot revealed one outlier (a relative); this subject was 
accordingly excluded from this analysis. THC induced detectable amounts of [18F] 
fallypride displacement, indicative of DA release, throughout the striatum in both 
patients and relatives, but not in controls (see figure 4 and 5 and table 3). On 
average, γ was positive, indicating DA release for all striatal subregions in the 
patient group, and for the caudate nucleus in the relatives (see table 4). 
Furthermore, there was a significant difference between the three groups with 
regard to the amount of ligand displacement in right and left caudate nucleus, left 
putamen, and right pallidum (see table 3 for group statistics). Post hoc pairwise 
comparisons showed that the amount of ligand displacement was significantly larger 
for patients and relatives versus controls, respectively, in left caudate nucleus (Bpatients 
= 0.18, p = 0.002, Brelatives = 0.18, p = 0.021), left putamen (Bpatients = 0.13, p = 
0.018, Brelatives = 0.12, p = 0.047) and left pallidum (Bpatients = 0.19, p = 0.032, 
Brelatives = 0.07, p = 0.020). In the right caudate nucleus, the only group difference 
was between patients and controls (B = 0.18, p = 0.032). No differences were 
observed between patients and relatives in any of the subregions. Tables 3 and 4 
summarize THC-induced changes in [18F]fallypride binding quantified as the number 
of voxels within a region exceeding the FDR-corrected significance threshold of 
p(α(FDR) = 5%) < 0.05, and mean parameter estimates, respectively. Ligand 
displacement was independent of age, gender, alcohol use, and nicotine use.  
 
Table 3. Mean percentages (SD) of THC-induced ligand displacement in striatal subregions 
 
 Controls 
(n = 9) 
Relatives 
(n = 9) 
Patients 
(n = 7a) 
 
Group statistics* 
Caudate Nucleus     
Right 3.5 (5.6) 12.6 (19.0) 15.3 (19.7) F (3, 21) = 2.18; p = 0.071 
Left 2.5 (3.0) 19.0 (19.5) 16.2 (16.9) F (3, 21) = 1.67; p = 0.058 
Average 3.0 (3.2) 15.7 (17.9) 15.9 (15.1) F (3, 21) = 2.48; p = 0.034 
Putamen      
Right 1.4 (1.5) 9.8 (17.3) 16.2 (19.8) F (3, 21) = 1.85;p = 0.042 
Left 2.4 (4.3) 14.6 (16.7) 13.7 (12.7) F (3, 21) = 2.14; p = 0.043 
Average 1.9 (2.5) 12.3 (14.9) 14.9 (15.5) F (3, 21) = 2.43; p = 0.025 
Pallidum     
Right 1.5 (2.7) 6.8 (7.6) 16.4 (21.8) F (3, 21) = 2.15; p = 0.022 
Left 3.3 (5.6) 15.7 (27.9) 11.6 (17.1) F (3, 21) = 0.54; p = 0.329 
Average 2.3 (2.8) 10.8 (15.5) 14.4 (15.6) F (3, 21) = 1.71;p = 0.048 
Nucleus Accumbens      
Right 2.2 (5.7) 3.4 (7.3) 10.9 (16.1) F (3, 21) = 1.37; p = 0.086 
Left 1.2 (2.9) 11.3 (22.4) 4.5 (6.4) F (3, 21) = 0.81; p = 0.440 
Average 1.7 (3.1) 7.4 (14.9) 7.7 (7.1) F (3, 21) = 1.51;p = 0.140 
 
Note. Numbers are percentages (SD) of voxels within a region exceeding the FDR corrected significance threshold of p(α(FDR) = 
5%) < 0.05, relative to the total number of voxels within the mask of the respective region. 
a One subject was identified as an outlier and accordingly excluded from this analysis. 
*adjusted for age, gender, alcohol and nicotine use 
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Figure 4. Mean statistical parametric t map of γ in sagittal (left) and coronal (right) sections overlaid on a MRI 
template, showing THC-induced [18F]fallypride displacement at the level of the striatum (x = 0, y = 11, z = -4) 
for controls (top row), relatives (middle row) and patients (bottom row). 
 
 
 
 
Figure 5. Percentage of voxels with significant THC-induced dopamine release in the caudate nucleus, putamen 
(top row), globus pallidus and nucleus accumbens (bottom row) for controls, relatives and patients. Horizontal 
lines indicate the mean value for each group 
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Discussion 
 
The present study revealed the novel finding of striatal DA release following 
pulmonary administration of THC in a group of patients with psychotic disorder and 
unaffected relatives. Consistent with most previous work, no DA release was 
detected in healthy control participants.  
THC-induced dopamine release: the mechanism behind cannabis-induced psychosis? 
Numerous animal studies suggest that exogenous cannabinoids such as THC stimulate 
burst firing of midbrain DA neurons and, as a consequence, facilitate striatal DA 
release through activation of cannabinoid 1 (CB1) receptors [15, 22, 52-56]. In 
humans however, evidence that DA may mediate acute effects of THC is scarce, and 
whether or not DA mediates in part the psychotogenic effects of cannabis remains 
unclear [6]. The results of three imaging studies investigating THC-induced dopamine 
release in the human striatum are inconsistent. While Bossong and colleagues [24] 
report a small, but significant increase in striatal DA, more recent work by Stokes 
and colleagues [25] as well as Barkus and colleagues [26] did not observe such an 
effect. Our present study agrees with the most recent studies, as no THC-induced DA 
release was detected in healthy controls. However, in both patients with psychotic 
disorder and unaffected relatives, pulmonary administration of THC was associated 
with a subsequent increase in striatal DA. This is in line with  epidemiological and 
experimental work,  demonstrating that patients with a psychotic disorder as well as 
individuals at risk for psychosis show increased vulnerability to the psychosis-inducing 
effects of cannabis at the behavioral level [28, 30, 31, 57, 58]. Thus, our findings 
suggest that in individuals at risk for psychotic disorder, increased sensitivity to the 
effects of cannabis may be mediated by striatal dopamine. Notably, in both 
patients and relative,, dopamine release was most pronounced in the caudate 
nucleus, and dopaminergic hyperactivity in this region is thought to play an 
important role in the pathophysiology of psychotic symptoms [59]. The apparent 
discrepancy in the findings presented by Bossong and colleagues [24] may thus be 
explained by sample admixture of individuals with higher than average liability for 
psychotic disorder. 
 
The present findings fit with animal work demonstrating interaction between the 
endocannabinoid and the DA system, in particular with regard to regulation of 
mesolimbic DA transmission [56, 60]. However, it has also been shown that part of 
the signaling activity mediated by the endocannabinoid system actually takes place 
downstream of DA neurotransmission in terms of D2 receptor activation [61, 62], and 
DA may conversely regulate endocannabinoid function [63]. In line with this, acute 
psychosis, which is thought to be characterized by dopaminergic hyperactivity in 
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striatal brain regions, has been associated with increased levels of the 
endocannabinoid anandamide in cerebrospinal fluid (CSF), independent of cannabis 
use and inversely correlated with psychotic symptoms [64, 65]. In addition, patients 
treated with D2 receptor blocking agents had lower CSF levels of anandamide [65]. 
Moreover, elevated levels of anandamide may be present in patients in the 
prodromal phase of psychotic disorder [66]. Research has additionally indicated 
that the density of CB1 receptors may be altered in individuals with psychotic 
disorder [67, 68]. Together, these observations suggest an important role of the 
endocannabinoid system in the pathophysiology of schizophrenia and may 
furthermore explain our finding that exogenous cannabinoids such as THC affect DA 
neurotransmission particularly in individuals at risk for DA dysregulation, such as 
patients with psychotic disorder and first degree relatives.  
 
Taken together, the results of the present study are in line with earlier studies 
demonstrating that THC does not significantly increase striatal DA in healthy 
volunteers. However, the novel finding that in patients with psychotic disorder as well 
as in their first-degree relatives, THC was associated with increased DA release in 
striatum, most markedly in the caudate nucleus, may explain previous discrepancies. 
DA thus may mediate in part the psychosis-inducing effects of cannabis, conditional 
on additional risk of DA dysregulation.  
Limitations  
The present findings have to be interpreted in the light of some limitations. The use 
of the LSRRM has several practical advantages, such as the requirement for only a 
single radiochemical synthesis and administration and avoidance of session effects. 
However, practical implementation of the model implies that time-dependent 
alterations in regional cerebral blood flow (rCBF) are not fully accounted for. Still, 
as argued by Christian and colleagues [34], using a single injection protocol in 
combination with the in vivo kinetics of [18F]fallypride may minimize the possible 
confounds of changing rCBF associated with drug administration. Second, due to the 
constraint of a one-day protocol, the order of drug administration was only single-
blind, so that drugs were not administered randomly, but in the same order for 
every subject. However, since individuals were told that the order of administration 
would occur randomly, and the majority of individuals was not able to accurately 
indicate the active drug when asked at the end of the experiment expectation bias 
seems unlikely, and would not explain differential effects across the three groups. 
Third, maximum levels of THC were relatively low in the present study compared to 
studies using the same amount of THC under the same administration protocol [24, 
39]. From these studies, it is known that THC reaches a peak concentration in plasma 
at 5 minutes after administration and decreases rapidly thereafter. In our study, due 
to practical reasons and despite major effort, blood samples were not always taken 
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at exactly 5 minutes after THC inhalation. Therefore, the relatively low THC plasma 
concentrations in the present study are likely due to the fact that the maximum peak 
was missed in some individuals. Subtle differences in the timing of blood sampling 
might also explain the relatively high between-subject variability. Also, since our 
sample included frequent cannabis users, of whom the majority used daily, it is not 
surprising that urinalysis was positive for 18 participants, which equals 
approximately 70% of the sample. Therefore, compliance with the study protocol 
(i.e. abstinence from cannabis during the 5 days prior to scanning) could only be 
confirmed by interview. Finally, the present finding of a group difference in ligand 
displacement in several subregions of the striatum has to be interpreted in light of 
rather low power (0.6). Replication in a larger group is therefore imperative.  
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Abstract 
 
The prevalence of cannabis use among individuals with psychotic disorder is 
considerable. However, little is known about patterns of use and factors contributing 
to continuation of use in this vulnerable population. The present study therefore 
investigated the role of craving, a central feature of drug-using behavior, in relation 
to cannabis use in patients with psychotic disorder and healthy controls. Craving was 
assessed cross-sectionally with the Obsessive Compulsive Drug Use Scale (OCDUS) 
for cannabis, as well as in the flow of daily life using the Experience Sampling 
Method (ESM - a structured diary method assessing individuals in daily life). Patients 
scored higher on the OCDUS than controls, but did not differ from controls in ESM 
indices of craving in daily life. Nevertheless, the ESM measure of craving better 
predicted daily life cannabis use and this association was stronger in controls. 
Craving was not moderated by antipsychotic medication in the patient group. The 
results indicate that the association between craving and cannabis use is assessed 
most accurately when assessed in the moment in daily life. 
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Introduction 
 
The use of cannabis is common in users of mental health services, particularly in 
patients with psychotic disorder [1, 2] in whom cannabis use has been associated 
with poor treatment concordance and higher relapse rates [3]. Although cannabis 
use thus constitutes a major concern in the treatment of patients with psychotic 
disorder [4], little is known about patterns and mechanisms of continuation of use in 
this vulnerable population, particularly in association with craving for cannabis.   
 
Craving constitutes a central feature of drug-using behavior and addiction. It is 
assumed that craving develops as a result of associative learning processes, in which 
the repeated use of addictive drugs is reinforced by the attribution of (aberrant) 
incentive salience to the act of drug taking [5, 6]. Recently, it has been suggested 
that craving for cannabis is increased in psychosis as patients, independent of 
frequency of use, experienced significantly more craving than cannabis-using 
healthy controls [7]. Another recent study suggested that in patients with psychotic 
disorder, craving was associated with antipsychotic treatment [8], which produces 
blockade at dopamine D2 receptors. Patients who were receiving risperidone 
experienced significantly more craving compared to patients treated with 
olanzapine or clozapine. These antipsychotics differ in D2 receptor occupancy rate, 
D2 receptor dissociation rate and D1/D2 receptor occupancy rate [9], risperidone 
having a higher D2 occupancy rate, a lower D1/D2 occupancy rate and a lower 
dissociation rate [8, 9]. Thus, there is evidence that craving is increased in psychosis, 
possibly in association with the use of antipsychotic medication. As craving for 
cannabis may be particularly instrumental for continuation of cannabis use in patients 
with psychotic disorder and constitutes an important aspect of drug-using behavior, 
this issue requires further clarification. 
 
In the above mentioned studies, craving for cannabis was measured primarily with 
the Obsessive Compulsive Drug Use Scale (OCDUS), which was recently validated 
for cannabis use [7]. It is a 12-item Likert-rated scale based on the Obsessive 
Compulsive Drinking Scale [10]. However, the use of cross-sectional questionnaires 
arguably is inaccurate as it does not allow assessment of dynamic, real-life 
fluctuations in craving and its association with cannabis use, which are important in 
users of mental health service given the complexity of drug-using behavior in 
relation to fluctuating psychiatric symptoms. Therefore, the current study used the 
Experience Sampling Method (ESM), a real-life self-assessment random time 
sampling technique, to extend existing findings on craving for cannabis in psychosis 
to the dynamic context of daily life. The following research questions were examined. 
First, is craving, measured both with the OCDUS and with ESM, increased in patients 
with psychotic disorder compared to healthy controls? Second, do OCDUS scores 
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reflect craving in daily life measured with ESM? And third, are OCDUS and/or ESM 
craving associated with cannabis use in daily life and does this association differ 
between groups? In addition, analyses were carried out in order to investigate the 
influence of antipsychotic medication in the patient group.  
 
Method 
Participants 
The study included 58 patients with a diagnosis of psychotic disorder and 63 healthy 
controls. Patients were recruited through in- and out-patient mental health service 
facilities in South Limburg, The Netherlands, in the context of a treatment study on 
the effectiveness of motivational interviewing for patients with psychotic disorder 
and co-morbid cannabis abuse. All patients were frequent cannabis users and willing 
to receive treatment. Controls were recruited using flyers in local ‘coffeeshops’ (cafes 
where cannabis is sold and consumed legally) and through word-by-mouth 
advertising. Inclusion criteria were i) aged between 18 to 55 years, ii) using 
cannabis minimally three times a week, and iii) patients only: a diagnosis of 
psychotic disorder according to the Operational Criteria Checklist (OPCRIT) [11], 
yielding diagnoses according to Research Diagnostic Criteria after running the 
OPCRIT computer program. Exclusion criteria were i) weekly use of illicit drugs other 
than cannabis, ii) alcohol use in excess of five units per day, iii) presence of 
neurological or psychiatric disorder other than psychosis (patients only) and iv) 
presence of any neurological or psychiatric disorder (confirmed by OPCRIT) and 
family history of psychosis (controls only).  
Instruments 
Clinical measures  
The Positive and Negative Syndrome Scale (PANSS) [12] was used to assess severity 
of psychotic symptoms in the patient group. The Obsessive Compulsive Drug Use 
Scale (OCDUS) for cannabis use [8] was used to assess craving for cannabis in both 
patients and controls. The OCDUS is a 12-item Likert-rated scale, originally 
described by Anton and colleagues in work relating to alcohol use [10]. A cannabis-
specific version of the OCDUS was recently validated by Dekker and colleagues [7] 
and successfully applied by Machielsen and colleagues [8], confirming the existence 
of three subscales which can be best described as ‘craving/urge’, ‘resistance’, and 
‘impact’. In order to capture levels of symptomatology and craving during the ESM 
week, both scales were administered after the week in which ESM was carried out. 
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The Experience Sampling Method (ESM) 
ESM is a pseudo-random self-assessment time sampling technique. Feasibility, 
validity and reliability of ESM in patients with schizophrenia have been 
demonstrated previously [13, 14]. Participants received a digital wrist watch and 
paper-and-pencil ESM booklet. Twelve times a day on six consecutive days, the 
watch emitted a beep at random moments in 85-minute time blocks between 07:30 
h and 1:30 h. After each beep, participants were asked to fill in a self-assessment 
form, collecting reports of affect, craving, severity of symptoms and activity rated on 
7-point Likert scales at the moment of the beep. Participants were instructed to 
complete the form immediately after the beep to minimize memory distortion and to 
record the time at which they completed their report. In addition to filling in self-
assessment forms after each beep, participants were asked to fill in a day-
evaluation form at the end of each day before they went to sleep. During a briefing 
session, the ESM procedure was explained and a practice booklet was completed 
and discussed with the participant to confirm that the scale format was accurately 
understood. During the ESM week, participants were contacted by phone in order to 
ensure that they complied with the instructions. Participants were requested not to use 
illicit drugs other than cannabis during the ESM week and if they did, to tell the 
investigator about this use. None of the participants was a regular user of drugs 
other than cannabis. At each beep, when forms were completed, participants were 
asked to report the exact time. Reports completed more than 5 minutes before and 
15 minutes after the beep were excluded from the analyses, given that previous 
research has shown that remote answers are less reliable and less valid [15]. In 
addition, given that previous work has shown that measures of individuals with less 
than 30% of completed reports are less reliable, participants with less than 24 valid 
beeps were similarly excluded from the analyses [15]. 
ESM measures 
Measures of craving and use of cannabis in the flow of daily life were derived from 
the ESM reports as described below.  
Craving intensity was assessed with the item ‘I would like to use cannabis’. This item 
was rated on a 7-point Likert scale from ‘not at all’ to ‘very much’. The score on this 
item formed a continuous variable (‘ESM craving intensity’) referring to the moment 
of the beep. The mean score per person across all beeps (‘mean ESM craving 
intensity’) was used to investigate overall group differences on this item.  
Craving frequency was measured by calculating the proportion of beeps per person 
at which craving was reported (dichotomous, cut-off score of > 2 on the craving 
item), relative to the number of valid beeps.  
Craving variability was defined as the mean square successive difference (MSSD), 
which is calculated as the average of the squared difference between successive 
continuous craving scores. The MSSD measure is suggested by several authors as a 
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measure of variability on a certain item across moments in momentary assessment 
studies and was accordingly adapted to represent variability in craving across 
measurement moments [16, 17]. 
Cannabis use was assessed with the item ‘Since the previous beep I have used 
cannabis’ and was dichotomously coded yes versus no. This item formed the variable 
‘momentary cannabis use’ (dichotomous, yes versus no) and referred to cannabis use 
in the period between two beeps (see figure 1). In addition, to obtain a measure of 
frequency of cannabis use throughout the ESM week, we calculated the percentage 
of beeps per person at which cannabis use was reported, relative to the number of 
valid beeps. This score formed the continuous variable ‘cannabis use frequency’.  
Antipsychotic medication 
Conform previous work [8, 18], antipsychotic medication was classified as tight 
(haloperidol, flupentixol, penfluridol, risperidone) or loose binding (olanzapine) 
based on published D2 receptor occupancy and dissociation rates.  
Statistical analysis 
Data were analyzed using Stata© release 11.0. All analyses were a priori adjusted 
for age and sex.  
Individual-level analyses testing differences between groups 
Linear regression models were used to investigate i) overall group differences on 
OCDUS scores, mean ESM craving intensity, mean ESM craving frequency, mean 
ESM craving variability and cannabis use frequency, ii) the association between 
OCDUS scores and mean ESM craving intensity with cannabis use frequency on the 
one hand, and iii) the association between scores on the OCDUS, including its 
subscales, and mean ESM craving intensity on the other. Additional analyses were 
performed in order to investigate the effect of antipsychotic medication in the 
patient group. 
Momentary-level ESM analyses 
Due to the multilevel structure of ESM (i.e. multiple assessments clustering within 
subjects) multilevel random effects regression analysis was applied using the xtgee 
routine, yielding odds ratio’s (OR), to test the association between ESM craving 
intensity at time point (t) (independent variable) and momentary cannabis use 
reported at time point (t+1) dependent variable (figure 1). The interaction with 
group was calculated in order to investigate whether this association differed 
between groups. These analyses were additionally adjusted for cannabis use, 
reported at time point (t). Analyses were performed in order to investigate the 
effect of antipsychotic medication in the patient group.  
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‘Since the last beep 
I have used cannabis’craving
t                                                               t+1
 
 
Figure 1. Moment-to-moment analyses of association between ESM craving intensity at time t and momentary 
cannabis use between t and t+1, under additional adjustment for cannabis use reported at time t.  
 
Results 
Sample 
Of the 58 patients, 18 (31.0 %) had fewer than 24 valid reports and were 
therefore excluded from the analyses. Of the 63 controls, 6 (9.5 %) were excluded 
due to fewer than 24 valid reports. Thus, the final sample consisted of 40 patients 
with psychotic disorder (24 male, 60.0 %; for OPCRIT diagnoses see table 1) and 
57 controls (41 male, 71.9 %). Eight participants (3 patients and 5 controls) used 
cannabis in combination with other drugs during a total of 12 (0.9 %) of all beeps at 
which cannabis use was reported (n = 1347). To avoid confounding by other drug 
use, these observations were excluded from the analyses. Patients were receiving 
either tight binding agents (N = 12), loose binding agents (N = 14), a combination 
of antipsychotics (N = 10) or no medication (N = 4). On average, patients were 
older, had lower educational level and, per definition, had higher PANSS scores 
than controls. Furthermore, patients had collected less valid ESM reports than controls. 
Demographic and clinical characteristics are summarized in table 1.  
Individual-level analyses: group differences 
Patients scored significantly higher on the total OCDUS than controls (B = 1.18, p = 
0.022). Patients scored significantly higher than controls on the OCDUS subscale 
‘craving/urge’ (B = 1.39, p = 0.036) and on the subscale ‘impact’ (B = 1.43, p = 
0.009), whereas patients and controls did not differ on the subscale ‘resistance’ (B = 
0.05, p = 0.958). No differences between patients and controls were apparent with 
regard to mean ESM craving intensity (B = 0.43, p = 0.168) or mean ESM craving 
frequency (B = 12.67, p = 0.062). The two groups also did not differ in mean ESM 
craving variability (B = 2.17, p = 0.289), and similarly did not differ in mean ESM 
cannabis use frequency (B = 7.36, p = 0.139). See table 2 for mean scores per 
group.  
154 IS CRAVING FOR CANNABIS INCREASED IN PATIENTS WITH PSYCHOTIC DISORDER? 
 
 
Both OCDUS total score and mean ESM craving intensity were significantly 
associated with mean ESM cannabis use frequency (BOCDUS = 14.05, p < .001; 
BESMcraving = 13.49, p < 0.001), and this association did not differ between patients 
and controls (p > 0.05) When OCDUS total score and mean ESM craving intensity 
were entered in the model simultaneously, only mean ESM craving intensity remained 
significantly associated with mean ESM cannabis use frequency (BESMcraving =  13.08, 
p < 0.001; BOCDUS = -2.11, p =  0.619).   
 
OCDUS total score was significantly associated with mean ESM craving intensity (B = 
4.33, p < 0.001). Regarding the OCDUS subscales, significant associations with 
mean ESM craving intensity were found for ‘craving/urge’ (B = 0.48, p < 0.001) 
and ‘impact’ (B = 0.33, p < 0.001), but not for ‘resistance’ (B = 0.11, p = 0.223).  
 
Analyses did not reveal any differences in scores on the OCDUS, mean ESM craving 
intensity, mean ESM craving frequency or mean ESM craving variability between 
patients receiving tight binding agents versus patients receiving loose binding agents 
or no antipsychotic medication (all p > 0.05, see table 3 for mean scores per 
medication group).  
Momentary-level ESM analyses 
Momentary ESM craving intensity was significantly associated with subsequent 
momentary cannabis use (OR = 1.49, p < 0.001), and this association was 
somewhat stronger in controls as compared to patients (Fig. 2, p = 0.001). The 
association between ESM craving intensity and momentary cannabis use was not 
moderated by medication status in the patient group (all p > 0.05).  
 
 
 
 
Figure 2. Moment-to-moment association between ESM craving intensity at time (t) (ranging from 1 = not at all 
to 7 = very much) and momentary cannabis use (yes versus no) between t and (t+1). 
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Table 1. Demographic and clinical characteristics 
 
 
 Patients Controls Patients vs. Controls 
N 40 57 n.a. 
Mean age (SD) 37.7 (9.15) 27.4 (9.16) F(1, 95) = 28.22, p < 0.001 
Male % (n) 61.5 (24) 71.9 (41) χ2 (1) = 1.14, p = 0.285 
Education % (n)*    
Elementary 27.8 (10) 14.3 (8) 
 
χ2 (2) = 11.6, p = 0.003 
Secondary 61.1 (22) 41.1 (23) 
Higher 11.1 (4) 44.6 (25) 
Mean PANSS scores (SD)     
Positive symptoms 1.73 (0.77) 1.05 (0.10) F(1, 91) = 42.41, p < 0.001 
Negative symptoms 1.58 (0.61) 1.22 (0.23) F(1, 89) = 25.61, p < 0.001 
Global symptoms 1.53 (0.44) 1.10 (0.16) F(1, 86) = 45.81, p < 0.001 
OPCRIT diagnoses % (n)    
Schizophrenia  40.0 (16) n.a. n.a. 
Schizoaffective disorder 5.0 (2) n.a. n.a. 
Other psychoses 55.0 (22) n.a. n.a. 
Current use of medication % (n) 90.0 (36) 0.00 (0) n.a. 
Tight binding antipsychotics 33.3 (12) n.a. n.a. 
Loose binding antipsychotics 38.9 (14) n.a. n.a. 
Other/combination 27.8 (10) n.a. n.a. 
Mean valid ESM reports % (n) 44.4 (32) 56.9 (41) F(1, 95) = 14.99, p = 0.002 
Cannabis use frequency % (n)  40.6 (13) 36.6 (15) F(1, 93) = 0.47, p = 0.496 
 
Note. Some percentages do not total 100 due to rounding.  
* Information is missing in n = 1 control subject and n = 4 patients. 
 
 
 
Table 2. Mean ESM and OCDUS scores per group. 
 
 
 
Patients 
 
Controls 
Mean ESM craving intensity (SD) 3.57 (1.31) 3.20 (1.26) 
ESM craving frequency % (SD) 61.43 (29.20) 52.71 (27.82) 
ESM craving variability MSSD (SD) 15.58 (8.69) 13.90 (9.14) 
Mean OCDUS scores (SD)   
Craving/urge 3.08 (1.02) 2.45 (0.69) 
Resistance 3.21 (1.02) 3.20 (1.21) 
Impact 2.27 (0.80) 1.65 (0.63) 
Total score 2.76 (0.80) 2.24 (0.55) 
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Table 3. Mean scores per medication group (patients only; all p > 0.05). 
 
 
Tight 
(N = 12) 
Loose 
(N = 14) 
No medication 
(N = 4) 
Mean ESM craving intensity (SD) 3.27 (1.63) 3.83 (1.14) 2.92 (0.73) 
ESM craving frequency % (SD) 51.30 (29.57) 70.04 (26.33) 48.13 (19.72) 
ESM craving variability MSSD (SD) 14.04 (11.56) 16.70 (6.90) 11.62 (4.30) 
Mean OCDUS scores (SD)    
Craving/urge 3.07 (1.41) 3.38 (1.01) 2.65 (0.19) 
Resistance 3.05 (1.33) 3.14 (1.19) 3.38 (0.75) 
Impact 2.29 (1.13) 2.51 (0.59) 2.05 (0.93) 
Total score 2.74 (1.10) 2.98 (0.74) 2.52 (0.41) 
Note. Classification of medication according to high or loose binding characteristics  at D2 receptors was done 
in agreement with Lataster and colleagues [18].  
 
Discussion 
 
The present study demonstrated that craving is increased in patients with psychotic 
disorder, when measured with the OCDUS. Yet, in daily life, patients and controls 
did not differ with regard to craving intensity, craving variability or craving 
frequency. In patients and controls, both OCDUS craving and ESM craving intensity 
were associated with frequency of cannabis use. However, ESM craving appeared 
to be a better predictor of cannabis use in daily life, given that when both terms 
were entered in the individual-level prediction model of cannabis use simultaneously, 
only ESM craving remained significant. Analysis of moment-to-moment assessment of 
craving in association with cannabis use showed that craving intensity was predictive 
of subsequent cannabis use. Although sample sizes per medication subgroup were 
small and individual-level comparisons likely had low power, no differences were 
revealed between patients receiving tight or loose binding agents or no medication.  
Craving for cannabis in daily life  
In line with the findings of Dekker and colleagues [7], increased craving was 
apparent in patients with psychotic disorder, relative to controls, in a comparison of 
OCDUS scores. Yet, when craving was measured in the moment with ESM, patients 
and controls reported comparable levels of craving intensity. One possibility to 
account for this discrepancy is that our ESM craving measure is not a valid tool for 
the assessment of craving for cannabis. However, OCDUS craving and ESM craving 
were significantly associated with each other, with the exception of the OCDUS 
subscale ‘resistance’, suggesting that at least part of the concept of craving is 
reflected by our daily life ESM craving measure. In addition, when both OCDUS 
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scores and mean ESM craving intensity were simultaneously entered in the prediction 
model, only mean ESM craving remained significantly associated with frequency of 
cannabis use in daily life, suggesting that OCDUS is reducible to the ESM measure in 
this regard. Together with the finding that momentary ESM craving intensity was 
significantly associated with subsequent cannabis use, this supports the validity of 
ESM craving and furthermore indicates that craving as captured by the OCDUS is 
less predictive for daily life cannabis use. One explanation for this finding is that 
reporting on cross-sectional questionnaires is subject to interpretation, in comparison 
with reporting in the moment with ESM. In OCDUS, patients may report their 
(sometimes erroneous) interpretation of cannabis use as beneficial for symptoms  [19], 
resulting in higher OCDUS craving scores, whereas during ESM individuals report 
momentary craving without interpretation of the perceived relationship between 
cannabis use and symptoms. 
 
The association between ESM craving intensity and subsequent cannabis use was 
stronger for controls than for patients, yet no differences emerged with regard to 
overall craving intensity, craving frequency and craving variability. Since patients 
and controls did not differ with regard to the OCDUS subscale ‘resistance’ it is 
unlikely that the weaker association in patients with psychotic disorder is due to 
being more resistant to urges of craving. One explanation may be that patients with 
psychotic disorder are prevented from use more often than controls, for example 
due to lack of money or limited access to sites where cannabis may be obtained. 
Alternatively, cannabis use in patients may occur more independently of inner cues 
such as craving and may instead be under stronger guidance by other, unmeasured 
factors, such as fluctuating mental states. 
Antipsychotic medication and craving in patients with psychotic disorder 
In contrast to Machielsen and colleagues [8], who showed that patients receiving 
tight binding agents experienced significantly more craving than patients treated 
with loose binding antipsychotics, our study did not reveal any significant differences 
with regard to antipsychotic medication. Moreover, inspection of the mean OCDUS 
or ESM craving scores suggests that patients treated with tight binding agents 
experience less craving, both with regard to intensity and frequency, than patients 
receiving loose binding agents. Medication-free patients, on the other hand, had the 
lowest mean scores. Yet, none of these differences reached significance in our 
analyses. One explanation may be lack of power due to small sample sizes, 
although this would not explain the different directionality of the findings compared 
to Machielsen and colleagues (2011), and the ESM-level analyses were more 
powerful than the individual-level analyses. Therefore, the current results may also 
indicate that craving is increased in psychosis, independently of antipsychotic 
medication, supporting the later findings by Dekker and colleagues (in press).  
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Limitations 
The current results have to be interpreted in the light of several methodological 
limitations. First, compliance with the research protocol is a crucial element of the 
ESM research method. Some authors have cast doubt on compliance in paper-and-
pencil ESM studies and preferred the use of electronic devices [20]. However, two 
studies in which paper-and-pencil diary and electronic diary data were collected 
using comparable procedures, suggested good compliance rates with the time 
protocol and demonstrated that both methods yielded data comparable in terms of 
both psychometric features and research findings [21, 22] . Second, reports on 
craving and cannabis use were based on self-report and not confirmed by objective 
measures, such as urine analysis. However, underreporting of cannabis use is unlikely, 
as consumption of cannabis is legal in The Netherlands and participants reported 
cannabis use at 50% of the beeps. Finally, the current ESM protocol assessed 
craving with the use of a single item, which may not be sufficient to capture the 
complex concept of craving, compared to multi-item questionnaires such as the 
OCDUS. However, the current analyses suggest that our ESM craving measure is a 
better predictor of daily life cannabis use than the OCDUS, lending support to the 
validity of the ESM craving item.  
 
Conclusion  
 
Taken together, and several limitations notwithstanding, the findings suggest that 
craving is increased in patients with psychosis, independent of antipsychotic 
medication, when assessed with cross-sectional questionnaires such as the OCDUS 
that may carry more interpretational judgments than in-the-moment ESM reports. In 
contrast, daily life craving does not seem to differentiate between patients and 
controls, yet craving at ESM level is strongly associated with daily life cannabis use, 
independent of the cross-sectional OCDUS measure. Therefore, the current results 
emphasize the need to further investigate craving as a factor maintaining cannabis 
use in patients with psychotic disorder, especially regarding the influence of 
antipsychotic medication. Deeper insight into patterns of craving in relation to 
cannabis use in psychosis is crucial for understanding the co-morbidity between 
psychosis and cannabis use disorders and for developing new and effective 
treatment programs.  
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Summary 
 
A recent study by Morgan and colleagues found that cannabidiol attenuates the 
acute cognitive effects of delta-9-tetrahydrocannabinol (THC). This is of interest as 
THC has been associated with the detrimental effects of cannabis on mental health in 
at-risk users, and the potency of cannabis is increasing across Europe. 
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Introduction 
 
The paper by Morgan and colleagues published in this issue [1] adds to the idea 
that cannabidiol (a cannabis compound) antagonises the effects of delta-9-
tetrahydrocannabinol (THC, the main psychoactive compound of cannabis). 
Cannabidiol itself has no psychoactive properties but instead, as Morgan et al 
showed, may protect against the cognitive effects of THC. In their naturalistic study, 
participants consumed their own, self-chosen cannabis and were subsequently tested 
on a number of cognitive task and questionnaires. Individuals whose self-chosen 
cannabis contained high levels of cannabidiol showed no memory impairment after 
consumption of their cannabis, in contrast to the individuals whose self-chosen 
cannabis contained low levels of cannabidiol: here, cannabis significantly worsened 
memory performance.  
 
Cannabis is the most frequently used drug in the world and although recent data 
suggest a stabilisation of cannabis use in most countries in Europe, its use remains 
particularly popular among young adolescents. That this is of great concern follows 
from epidemiological studies showing that heavy use during adolescence is 
particularly detrimental with respect to long-term effects on cognition and mental 
health. The findings by Morgan and colleagues [1] emphasise the importance of 
taking into account differences in potency of cannabis preparations. Cannabis 
potency varies widely between and within countries and between different products. 
Data from the UK, for instance, show that, on average, cannabis resin contains 
approximately equal levels of THC and cannabidiol, whereas herbal cannabis 
contains only moderate levels of THC and almost no cannabidiol. By contrast, 
sinsemilla, or skunk, contains high levels of THC and almost no cannabidiol [2]. 
European data show that the use of resin has remained relatively stable over the 
past years. The use of skunk, however, has significantly increased in the UK and 
other European countries. It is quite established that the detrimental effects of 
cannabis on mental health are primarily attributable to THC. In this light, the findings 
by Morgan and colleagues are relevant as they show that different types of 
cannabis may moderate the risk for mental health problems to different extents, 
depending largely on the potency of the cannabis preparation. This is also of 
relevance for the cannabis–psychosis causality debate and could help to explain 
why not everyone exposed to cannabis will develop cognitive impairments or 
psychiatric symptoms. Although a clear dose–response association has consistently 
been shown between cannabis exposure and psychosis risk, none of the published 
epidemiological studies differentiated between potency and content of the cannabis 
they studied. The first evidence that different strains of cannabis may indeed have a 
differential impact on mental health risk was provided by Di Forti and colleagues 
[3]. They investigated different types of self-chosen cannabis and found that 
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individuals with a first episode of psychosis had used higher-potency cannabis (i.e. 
skunk) for a longer period of time and with greater frequency than healthy controls 
[3]. Thus, use of skunk containing high concentrations of THC but low concentrations of 
cannabidiol was associated with a higher risk of mental health problems. 
 
Does cannabidiol reverse the acute effects of THC? 
 
In Morgan and colleagues’ current study, cannabidiol antagonised the effects of THC 
on memory [1]. However, no such reversal effects were observed for transient 
psychotic-like symptoms or anxiety. In a previous study, the authors did show that 
individuals who smoked cannabis low in cannabidiol reported significantly more 
psychotic experiences compared with those who smoked cannabis containing high 
levels of cannabidiol [4]. Although the authors assessed psychosis proneness as 
opposed to state-related psychotic experiences in that study, the results suggest that 
cannabidiol may protect against the psychotogenic properties of THC. Experimental 
studies are in line with this, showing that cannabidiol has the ability to reduce 
anxiety and psychotomimetic symptoms as well as psychosis-related cognitive 
distortions induced by THC [5, 6]. It remains largely unknown, however, how 
cannabidiol brings about the THC-antagonising effects, since its pharmacological 
actions are still elusive. Although cannabidiol seems to have only low affinity for the 
cannabinoid 1 (CB1) receptor (the main binding site for THC), some interaction 
between cannabidiol and the CB1 receptor has been suggested [7]. Also, 
cannabidiol may exert its effects by inhibiting reuptake of the endogenous 
cannabinoid anandamide [7]. In an effort to understand the biological mechanisms 
underlying the interaction between THC and cannabidiol, Bhattacharyya and 
colleagues [5] demonstrated opposing effects of THC and cannabidiol on brain 
activity by using functional magnetic resonance imaging. Delta-9-
tetrahydrocannabinol attenuated striatal activity and concurrently induced psychotic 
symptoms, whereas the reverse (i.e. increases in striatal activity) was observed under 
cannabidiol conditions. Clearly, the molecular actions of cannabidiol are in urgent 
need of further investigation. 
 
Cannabidiol as a potential antipsychotic drug 
 
The fact that cannabidiol is able to reduce the acute anxietyinducing and 
psychotomimetic effects of THC has raised the question whether cannabidiol might 
also be effective in treating patients with established psychotic disorder [8]. 
Evidence, although limited, seems promising: Zuardi and colleagues reported 
improvement in two patients treated with cannabidiol, whose symptoms worsened 
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after discontinuation of cannabidiol. In two other patients, cannabidiol had no 
therapeutic effects; however, these two patients did not respond to other 
antipsychotic medication either [8]. Preliminary data on a clinical trial including 42 
patients described similar positive effects for cannabidiol on Positive and Negative 
Syndrome Scale scores, but with fewer side-effects than regular treatment with 
amisulpride [9]. 
 
Cannabis and genetic liability 
 
It seems clear from the above that cannabidiol has the ability to reverse some of the 
acute effects of THC and may even reduce psychotic symptoms in some patients.  
Differences in cannabidiol content and THC/cannabidiol ratio between different 
cannabis preparations may furthermore help to explain why only a minority of 
cannabis users develop a psychotic illness. Underlying genetic liability for psychosis, 
however, has been found to determine cannabis sensitivity as well. In a recent study, 
it was found that individuals at (genetic) risk for psychosis may be more sensitive not 
only to the psychosis-inducing effects of cannabis in daily life, but also to the 
positive, mood-enhancing effects of cannabis [10]. Moreover, the rewarding effects 
of cannabis on mood seem to be acute, whereas psychotic experiences emerge 
subacute. These findings fit with the idea that different components may have 
different or even opposing effects, with THC being responsible for the psychosis-
inducing effects and cannabidiol for the anxiolytic effects. Although numerous studies 
have shown that cannabis has a negative impact on mental health, especially in 
individuals with established psychotic disorder, the intriguing question remains as to 
why patients continue to use these highpotency types of cannabis. Di Forti’s data 
seem to indicate that individuals at increased genetic risk for psychosis (i.e. patients 
with first-episode psychosis) prefer smoking the higher-potency cannabis. Morgan 
and colleagues, however, found no evidence that healthy controls with elevated 
schizotypy scores show preference towards the high THC/low-cannabidiol variants, 
as the ‘high-cannabidiol’ and ‘low-cannabidiol’ groups did not differ with regard to 
schizotypy [1].  
 
Thus, as different types of cannabis clearly affect mental health differentially, more 
research is needed to understand how genetic liability may increase sensitivity to 
and preference for specific types of cannabis. Furthermore, the study by Morgan 
and colleagues stresses the importance of taking into account differences in cannabis 
potency when studying acute and long-term effects of cannabis use. Also, when 
treating patients with psychosis and comorbid cannabis dependence, the type of 
self-chosen cannabis needs to be considered in order to better understand how not 
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only the rewarding and anxiolytic, but also the psychosis-inducing properties of the 
drug determine patterns and continuation of use. 
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Discussion 
 
This thesis applied epidemiological, observational and experimental neurochemical 
imaging techniques to study several aspects of the cannabis-psychosis relationship. 
First, the temporal association between exposure to cannabis and the incidence of 
psychotic symptoms was studied. Second, it was investigated whether differential 
sensitivity to the psychosis-inducing effects of cannabis is influenced by the 
environment. Third, biological mechanisms that might underlie the association 
between exposure to cannabis and increased risk for psychosis were elucidated. 
Finally, in order to increase our understanding of patterns and mechanisms of use in 
clinical populations, craving for cannabis was investigated as a maintaining factor 
for continuation of cannabis use in daily life of patients with psychotic disorder, 
among which cannabis use is particularly prevalent.  
 
Results presented in this thesis show that the use of cannabis preceded the onset of 
incident, subclinical psychotic symptoms in individuals who had never experienced 
any psychotic symptoms previously (chapter 2). It was also revealed that continued 
use of cannabis was associated with an increased risk of persistence of these 
subclinical psychotic symptoms (chapter 2). Furthermore, it could be demonstrated 
that individuals who grew up in an urban environment were particularly sensitive to 
the long-term psychosis-inducing effects of cannabis, providing evidence for 
environmental moderation of vulnerability to the long-term psychosis-inducing effects 
of cannabis (chapter 3). Yet, the previously reported link between childhood trauma 
and increased sensitivity to the effects of cannabis on psychosis risk could not be 
replicated (chapter 4). With regard to possible neurobiological mechanisms of the 
cannabis-psychosis relationship, it was shown that part of the psychosis-inducing 
effects of cannabis might be mediated by THC-induced dopamine release in striatal 
brain regions, in particular in patients with established psychotic disorder and 
individuals at risk for psychosis (chapters 5, 6 and 7). Finally, it was indicated that 
patients with established psychotic disorder experience higher levels of craving for 
cannabis as indicated by higher scores on the Obsessive Compulsive Drug Use Scale 
(OCDUS) for cannabis. Yet in daily life, craving did not seem to differentiate 
between patients and controls (chapter 8).  
Cannabis and psychosis: A causal association? 
Primarily based on the results of numerous epidemiological studies, the link between 
exposure to cannabis and increased psychosis risk has been well established [1-3]. 
However, cannabis use is much more prevalent among patients with psychotic 
disorder compared to the general population [4-6]. Therefore, it has remained a 
matter of debate, whether the association between cannabis use and the onset of 
psychosis is indeed causal, or else is due to reverse causality, e.g. in form of self-
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medication, or residual confounding by preexisting symptoms or underlying 
vulnerability [7, 8]. This issue was systematically addressed in chapter 2 of this thesis 
by analyzing data from a prospective population-based cohort study of adolescents 
and young adults. Due to the long follow-up period, individuals with carefully 
assessed pre-existing psychotic symptoms could be excluded from the analyses. Still, 
the study revealed a strong association between cannabis use in the period between 
baseline and first follow-up and incident psychotic symptoms four years later at 
second follow-up [9]. Moreover, the presence of psychotic symptoms at baseline did 
not predict cannabis use at follow-up. This is in accordance with previous research in 
the same cohort [10] and in contrast to the self-medication hypothesis, which implies 
that cannabis use is caused by the intention to relieve pre-existing psychotic 
symptoms or distress resulting from mental illness [11]. The study presented in this 
thesis thus clarifies the temporal association between exposure to cannabis and the 
development of psychotic symptoms and, together with the observation that 
continuation of use is particularly detrimental, provides further evidence for a causal 
relationship. Of note, in a large Danish cohort study, age of onset of schizophrenia 
was significantly lower in patients with a history of cannabis use, compared to 
patients who were never exposed [12]. This link between cannabis use and earlier 
age of onset of psychotic disorders was recently established by meta-analytic work 
[13].  
 
Thus, the research presented in this thesis strengthens the evidence that cannabis use 
is causally linked with increased risk of psychotic disorder [9], the first stage of which 
is expressed as abnormal persistence of subclinical psychotic symptoms [9, 14]. 
Alternatively, it has been argued that the link between cannabis and psychosis is due 
to shared etiology, where similar neuropathology, including alterations in mesolimbic 
dopamine transmission and dysregulation of cortical, temporal and mesoaccumbens 
circuits, give rise to both cannabis use and psychotic disorder [15]. However, 
individuals differ in their sensitivity to the effects of cannabis and not all patients 
with psychotic disorder have been exposed to cannabis. Hence, cannabis use most 
likely constitutes a component cause of psychosis, co-depending on other causal 
influences [16]. Previous research has shown that underlying psychosis liability (as 
indicated by higher than average scores on scales measuring schizotypy or by 
familial predisposition) as well as variation in specific genetic polymorphisms may 
render some individuals more vulnerable to the effects of cannabis than others [10, 
17-20]. Little is known however about possible environmental moderation. Therefore, 
this thesis investigated the influence of two environmental candidates, urbanicity and 
trauma. Urbanicity is one of the major risk factors of schizophrenia [21] and trauma 
has been previously suggested to interact with cannabis use in increasing psychosis 
risk [22-24]. In agreement with the proposed mechanism of environmental 
moderation, the results described in chapter 3 indicate that the risk of developing 
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psychotic symptoms is greater in individuals growing up in an urban environment 
compared to individuals from rural areas [25]. On the contrary, as discussed in 
chapter 4 of this thesis, interaction between trauma and cannabis use could not be 
confirmed [26]. Still, our findings lend support to the idea that in addition to gene-
environment interaction, mechanisms of environment-environment interaction play a 
causal role in the pathway to psychosis.  
Cannabis and psychosis: A role for sensitization? 
As outlined above and discussed in this thesis, cannabis use increases the risk of 
incident subclinical psychotic symptoms, and moreover, impacts negatively on the 
persistence of these subclinical symptoms [9]. Previous research has shown that 
developmental expression of subclinical psychotic experiences in adolescence is 
mostly transient [27]. Yet, repeated exposure to environmental risk factors, including 
cannabis use as shown in chapter 2, may cause subclinical psychotic experiences to 
persist and become more severe, resulting in onset of psychotic illness in a minority of 
individuals [9, 28, 29]. This is in line with the psychosis-proneness-persistence model, 
in which genetic predisposition for psychosis synergistically combines with increasing 
levels of environmental exposure to cause clinical impairment and the onset of 
psychotic disorder [14]. This has been previously demonstrated for the additive 
effects of cannabis, trauma and urbanicity [30] and receives further support by our 
recent finding of interaction between cannabis use and urbanicity. Intriguingly, while 
cannabis, trauma, and urbanicity do not reflect the same environmental influence, 
they all impact on the same (psychotic) outcome [31]. This implies a shared 
interactive pathway. A mechanism of developmental sensitization has been 
suggested to underlie this pathway, referring to the observation that repeated 
exposure to a stimulus elicits progressively greater responses over time [32]. Studies 
demonstrating increasing effects on psychosis risk dependent on cumulative 
environmental exposure are in agreement with a process of sensitization [9, 33-35] 
Moreover, the aforementioned synergistic effects between different risk factors, 
including cannabis use and urbanicity (chapter 3), are suggestive of a mechanism of 
cross-sensitization underlying the developmental pathway to psychosis [25, 30, 36].  
 
Biologically, the mechanism of sensitization remains understudied and not well 
understood, at least concerning the evidence in humans. Only one study so far has 
investigated neurochemical correlates of sensitization to amphetamine in humans and 
demonstrated alterations in dopaminergic signaling induced by the repeated 
administration of amphetamine [37]. This is in line with animal studies demonstrating 
increased activity of dopamine neurons in the VTA [38] and increased dopamine 
release in the striatum [39-41] following amphetamine sensitization. Yet, as 
discussed in chapter 6 of this thesis, neurobiological evidence for sensitization 
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induced by exposure to cannabis is scarce, although some studies in rats do suggest 
a dopaminergic mechanism of cannabis sensitization [42, 43].  
Cannabis and psychosis: Do all roads lead to dopamine? 
While the epidemiological link between cannabis and psychosis has received 
considerable attention, very little is known about the biological underpinnings. The 
important role of a dopamine dysfunction in psychosis and schizophrenia – 
summarized in chapter 5 – together with evidence from animal work suggesting 
interaction between the endocannabinoid and the dopamine system – discussed in 
chapter 6 – has given rise to the hypothesis that part of the psychosis-inducing 
effects of cannabis are mediated by dopamine [44]. This hypothesis has been tested 
recently by groups in the UK and The Netherlands, yet with inconsistent results. While 
Bossong and colleagues [45] found evidence for dopamine release induced by THC, 
Stokes and colleagues [46] and Barkus and colleagues [47] did not find such an 
effect. Notably, these studies were conducted in healthy male subjects who used 
cannabis only recreationally. However, patients with established psychotic disorder 
as well as their unaffected relatives have been shown to be more vulnerable to the 
psychosis-inducing and behavioral effects of cannabis [17, 48]. It is therefore 
important to investigate the effects of THC on dopamine release in these at-risk 
populations. Chapter 7 of this thesis presents the first neurochemical imaging study 
of THC-induced dopamine release in patients with psychotic disorder, unaffected 
relatives of patients with psychotic disorder and healthy controls. In line with Stokes 
and colleagues [46] and Barkus and colleagues [47], THC did not induce dopamine 
release following pulmonary administration of THC in healthy controls. Yet in both 
patients and relatives, administration of THC was associated with a subsequent 
increase in striatal dopamine. This suggests that the psychosis-inducing effects of 
cannabis are mediated by a mechanism of increased striatal dopamine release in 
individuals at risk for dopamine dysregulation, and thus provides evidence for 
differential sensitivity towards cannabis on a neurobiological level (chapter 7). 
However, previously it was demonstrated that pre-treatment with haloperidol, a D2 
receptor antagonist, did not prevent the behavioral and psychotomimetic effects 
produced by administration of THC and even worsened some of the cognitive effects 
of THC [49]. Although this might corroborate the evidence concerning interaction 
between the dopaminergic and endocannabinoid system, the findings suggest that 
the psychosis-inducing and perceptual effects of cannabis involve pathways other 
than increased dopamine turnover [49]. This would also explain the observation that 
THC does not induce dopamine release in healthy controls. A recent review on the 
neuropharmacological mechanisms of endocannabinoid action suggests that, in the 
striatum, dopaminergic neurotransmission is actually upstream of endocannabinoid 
function  and D2 receptor stimulation leads to endocannabinoid-mediated 
depression of cortical inputs [50]. Moreover, it appears that drugs which follow this 
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mechanism and weaken cortical inputs to medium spiny neurons of the indirect 
pathway are pro-psychotic [50]. Yet, findings from animal studies indicate that, in 
the ventral tegmental area, THC might stimulate burst firing of DA neurons and as a 
consequence increase DA levels in the striatum [44], which is in agreement with the 
results in chapter 7, at least concerning patients with psychotic disorder and first-
degree relatives. Thus, the pathway from cannabis to psychosis most likely involves 
multiple mechanisms and THC might exert its effects by both increasing striatal 
dopamine and directly influencing synaptic plasticity via a mechanism downstream 
of dopamine. Still, the former might be particularly true in individuals at risk for 
psychosis, who are especially prone to dopamine dysregulation (chapter 7).  
 
Notably, early adolescence has been shown to be a particularly vulnerable period 
for the long-term effects of cannabis, as the risk to develop psychosis later in life is 
higher for those who started to use cannabis before the age of 15 compared to 
those who started at a later age [51, 52]. This is in agreement with preclinical 
evidence from studies in rats: Chronic treatment with THC led to long-lasting 
cognitive as well as behavioral changes in both pubertal and adult rats, yet the 
effects of acute administration were significantly more pronounced in the pubertal 
rats [53]. Adolescence represents a highly vulnerable period with regard to brain 
development in general and the development of the endocannabinoid system in 
particular [54]. Although our understanding of the function and development of the 
endocannabinoid system is still limited, this system is thought to play a crucial role in 
the fine-tuning of synaptic transmission, modulating GABAergic, glutamatergic and 
dopaminergic neurotransmission [55]. Early exposure to exogenous cannabinoids 
such as THC might accordingly lead to profound disturbances in the development of 
cortical as well as subcortical neural networks, providing the basis for vulnerability 
towards mental health problems, including psychosis, later in life [56]. Interestingly, 
schizophrenia has been associated with functional impairments in the 
endocannabinoid system, independent of cannabis use. In acutely psychotic patients 
with schizophrenia as well as in individuals with prodromal schizophrenia pathology, 
levels of the endogenous cannabinoid anandamide were elevated and inversely 
correlated with both positive and negative symptoms [57-59]. In addition, studies on 
the availability of cannabinoid 1 (CB1) receptors, the primary binding site of both 
endocannabinoids and THC, suggest increased levels of cortical CB1 receptors in 
schizophrenia [60-63]. Yet other studies are not consistent with this and found no 
elevation in CB1 receptor density [64, 65]. Surprisingly, no study so far has looked 
at CB1 receptor density in healthy cannabis users. The results of an early rat study 
are indicative of downregulation of CB1 receptor availability following chronic 
administration of THC [66].   
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Taken together, the biological pathways from cannabis to psychosis appear to be 
diverse and research on this topic is still in its infancy. The research presented in this 
thesis is in line with a role for dopamine in bringing about the psychotomimetic 
effects of cannabis, at least in individuals at risk for psychosis. Alternatively, studies 
into the functional role of the endocannabinoid system in both healthy individuals 
and patients with schizophrenia suggest that (early) exposure to cannabis might 
induce psychosis risk by disrupting crucial cortical and subcortical neural networks 
necessary for a well-functioning endocannabinoid system [67]. Further research into 
the developmental processes and mechanisms of endocannabinoid-mediated 
neurotransmission in the human brain is therefore warranted. 
Cannabidiol as a protective agent 
So far, research on the effects of cannabis in relation to psychosis risk has primarily 
targeted THC as the main psychoactive ingredient in cannabis. However, apart from 
THC, cannabis contains a range of other cannabinoids, among others cannabidiol 
(CBD), and street preparations of cannabis differ largely in their composition [68]. 
Notably, in contrast to THC, CBD has been shown to have antipsychotic and 
anxiolytic properties [69] and, as has been suggested among others by Morgan and 
colleagues [70, 71], might antagonize the effects of THC. Chapter 9 of this thesis 
provides an editorial on this topic and concludes that it is inevitable to consider 
differences in the potency (i.e. the amount of THC) of cannabis when studying its 
effects on behavior, cognition and mental health. Yet so far, only few studies have 
differentiated between high and low potent cannabis preparations in that regard. In 
an epidemiological study, Di Forti and colleagues [72] investigated 280 cases 
presenting with a first episode of psychosis and 174 controls to study the differential 
effects of high versus low potency cannabis. It was revealed that, among those who 
used cannabis, first-episode patients were almost seven times more likely to have 
used high potency cannabis than the controls, independent of confounding factors. 
Additionally, there was evidence for a dose-response relationship as those who used 
high-potency cannabis daily were six times more likely to be in the patient group 
compared to those who used it less frequently [72]. The link between patient status 
and high-potency cannabis might imply that patients have a preference for stronger 
cannabis preparations. On the other hand, these findings emphasize that the 
psychosis-inducing effects of cannabis are primarily attributable to and dependent 
on the concentration of THC. A study by Morgan and colleagues, who analyzed hair 
samples of 140 healthy individuals with regard to traceable levels of THC and CBD, 
confirmed this link: The group of individuals who had only THC in hair showed the 
highest levels of psychotic experiences compared to individuals with THC and CBD in 
hair and those without any cannabinoids in hair [70]. In a set of subsequent 
naturalistic studies, in which healthy participants were tested while intoxicated with 
their own chosen cannabis, the researchers further revealed that cannabidiol 
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antagonized the negative effects of THC on cognition, both acutely and longer term 
[71, 73], and attenuated the incentive salience of cannabis-associated cues, 
including self-rated indices of liking of the drug [74]. Similar evidence stems from 
imaging studies documenting opposite effects of THC and CBD on both brain function 
and behavioral parameters in healthy individuals [75, 76].  
 
In agreement with the above, CBD has been discussed as an antipsychotic drug [77, 
78], but might also be of relevance for the treatment of drug addiction [79]. Future 
research should therefore focus on the identification of mechanisms of action of both 
endogenous cannabinoids and exogenous cannabinoids such as THC and CBD to 
advance our understanding of the etiology as well as treatment of schizophrenia 
and co-morbid cannabis abuse.  
Clinical relevance 
Notably, the prevalence of cannabis use is much higher among patients with 
psychotic disorder compared to the general population [4-6]. Research on the 
reasons and motives of cannabis use has shown that patients with psychotic disorder 
and healthy controls share similar intentions [80, 81]. Both groups most often report 
using cannabis to get ‘high’, to enhance mood and relieve dysphoria, and for 
reasons of social participation and relaxation. Yet patients with psychotic disorder 
are more likely to also use cannabis out of boredom and to avoid social isolation 
[82]. Studies on the effects of cannabis use in daily life are scarce, in particular in 
patients with psychotic symptoms. Accordingly, much on this topic remains unclear, 
including the question of why patients are particularly prone to continue to use 
cannabis. A recent study on the patterns of cannabis use in psychosis employed the 
Experience Sampling Method in a group of patients and revealed both a positive 
mood enhancing effect of cannabis and a negative hallucinogenic effect [83]. 
Notably, while the positive effects on mood occurred quite immediately, the 
negative effect on psychotic symptoms emerged only sub-acute [83]. The authors 
concluded that this bi-phasic pattern of cannabis effects in psychosis might be 
indicative of a vicious circle: The positive effects are directly linked to the use of 
cannabis, while the delayed experience of symptom worsening is not associated with 
drug taking anymore and instead fosters further use [83]. In an attempt to replicate 
the bi-phasic effect of cannabis in psychosis, a second cohort of patients was 
recently investigated applying the same technique [84]. Again, cannabis had a 
positive effect on mood and a negative effect on hallucinations, yet the effects co-
occurred acutely and could not be temporally disentangled [84].  
 
Despite these initial attempts to shed light on patterns of cannabis use in patients 
with psychosis, this issue remains in need for investigation, especially with regard to 
mechanisms of continuation of cannabis use in this vulnerable group. Therefore, 
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another aim of this thesis was to further investigate factors that contribute to 
maintenance of use in psychosis (chapter 8). A central feature of drug-using 
behavior is craving, the strong urge or desire for the drug, also called wanting [85]. 
Chapter 8 accordingly investigated craving in relation to cannabis use in a group of 
patients with psychotic disorder and healthy controls. An earlier study, employing the 
cross-sectional Obsessive Compulsive Drug Use Scale (OCDUS) for cannabis use, had 
suggested that craving levels are increased in patients with psychotic disorder [86]. 
In line with this, our study also revealed higher levels of craving in patients with 
psychosis compared to healthy controls independent of frequency of use, when 
measured with the OCDUS. When measured with the Experience Sampling Method 
in daily life however, no differences emerged with regard to mean levels of craving 
intensity or frequency during the last week. Yet, craving measured with ESM in daily 
life better predicted daily life cannabis use compared to the OCDUS, implying that 
craving is assessed most accurately when measured in the moment in daily life. 
Moreover, although craving in daily life was significantly associated with cannabis 
use in daily life in both groups, this association was stronger in the controls than the 
patients, possibly implying that patients are prevented from use more often, for 
example due to lack of money or limited accessibility. Alternatively, patients might 
be using cannabis widely independent from inner cues such as the experience of 
craving, implying that use has become rather habit-like. This might be supported by 
the observation that patients often use cannabis to fight boredom [82]. Previously it 
had been suggested that craving levels might differ according to type of 
antipsychotic treatment – tight binding agents at D2 receptors were found to be 
associated with higher levels of craving compared to agents with a low binding 
profile [87]. In our study, no such differences were revealed, which is in line with one 
earlier study indicating no effects of olanzapine or risperidone on craving for 
cannabis in schizophrenia [88]. Yet, numbers of individuals per treatment group in 
our study were low. Thus, failure to detect differences could also be due to a lack of 
power. Since Dekker and colleagues [86], who were the first to indicate higher levels 
of craving in psychosis patients, did not include any statistical adjustment for the 
effects of medication, this issue needs further clarification.  
 
Overall, cannabis use has been associated with poorer outcome and higher relapse 
rates in patients with psychotic illness [89], while cessation of use after a first 
episode of psychosis has been shown to have beneficial effects on mental health 
outcomes [90]. Accordingly, cannabis use constitutes a major concern in the treatment 
of co-morbid patients and research has put effort in the development and 
evaluation of effective treatment strategies [91]. Cognitive Behavioral Therapy in 
combination with motivational interviewing had been suggested to be of particular 
promise [91, 92]. However, a recently evaluated trial in patients with psychotic 
disorder and co-morbid substance use indicated only little improvement in terms of a 
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reduction in the amount of substance used per day [93]. No improvement was 
observed with regard to overall frequency of use or in relation to any form of 
clinical or functional outcome or measures of psychopathology [93]. Together with 
our findings discussed in chapter 8 of this thesis, these observations emphasize the 
need to further elucidate patterns of cannabis use in patients with psychotic disorder. 
  
Conclusion 
 
Overall, the research presented in this thesis has contributed towards a better 
understanding of the mechanisms behind the association between exposure to 
cannabis and an increased risk of developing psychotic symptoms and schizophrenia, 
both from an epidemiological perspective and with regard to neurobiological 
underpinnings. Evidence could be strengthened that cannabis use precedes the onset 
of psychosis and negatively impacts on the persistence of subclinical psychotic 
symptoms. This thesis moreover provided evidence for environmental moderation of 
the psychosis-inducing effects of cannabis, in form of interaction between urbancity 
and cannabis use. With regard to the neurobiological mechanism by which exposure 
to cannabis might increase psychosis risk, the research presented in this thesis 
postulates an important, although clearly not exclusive, role for the dopamine system. 
Finally, it was shown that craving for cannabis, which might be most accurately 
assessed in the moment in daily life, is strongly associated with cannabis use and 
might thus play a central role in maintaining drug use.  
 
Future research should be dedicated to shedding further light on the involvement of 
the endocannabinoid system in psychotic disorders as well as in drug-addiction. 
Especially the involvement of the CB1 receptor in the mediation of the effects of 
cannabis on the brain is in urgent need of further investigation. Moreover, the 
mechanisms of action of cannabinoids other than THC, such as CBD, remain widely 
unknown and knowledge on how CBD brings about its potentially antipsychotic 
effects would greatly advance the development of novel pharmacological treatment 
strategies. Finally, it is of major importance to gain better insight into patterns of 
initiation and continuation of use in vulnerable populations such as patients with 
psychotic symptoms, in particular with regard to the influence of antipsychotic 
medication on levels of craving for cannabis. Together, such research advances will 
hopefully translate into prevention and treatment strategies that will not only 
improve quality of life of many patients but also help to inform adolescents towards 
a sensible dealing with cannabis.  
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SUMMARY  
 
The use of cannabis has been widely established as a risk factor for psychosis. Yet, 
the exact nature of the association still remains unclear, including the issue of self-
medication or reverse causality. Previously it had been suggested that the link 
between cannabis and psychosis might best be understood in terms of interaction 
between genes and environment, where individual vulnerability combines with 
environmental risk such as cannabis use in causing psychotic disorder. However, it is 
widely unknown whether cannabis use might also interact with other environmental 
risk factors. In addition, the biological mechanisms behind such findings remain 
elusive.  
 
This thesis therefore considered epidemiological (studied in chapters 2, 3 and 4) as 
well as biological mechanisms (discussed in chapters 5, 6, 7, and 9) that may 
underlie the association between exposure to cannabis and the development of 
psychotic symptoms and schizophrenia.  
 
CHAPTER 1 provides an overview on the epidemiology and etiology of psychotic 
disorders such as schizophrenia and discusses cannabis use as an important 
environmental risk factor. Furthermore, epidemiological studies on the link between 
cannabis use and psychosis are reviewed and an outlook is given on potential 
biological correlates of this association, concluding that dopamine might play a role 
in mediating the effects of cannabis on psychosis risk. The chapter subsequently 
discusses existing findings on differential sensitivity to the effects of cannabis, 
indicating that genetic predisposition for psychosis as well as variation in specific 
molecular polymorphisms might give rise to increased vulnerability. Also, cannabidiol 
is introduced as another cannabinoid and ingredient of cannabis with potential 
antipsychotic properties. Finally, research gaps in the study of cannabis as cause of 
psychosis are identified and the aims of the current thesis are outlined.  
 
CHAPTER 2 deals with the temporal association between exposure to cannabis and 
the development of psychotic symptoms to shed further light on the nature of this 
association. In addition it was of interest whether cannabis use increases psychosis 
risk by impacting on the persistence of subclinical psychotic symptoms. For this 
purpose, data from a large German prospective cohort study of adolescents and 
young adults (Early Developmental Stages of Psychopathology, EDSP) were 
analyzed. The following research questions were formulated: i) Does cannabis use 
precede the onset of incident subclinical psychotic symptoms in adolescence and 
young adults? And ii) Does cannabis use increase psychosis risk by negatively 
impacting on the persistence of these subclinical psychotic symptoms? Analyses of the 
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data revealed that, in individuals who were cannabis naïve at baseline, use of 
cannabis between baseline and first follow-up was significantly associated with 
increased risk of incident psychotic symptoms at second follow-up. Moreover it was 
revealed that continued use of cannabis (i.e. cannabis use at both baseline and first 
follow-up) increased the risk that subclinical psychotic symptoms persisted throughout 
the period between first and second follow-up. Together these findings provide 
further evidence for a causal role of cannabis use in the etiology of psychosis. 
Moreover, a mechanism of abnormal persistence of subclinical psychotic symptoms is 
suggested to form part of the pathway from cannabis to psychosis.  
 
CHAPTER 3 considers the possibility of environmental moderation of the cannabis-
psychosis relationship. In particular we investigated whether urbanicity – growing up 
in an urban environment – played a role for the long-term psychosis-inducing effects 
of cannabis. Again, data from the German EDSP study were analyzed and the 
interaction between urbanicity and cannabis use at follow-up was calculated. To 
ensure the prediction of incident psychotic symptoms, all individuals with preexisting 
psychotic symptoms at baseline were excluded from the analyses. It was revealed 
that the risk to develop psychotic symptoms following cannabis use was much higher 
for individuals who grew up in an urban environment compared to individuals from 
the rural surroundings. This suggests that, in addition to genetic factors, exposure to 
environmental risk factors may induce increased sensitivity to the psychosis-inducing 
effects of cannabis.  
 
CHAPTER 4 presents a further epidemiological study on environmental moderation 
of the cannabis-psychosis relationship. Previous research had indicated that trauma 
interacts with cannabis use in causing psychosis: Individuals who were exposed to 
trauma during childhood had a higher risk of developing psychotic symptoms and 
schizophrenia following cannabis use later in life. The present study aimed at 
replication of this finding in the large cohort of the prospective German EDSP study. 
Contrary to our hypothesis and to previous findings, trauma was not associated with 
increased risk of developing psychotic symptoms after cannabis use.  
 
CHAPTER 5 provides an update on the dopamine dysfunction in psychosis and 
schizophrenia. This includes neurochemical imaging studies on mechanisms of 
presynaptic and postsynaptic dopamine function in both striatal and extrastriatal 
regions of the brain, including prefrontal areas. It is concluded that contrary to the 
long-standing claim of involvement of mesolimbic dopamine dysregulation, it is 
rather a dysfunction in nigrostriatal dopaminergic pathways and in particular 
associative striatum that is associated with (early) expression of symptomatology in 
psychosis.  
SUMMARY 193 
 
 
In order to elucidate the role of dopamine in the psychosis inducing effects of 
cannabis, CHAPTER 6 summarizes and integrates research across different 
disciplines on the interaction between the dopamine and the endocannabinoid 
system. Dopamine plays a central role in the emergence as well as experience of 
psychotic symptoms. Striatal dopaminergic hyperfunction has been implicated in the 
positive symptoms of psychosis, while dopaminergic hypoactivity in prefrontal brain 
regions has been assumed to underlie the expression of negative symptoms. 
Evidence from animal research suggests that endocannabinoids are key components 
in the regulation of dopaminergic neurotransmission, both in striatal and prefrontal 
brain regions. Moreover, THC has been shown to differentially affect these 
pathways. It is concluded that the repeated administration of THC might alter PFC 
function and impair cognition by acting on dopamine signaling via activation of CB1 
receptors. In the ventral tegmental area, it seems that THC leads to burst firing of 
dopamine neurons and as a consequence increased dopamine levels in the striatum. 
Here, THC might additionally exert its effects by directly influencing synaptic 
plasticity. Yet, most of the evidence discussed in this chapter stems from animal 
research, and research into the processes underlying cannabis-induced psychosis in 
the human brain is demanded.  
 
In line with the considerations put forward in chapter 6, CHAPTER 7 tests the 
hypothesis that THC increases the risk of developing psychotic symptoms by 
stimulating striatal dopamine neurotransmission. For this purpose, Positron Emission 
Tomography and [18F] fallypride was used to study ligand displacement at D2 
receptors – indicative of increased dopamine release – following pulmonary 
administration of THC in 9 patients with psychotic disorder, 9 first-degree relatives 
and 10 healthy controls. Analyses revealed significant dopamine release associated 
with administration of THC in both patients with psychotic disorder and first-degree 
relatives. In line with previous findings, no THC-induced dopamine release was found 
in healthy controls. These findings support a dopaminergic mechanism of cannabis-
induced psychosis in individuals at risk for psychosis. 
 
CHAPTER 8 investigates patterns of cannabis use in relation to craving for cannabis 
in daily life of patients with psychotic disorder and healthy controls. The study makes 
use of the Experience Sampling Method (ESM), a structured diary technique that 
pseudo-randomly collects multiple observations per person during several 
consecutive days. Participants received a digital wrist watch and a paper-and-pencil 
ESM booklet. Twelve times a day on six consecutive days, the watch emitted a beep 
at random moments. After each beep, participants were asked to fill in a self-
assessment form, collecting reports on craving intensity, severity of symptoms and 
cannabis use rated on 7-point Likert scales at the moment of the beep. In addition to 
collecting information on craving levels by means of the ESM booklets, craving was 
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assessed with the Obsessive Compulsive Drug Use Scale (OCDUS) for cannabis use. 
It was revealed that patients with psychotic disorder displayed higher levels of 
craving when measured with the OCDUS, but did not differ from healthy controls in 
craving intensity when measured in daily life with ESM. Also ESM craving was a 
better predictor of cannabis use during the ESM week than scores on the OCDUS. 
Craving in daily life was significantly associated with cannabis use in daily life. 
Notably, this association was stronger for controls than for patients, suggesting that 
patients are either prevented more often from use or alternatively use cannabis 
rather independent from inner cues. In general, no differences were found between 
patients receiving different types of antipsychotics, yet failure to detect such 
differences might be due to a lack of power. Overall, the study emphasizes the 
need to further elucidate the role of craving in relation to cannabis use in patients 
with psychosis, in particular with regard to the influence of antipsychotic medication. 
Better insight into mechanisms of cannabis use might ultimately guide the 
development of effective treatment strategies.  
 
CHAPTER 9 presents an editorial addressing the issue of differences in potency of 
cannabis (i.e. the amount of THC) in relation to its effects on psychosis and cognition. 
Apart from THC, cannabis contains a range of other cannabinoids, among others 
cannabidiol. Notably, cannabidiol has been shown to act anxiolytic and, as 
suggested by studies by Morgan and colleagues, might antagonize the negative 
effects of THC. This is of relevance as the composition of cannabis differs widely with 
regard to the ratio of cannabidiol and THC. It is concluded that future research on 
this topic is warranted in order to shed further light on the possibly antipsychotic 
mechanisms of action of cannabidiol. Furthermore the importance of considering 
differences in the cannabidiol:THC ratio of cannabis when studying its effects on 
human behavior and mental health is emphasized.  
 
Finally, CHAPTER 10 briefly summarizes the results of the studies presented in this 
thesis, which includes three epidemiological studies, an experimental neuroimaging, 
an observational study, two reviews and an editorial. The relevance of the current 
results is discussed on the background of existing findings. Furthermore, clinical 
implications are considered. Directions for future research are provided.  
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